7 Safe Stocks to Buy for Volatility Insurance
- The concept of safe stocks arguably couldn't be timelier. Recently, the technology sector encountered significant turmoil, with many experts questioning the sustained success of artificial intelligence and related innovations.
- 07/18/2024
|
Abbott Laboratories Posts Big Drop in COVID-19 Testing Revenue
- Shares of Abbott Laboratories (ABT) declined in intraday trading Thursday as the healthcare products maker's sales of COVID-19 tests slumped with the pandemic ending.
- 07/18/2024
|
Nasdaq Down Over 100 Points; Abbott Laboratories Earnings Beat Views
- U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Thursday.
- 07/18/2024
|
Abbott plans marketing push for glucose monitors beyond diabetes
- Abbott Laboratories will use a mix of TV advertisements and guerilla marketing as well as seek to personalize health data to tap people without diabetes for the U.S. launch of its glucose monitoring device, CEO Robert Ford said on Thursday.
- 07/18/2024
|
Should you buy Abbott stock? CEO sees multi-billion dollar opportunity in new product
- Abbott Laboratories (NYSE: ABT) faced a 3.0% decline in stock price this morning despite reporting a strong second quarter and raising its full-year guidance. Meanwhile, CEO Robert B.
- 07/18/2024
|
Abbott Laboratories (ABT) Q2 2024 Earnings Call Transcript
- Abbott Laboratories (NYSE:ABT ) Q2 2024 Earnings Conference Call July 18, 2024 9:00 AM ET Company Participants Robert Ford - Chief Executive Officer Phil Boudreau - Executive Vice President, Finance, Chief Financial Officer Mike Comilla - Vice President, Investor Relations Conference Call Participants Larry Biegelsen - Wells Fargo Travis Sneed - Bank of America Robbie Marcus - JP Morgan Josh Jennings - TD Cowen David Roman - Goldman Sachs Danielle Antalffy - UBS Vijay Kumar - Evercore ISI Operator Good morning and thank you for standing by. Welcome to Abbott's second quarter 2024 earnings conference call.
- 07/18/2024
|
Jobless Claims Increased More Than Expected
- Another Thursday morning, another Weekly Jobless Claims report. On an Initial Claims basis, we jump back up to where we were two weeks ago, to +243K new claims — a near-term high going back to August of last year.
- 07/18/2024
|
Abbott (ABT) Q2 Earnings Surpass Estimates, Margins Expand
- Abbott (ABT) delivers a strong underlying base business performance in the second quarter of 2024.
- 07/18/2024
|
Abbott Labs CEO on Q2 earnings
- Abbott Labs CEO Robert Ford joins 'Squawk on the Street' to discuss what's driving the company's double-digit gains in the quarter, his take on the 2024 election, and more.
- 07/18/2024
|
Compared to Estimates, Abbott (ABT) Q2 Earnings: A Look at Key Metrics
- While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 07/18/2024
|
Abbott (ABT) Q2 Earnings and Revenues Top Estimates
- Abbott (ABT) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $1.10 per share. This compares to earnings of $1.08 per share a year ago.
- 07/18/2024
|
2 Healthcare Stocks For Your Mid-July 2024 Watchlist
- Healthcare stocks to check out in the stock market right now.
- 07/18/2024
|
Why This Leading Health Stock is a Buy No Matter the Market Move
- Abbott Laboratories NYSE: ABT is a premier buy-and-hold stock because of its foresightful management, quality operation, portfolio, pipeline, cash flow, and capital return. It's not always a good buy; all healthcare stocks have ups and downs in their cycles, but Abbott is a buy today, no matter how it moves.
- 07/18/2024
|
Abbott raises annual profit forecast as strong medical device sales power quarterly beat
- Abbott Laboratories raised its annual profit forecast on Thursday and beat Wall Street estimates for second-quarter earnings, buoyed by strong sales of its cardiac and diabetes devices.
- 07/18/2024
|
Abbott Reports Second-Quarter 2024 Results and Raises Full-Year Guidance
- Sales of $10.4 billion driven by strong underlying base business performance Reported sales growth of 4.0 percent; organic sales growth for underlying base business of 9.3 percent1, led by double-digit growth in Medical Devices Continues to strengthen portfolio with new product approvals ABBOTT PARK, Ill., July 18, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2024.
- 07/18/2024
|
Don't buy the dip as the summer slump is officially here, says Goldman strategist
- A modest bounce for the Nasdaq Composite could be in the making for Thursday, following the worst one-day percentage drop for the tech index, as a recent rotation out of its biggest companies got amped by concerns the U.S. would hit tech companies with more China restrictions.
- 07/18/2024
|
2 Dividend Stocks to Buy and Hold Forever
- Microsoft and Abbott Laboratories have been leaders in their respective industries for decades. Both companies have important growth opportunities and impressive innovative abilities.
- 07/18/2024
|
Abbott Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
- Abbott Laboratories ABT is scheduled to release its financial results for the second quarter, before the opening bell on Thursday, July 18.
- 07/18/2024
|
Down 7% This Year Will Abbott Stock See Higher Levels Post Q2 Results?
- Abbott (NYSE: ABT) will report its Q2 2024 results on Thursday, July 18. We expect the company to post revenue of $10.3 billion and earnings of $1.10 on a per share and adjusted basis, broadly aligning with the street expectations.
- 07/17/2024
|
Utility says Houston power will be mostly restored by Wednesday, as Abbott threatens punishment
- AUSTIN, Texs — The majority of Houston outages that followed Hurricane Beryl should be fixed within the next two days, the city's main utility company said Monday as Texas Gov. Greg Abbott threatened to punish CenterPoint Energy CNP, -6.67% even after the lights come back.
- 07/15/2024
|
The 7 Most Undervalued Healthcare Stocks to Buy in July 2024
- Over the years, especially the past three, I have become more cautious about the technology sector's blatant overvaluation. Nevertheless, it is difficult to ignore the capabilities of companies such as Nvidia (NASDAQ: NVDA ) and their innovative solutions for AI.
- 07/13/2024
|
Here's How Abbott (ABT) is Placed Ahead of Q2 Earnings Release
- Abbott Laboratories' (ABT) second-quarter 2024 results are likely to reflect broad-based strength across several businesses and solid progress in the pipeline.
- 07/11/2024
|
Wall Street Bulls Look Optimistic About Abbott (ABT): Should You Buy?
- Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
- 07/11/2024
|
53 July Dividend Kings: Buy 8, Watch 8 More
- "What is a Dividend King? A stock with 50 or more consecutive years of dividend increases."—suredividend.com. The 53 Dividend Kings, screened as of July 8, represented 8 of 11 Morningstar Sectors. Broker-targeted top-ten net-gains ranged 18.24%-30.31% topped-by Kenvue, and Genuine Parts. By yield, Altria tops-all. Top-ten July listings: SWK, FRT, KVUE, FTS, UBSI, BKH, NWN, CDUAF, UVV, MMM, & MO averaged 5.37% in yield.
- 07/10/2024
|
7 Healthcare Stocks to Buy for Positive Inflation-Adjusted Returns
- In my view, it's important for every individual to invest in equities. By just holding cash in a back account, there is bound to be loss of purchasing power when adjusted for inflation.
- 07/10/2024
|
Abbott (ABT) Stock Drops Despite Market Gains: Important Facts to Note
- In the latest trading session, Abbott (ABT) closed at $101.64, marking a -0.47% move from the previous day.
- 07/09/2024
|
3 buys and a bail: Merck, Abbott, Cigna, and Zoom
- Gina Sanchez, chief market strategist at Lido Advisors, joins CNBC's 'The Exchange' to discuss four stocks: Merck, Abbott, Cigna, and Zoom.
- 07/09/2024
|
Abbott trial on preterm infant formula linked to NEC disease kicks off this week
- Similac baby formula maker Abbott is expected to face a trial on Monday over claims that its formula for preterm infants used in neonatal intensive care units causes a potentially deadly bowel disease, the second trial out of hundreds of similar lawsuits in the United States.
- 07/08/2024
|
Abbott faces trial over claims that preterm infant formula caused dangerous disease
- Similac baby formula maker Abbott is expected to face a trial on Monday over claims that its formula for preterm infants used in neonatal intensive care units causes a potentially deadly bowel disease, the second trial out of hundreds of similar lawsuits in the United States.
- 07/08/2024
|
Abbott Laboratories: The Fantastic Mix Of Growth And Value - At A Great Price
- The S&P 500 gained 2% last week despite weak employment data and manufacturing sentiment, driven by optimism about potential Fed rate cuts. Abbott Laboratories, though lagging the S&P 500, shows promise with diversified growth in diagnostics, nutrition, diabetes care, and heart health. With a strong dividend and innovation-driven outlook, Abbott is well-positioned for long-term gains, although current high valuations suggest cautious optimism.
- 07/07/2024
|
The 3 Best Healthcare Stocks to Buy in July 2024
- The COVID-19 pandemic emphasized the importance of healthcare companies. Consistent breakthroughs, improved products and relatively consistent growth make these companies fan-favorite picks for investors.
- 07/04/2024
|
My Best Dividend Aristocrats For July 2024
- The ProShares S&P 500 Dividend Aristocrats ETF continues its positive run in 2024, posting a gain of 1.45% in May. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 35 months of tracking these strategies, two strategies are outperforming NOBL, while 1 remain relatively close.
- 07/01/2024
|
How Does The Current Fall In Abbott Stock Compare With The One During 2008 Recession?
- Abbott stock (NYSE: ABT) currently trades at $105 per share, 25% below its peak level of over $140 seen in December 2021. In comparison, its peer Boston Scientific stock (NYSE: BSX) has seen a nearly 90% rise over this period.
- 07/01/2024
|
3 MedTech Stocks to Buy for Healthy Gains
- Fundamentally, few sectors exist outside of the broad healthcare umbrella that offer what I would term permanent relevance. In this case, the concept of caring for other people is likely an eternal one.
- 07/01/2024
|
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
- Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- 06/28/2024
|
Buy 3 June Fortune 500 Industry Dividend Leaders (Watch 4 More)
- The June/July 2024 edition of Fortune Magazine revealed the 500 biggest U.S. companies by-revenue and profits. Dogcatcher's quest for dividend buys focused-on 66 industry-eaders (IL) using YCharts 6/26/24 data. Those 66 industry-leaders were segmented into 21 business-sectors, ranging (alphabetically) from apparel to wholesalers. 3 of 66 were private or foreign exchange-listed firms not tracked-by YChats, leaving 63-listed. 57 dividend yielding stocks led those 63 industry leaders and ranged 0.03% to 8.46% in annual yield and ranged -13.69% to 47.15% in broker estimated one-year target-price upsides.
- 06/28/2024
|
Abbott Hosts Conference Call for Second-Quarter Earnings
- ABBOTT PARK, Ill., June 27, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2024 financial results on Thursday, July 18, before the market opens.
- 06/27/2024
|
Abbott (ABT) Exceeds Market Returns: Some Facts to Consider
- In the closing of the recent trading day, Abbott (ABT) stood at $105.49, denoting a +0.18% change from the preceding trading day.
- 06/25/2024
|
Abbott's (ABT) EPD Expansion Continues Despite FX Headwind
- Banking on the successful execution of its Branded Generic operating model, Abbott's (ABT) EPD is well-positioned for sustained growth in many of the growing pharmaceutical markets.
- 06/24/2024
|
Wall Street Analysts Think Abbott (ABT) Is a Good Investment: Is It?
- Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
- 06/24/2024
|
Abbott Teams Up With the National Association of Community Health Centers to Expand Access to Nutritious Food and Improve Health
- Eight health centers across the U.S. participate in Innovation Incubator to find new ways to integrate healthy food into clinical care Now in its second year, the goal of the Innovation Incubator is to share what works with 1,400 health centers providing affordable care for 31+ million ABBOTT PARK, Ill. and BETHESDA, Md.
- 06/20/2024
|
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.
- Dividend stocks offer you a big advantage: regular income no matter what the market is doing. It's a great idea to choose stocks that have a long track record of dividend strength.
- 06/20/2024
|
Abbott (ABT) Stock Slides as Market Rises: Facts to Know Before You Trade
- Abbott (ABT) concluded the recent trading session at $103.45, signifying a -0.22% move from its prior day's close.
- 06/17/2024
|
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock
- Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- 06/17/2024
|
Forget The S&P 500 - Here Are 3 Low-Risk, High-Quality Dividend Bargains I Like
- The S&P 500 has seen impressive returns, largely driven by a few tech giants, raising concerns about diversification risks for investors. Investing in high-quality, anti-cyclical stocks can offer balanced growth and income, providing a safer alternative to the tech-heavy S&P 500. These selected stocks present attractive valuations and potential for long-term gains, making them solid choices for investors seeking growth and income stability.
- 06/17/2024
|
Abbott Declares 402nd Consecutive Quarterly Dividend
- ABBOTT PARK, Ill., June 14, 2024 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 55 cents per share.
- 06/14/2024
|
Abbott's (ABT) AVEIR DR Leadless Pacemaker System Gains CE Mark
- Abbott (ABT) receives a CE mark for AVEIR DR, the world's first dual chamber leadless pacemaker system.
- 06/12/2024
|
Abbott (ABT) Gets FDA Nod for Two Glucose Monitoring Systems
- Abbott's (ABT) glucose monitoring systems - Lingo and Libre Rio - based on Freestyle Libre technology, receive FDA clearance.
- 06/12/2024
|
2 Healthcare Stocks to Buy Hand Over Fist in June
- Vertex Pharmaceuticals and Abbott Laboratories are innovative healthcare leaders. Both companies have robust businesses and excellent potential opportunities.
- 06/12/2024
|
Abbott (ABT) Stock Sinks As Market Gains: Here's Why
- Abbott (ABT) closed the most recent trading day at $105.81, moving -1.56% from the previous trading session.
- 06/11/2024
|
2 Magnificent Dividend Growth Stocks to Buy Now
- Dividend growth stocks are superb wealth-creation vehicles. These two blue chips are among the best in the category.
- 06/11/2024
|
FDA approves two new Abbott over-the-counter continuous glucose monitors
- Abbott on Monday announced it has received FDA clearance for two new CGMs that will be available without a prescription. A CGM is a small sensor that pokes through the skin and tracks a person's glucose levels in real-time.
- 06/10/2024
|
US FDA clears Abbott's continuous glucose monitors for over-the-counter use
- Abbott said on Monday that the U.S. Food and Drug Administration has cleared its two continuous glucose monitoring systems for over-the-counter use.
- 06/10/2024
|
Abbott Snags U.S. Clearance To Enter The Obesity Arena, Rivaling Dexcom
- Abbott Laboratories gained U.S. clearance Monday for a pair of new CGMs. The news could push Abbott stock closer to a breakout.
- 06/10/2024
|
Abbott Receives U.S. FDA Clearance for Two New Over-the-Counter Continuous Glucose Monitoring Systems
- Abbott's consumer biowearable, Lingo™, is designed for general consumers who are looking to improve their overall health and wellness Libre Rio™ is designed for adults with Type 2 diabetes who do not use insulin and typically manage their diabetes through lifestyle modifications Both products are based on FreeStyle Libre® sensing technology, the world's most widely used1 continuous glucose monitoring (CGM) systems, pioneered by Abbott and used by about 6 million people globally2 ABBOTT PARK, Ill., June 10, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) clearance for two new over-the-counter continuous glucose monitoring (CGM) systems – Lingo™ and Libre Rio™, which are based on Abbott's world-leading FreeStyle Libre® continuous glucose monitoring technology1, now used by about 6 million people globally2.
- 06/10/2024
|
The Dividend Darlings: 3 Stocks That Will Shower Your Portfolio with Cash
- From 1930 to 2023, 70% of dividend stocks in the top two quintiles outperformed the S&P 500 during recessions. Dividends have contributed 40% of the stock market gain since 1930, increasing with rising inflation.
- 06/07/2024
|
Abbott (ABT) Is Considered a Good Investment by Brokers: Is That True?
- Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
- 06/06/2024
|
Abbott (ABT) Stock Dips While Market Gains: Key Facts
- In the closing of the recent trading day, Abbott (ABT) stood at $103.23, denoting a -0.19% change from the preceding trading day.
- 06/05/2024
|
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
- Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
- 06/05/2024
|
The 2 Most Important Charts I Want (Dividend) Investors To See
- Recent data indicates a heightened risk of stagflation, with slowing economic growth and persistent inflation. This poses challenges for the economy and portfolios, but also presents opportunities to buy beaten-down stocks with strong pricing power and growth potential. My focus remains on resilient dividend growth stocks and sectors like energy and healthcare, which are well-positioned for these conditions.
- 06/05/2024
|
Abbott Laboratories: Why I Agree With Wall Street On This One
- Wall Street analysts have a 'strong buy' rating on ABT stock, with 12 out of 24 analysts giving it this rating in the last 90 days. We agree with such bullish sentiment. Despite some risks, ABT stock has the potential to outperform the overall market by a large margin.
- 06/04/2024
|
Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients
- Tecarfarin, which recently received Orphan Drug Designation from the FDA for the prevention of thromboembolism and thrombosis in patients with an implanted mechanical circulatory support device, has the potential to improve the time in therapeutic range a factor correlated in the ARIES-HM3 trial with better patient outcomes PONTE VEDRA, Fla. , June 3, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions, today highlighted a groundbreaking presentation at the International Society for Heart & Lung Transplantation (ISHLT) 44th Annual Meeting & Scientific Sessions.
- 06/03/2024
|
Abbott (ABT) Rises As Market Takes a Dip: Key Facts
- The latest trading day saw Abbott (ABT) settling at $101.74, representing a +1% change from its previous close.
- 05/30/2024
|
Calls Of The Day: Eli Lilly, UnitedHealth Group, Abbott Labs and Johnson & Johnson
- The Investment Committee discuss the latest Calls of the Day.
- 05/30/2024
|
Wall Street Favorites: 3 Healthcare Stocks With Strong Buy Ratings for May 2024
- Healthcare stocks to buy are booming in the U.S. due to the nation's aging population. Spending on healthcare in the U.S. now totals $4.4 trillion, or $13,493 per person, each year — more than any other country on earth.
- 05/28/2024
|
Reliable Rewards: 7 Dividend Stocks to Count On in Any Market
- Earlier, the Federal Reserve stood poised to cut the benchmark interest rate, which boded well for reliable dividend stocks. Essentially, Uncle Sam's high yields wouldn't compete with the passive income stemming from private enterprises.
- 05/27/2024
|
Blue-Chip Bonanza: 3 Stocks to Ride the Market's Coattails to Riches
- The bull market continues; markets quickly dusted off the 5% correction in April and soared to new highs. With too much cash on the sidelines, every shallow correction has become a buying opportunity.
- 05/27/2024
|
Abbott (ABT) Stock Sinks As Market Gains: Here's Why
- Abbott (ABT) concluded the recent trading session at $103.95, signifying a -0.27% move from its prior day's close.
- 05/24/2024
|
Here's Why You Should Hold on to Abbott (ABT) Stock for Now
- Abbott's (ABT) share recovery in the Nutrition business buoys optimism.
- 05/21/2024
|
Wall Street Analysts See Abbott (ABT) as a Buy: Should You Invest?
- When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
- 05/21/2024
|
Panagora Asset Management Inc. Has $2.95 Million Stock Position in Abbott Laboratories (NYSE:ABT)
- Panagora Asset Management Inc. increased its holdings in Abbott Laboratories (NYSE:ABT – Free Report) by 2.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 26,804 shares of the healthcare product maker’s stock after purchasing an additional 724 shares during the quarter. Panagora Asset Management Inc.’s holdings in Abbott Laboratories were worth $2,950,000 at the end of the most recent reporting period. A number of other institutional investors and hedge funds have also bought and sold shares of ABT. Perigon Wealth Management LLC lifted its stake in shares of Abbott Laboratories by 5.2% in the fourth quarter. Perigon Wealth Management LLC now owns 47,080 shares of the healthcare product maker’s stock worth $5,182,000 after acquiring an additional 2,317 shares during the period. Boston Partners boosted its stake in shares of Abbott Laboratories by 634.6% in the 3rd quarter. Boston Partners now owns 29,758 shares of the healthcare product maker’s stock valued at $2,882,000 after purchasing an additional 25,707 shares during the last quarter. VisionPoint Advisory Group LLC increased its position in shares of Abbott Laboratories by 7.4% during the third quarter. VisionPoint Advisory Group LLC now owns 3,106 shares of the healthcare product maker’s stock worth $301,000 after buying an additional 215 shares during the period. Gradient Investments LLC raised its stake in Abbott Laboratories by 4.7% during the fourth quarter. Gradient Investments LLC now owns 257,508 shares of the healthcare product maker’s stock worth $28,344,000 after buying an additional 11,508 shares during the last quarter. Finally, BKM Wealth Management LLC bought a new stake in Abbott Laboratories during the fourth quarter valued at $2,111,000. 75.18% of the stock is currently owned by institutional investors and hedge funds. Insider Buying and Selling at Abbott Laboratories In other news, EVP Lisa D. Earnhardt sold 22,852 shares of the business’s stock in a transaction that occurred on Tuesday, May 7th. The stock was sold at an average price of $106.25, for a total value of $2,428,025.00. Following the transaction, the executive vice president now owns 61,462 shares in the company, valued at approximately $6,530,337.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Abbott Laboratories news, EVP Jr. Robert E. Funck sold 10,097 shares of the business’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $104.57, for a total value of $1,055,843.29. Following the transaction, the executive vice president now directly owns 211,341 shares in the company, valued at $22,099,928.37. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Lisa D. Earnhardt sold 22,852 shares of the firm’s stock in a transaction that occurred on Tuesday, May 7th. The stock was sold at an average price of $106.25, for a total transaction of $2,428,025.00. Following the sale, the executive vice president now owns 61,462 shares of the company’s stock, valued at approximately $6,530,337.50. The disclosure for this sale can be found here. In the last 90 days, insiders sold 46,884 shares of company stock worth $5,153,916. Insiders own 1.10% of the company’s stock. Wall Street Analysts Forecast Growth A number of research firms have issued reports on ABT. Royal Bank of Canada cut their price target on Abbott Laboratories from $128.00 to $125.00 and set an “outperform” rating on the stock in a report on Thursday, April 18th. Raymond James reissued a “buy” rating and set a $124.00 target price on shares of Abbott Laboratories in a research note on Wednesday, April 24th. Evercore ISI upped their price objective on shares of Abbott Laboratories from $120.00 to $125.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. Citigroup raised their target price on Abbott Laboratories from $126.00 to $128.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Finally, Barclays dropped their price target on Abbott Laboratories from $141.00 to $140.00 and set an “overweight” rating on the stock in a research note on Monday, April 22nd. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average target price of $121.50. Get Our Latest Analysis on ABT Abbott Laboratories Stock Down 0.7 % ABT stock opened at $104.09 on Monday. The stock’s 50 day moving average is $109.59 and its 200-day moving average is $109.43. Abbott Laboratories has a twelve month low of $89.67 and a twelve month high of $121.64. The firm has a market capitalization of $181.08 billion, a PE ratio of 32.43, a P/E/G ratio of 2.50 and a beta of 0.76. The company has a quick ratio of 1.11, a current ratio of 1.60 and a debt-to-equity ratio of 0.32. Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its quarterly earnings data on Wednesday, April 17th. The healthcare product maker reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.96 by $0.02. The business had revenue of $9.96 billion for the quarter, compared to analysts’ expectations of $9.88 billion. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.96%. The business’s revenue was up 2.2% on a year-over-year basis. During the same period last year, the business earned $1.03 EPS. Sell-side analysts expect that Abbott Laboratories will post 4.62 EPS for the current fiscal year. About Abbott Laboratories (Free Report) Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
- 05/20/2024
|
Paradigm Shift! 4 Of My Favorite Dividend Stocks To Buy Right Now
- I see a shift from growth to value stocks due to persistent inflation and interest rate challenges. Based on my thesis, I present four fantastic dividend growth stocks with great business models, attractive valuations, and favorable dividend profiles. These companies offer solid dividends, growth potential, and balanced risk/reward profiles. They are well-positioned to outperform the S&P 500, providing both value and security in a shifting market.
- 05/19/2024
|
Abbott Laboratories: Buying More Of This Top-Notch Dividend Growth Stock
- Abbott Laboratories is one of the smaller holdings in my portfolio, but that won't be the case for much longer. Strength throughout the base business powered the company's sales higher in the first quarter. ABT's interest coverage ratio approached 25 in the most recent quarter, which supports an AA- credit rating from S&P.
- 05/18/2024
|
These Dividend Stocks Are an Investor's Best Friend
- Fund managers have historically pivoted to top dividend stocks in low-interest-rate environments. With the Fed poised to start cutting interest rates within the next eight to 12 months, these two blue chip dividend stocks could be compelling buys.
- 05/16/2024
|
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
- Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
- 05/15/2024
|
JP Morgan Has 5 Blue Chip Passive Income Stocks as Top Picks for May
- If you want your portfolio to pay you cash like clockwork, it's time to stop blindly following conventional wisdom like relying on Dividend Aristocrats.
- 05/11/2024
|
Drugmaker Abbott India posts Q4 profit rise on higher sales
- Indian drugmaker Abbott India reported a 24% rise in fourth-quarter profit on Thursday, as strong sales outpaced the impact of government pricing caps on certain medicines.
- 05/09/2024
|
Here's why you should buy these 3 stocks and hold them forever
- Often overlooked, especially in times of AI revolution, the healthcare market is always a safe bet for investors, as it is a multiple trillion, highly innovative industry with no drawbacks like lack of demand per se.
- 05/08/2024
|
Got $1,000? 3 Dividend Stocks to Buy and Hold Forever
- Johnson & Johnson is a steady portfolio stalwart. Abbott Labs has exciting growth opportunities ahead.
- 05/08/2024
|
Appriss Retail Names Industry Veteran and Innovator Dean Abbott Chief Data Scientist
- IRVINE, Calif.--(BUSINESS WIRE)--Appriss Retail, a leading provider of data and analytics solutions designed to reduce retail losses, decrease returns, and provide a more seamless consumer experience, announced today that Dean Abbott has joined the team as the company's chief data scientist. The news comes amid Appriss Retail's recent solution advancements and global expansion. Abbott will work with Appriss Retail's global retail customers to optimize data and analytical processes in his new ro.
- 05/02/2024
|
Stock Market Crash Alert: 3 Must-Buy Healthcare Stocks When Prices Plunge
- Healthcare stocks certainly haven't set the world on fire lately. The S&P Health Care Index is up 3% so far in 2024 compared to an 8% gain in the benchmark S&P 500.
- 05/01/2024
|
Is Trending Stock Abbott Laboratories (ABT) a Buy Now?
- Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
- 05/01/2024
|
PBH vs. ABT: Which Stock Is the Better Value Option?
- Investors looking for stocks in the Medical - Products sector might want to consider either Prestige Consumer Healthcare (PBH) or Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks?
- 04/30/2024
|
7 Defensive Stocks Built to Withstand the Market's Worst Storms
- While the equities sector experienced a bump higher for the week ending April 26, potential headwinds incentivize the case for defensive stocks to buy. First and foremost, the geopolitical headlines don't support continued bullishness.
- 04/30/2024
|
Abbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee
- More than 20 million people in the U.S. are living with peripheral artery disease (PAD) yet there have been limited treatment options The first-of-its-kind Esprit™ BTK Everolimus Eluting Resorbable Scaffold dissolves over time after it has opened blocked arteries below the knee (BTK) The Esprit BTK System is a dissolving stent that offers the possibility of better outcomes for people with the most severe form of PAD ABBOTT PARK, Ill., April 29, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK).
- 04/29/2024
|
2 Beaten-Down Dividend Stocks to Buy and Hold Forever
- Apple and Abbott Laboratories are facing multiple issues. However, both have excellent track records and important growth avenues.
- 04/28/2024
|
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
- Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- 04/22/2024
|
Should You Pick Abbott Stock At $105 After An Upbeat Q1?
- Abbott (NYSE: ABT) recently reported its Q1 results, with revenues above and earnings exceeding our expectations. The company reported revenue of $10 billion and earnings of $0.98 on a per-share and adjusted basis, compared to our estimates of $9.9 billion and $0.95, respectively.
- 04/22/2024
|
20 Years To $300k? Building A $10,000 Dividend Portfolio From Scratch
- Focusing on consistent dividend growth can lead to higher returns in lower-risk areas. The portfolio emphasizes companies with wide-moat business models, strong financials, and a commitment to shareholder returns. Blending higher-yielding dividend stocks with those offering growth potential creates a balanced approach suitable for most investors.
- 04/20/2024
|
Abbott Labs Stock Falls as Q2 Guidance Outweighs Earnings Beat
- Shares of Abbott Laboratories (ABT) fell in intraday trading Wednesday, with second-quarter guidance seeming to outweigh first-quarter results that beat analyst estimates.
- 04/17/2024
|
Abbott Laboratories (ABT) Q1 2024 Earnings Call Transcript
- Abbott Laboratories (NYSE:ABT ) Q1 2024 Results Conference Call April 17, 2024 9:00 AM ET Company Participants Mike Comilla - Vice President, Investor Relations Robert Ford - Chairman and Chief Executive Officer Phil Boudreau - Senior Vice President, Finance and Chief Financial Officer Bob Funck - Executive Vice President, Finance Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Josh Jennings - Cowen Travis Steed - BofA Securities Vijay Kumar - Evercore, ISI Joanne Wuensch - Citi Matt Miksic - Barclays Danielle Antalffy - UBS Operator Good morning, and thank you for standing by. Welcome to Abbott's First Quarter 2024 Earnings Conference Call.
- 04/17/2024
|
Q1 Earnings Review
- Pre-market futures are up slightly at this hour. Markets look to rebound off a three-day losing streak on the S&P 500 and Nasdaq; the blue-chip Dow outperformed the field yesterday, closing +0.17%.
- 04/17/2024
|
Markets Try to Shake Off April Blues
- Late March highs -- including all-time S&P levels -- have given way to profit-taking and existential concerns.
- 04/17/2024
|
Abbott (ABT) Q1 Earnings Beat Estimates, Margins Contract
- Abbott (ABT) delivers double-digit organic sales growth in its underlying base business in the first quarter of 2024.
- 04/17/2024
|
Abbott (ABT) Reports Q1 Earnings: What Key Metrics Have to Say
- Although the revenue and EPS for Abbott (ABT) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 04/17/2024
|
Abbott (ABT) Tops Q1 Earnings and Revenue Estimates
- Abbott (ABT) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $1.03 per share a year ago.
- 04/17/2024
|
Abbott beats estimates, reports a 2.2% rise in Q1 sales
- Abbott Laboratories on April 17 reported a 2.2% rise of $10 billion in its 2024 first-quarter sales which includes the impact of the anticipated decline in COVID-19 testing-related sales as compared to the previous year. Organic sales grew for the underlying base business of 10.8%, which represents the fifth consecutive quarter of double-digit growth.
- 04/17/2024
|
Abbott Labs Stock Is Slipping. Disappointing Guidance Trumps a Strong Quarter.
- Healthcare-products firm Abbott Laboratories' first-quarter earnings beat expectations, but second-quarter guidance was light.
- 04/17/2024
|
Abbott Labs first-quarter results top estimates amid strong medical device sales
- Abbott Laboratories on Wednesday reported first-quarter sales and profit that topped expectations amid strength in its medical-device business. The healthcare-products company reported first-quarter net income of $1.225 billion, or 70 cents per share, versus $1.318 billion, or 75 cents per share, a year earlier.
- 04/17/2024
|
Abbott beats quarterly profit estimates on strong medical device sales
- Abbott Laboratories beat Wall Street estimates for quarterly profit on Wednesday and raised the lower end of its forecast, as robust demand for medical procedures boosted sales of its devices, including its glucose-monitoring products.
- 04/17/2024
|
Markets Mixed as Q1 Earnings, Powell Control News Headlines
- Wednesday morning brings us more Q1 earnings reports, including from Abbott Labs (ABT) and U.S. Bancorp (USB).
- 04/16/2024
|
After Nearly A 20% Rise In Six Months Will Abbott Stock See Higher Levels Post Q1?
- Abbott (NYSE: ABT) will report its Q1 2024 results on Wednesday, April 17. We expect the company to post revenue of $9.9 billion and earnings of $0.95 on a per share and adjusted basis, aligning with the street expectations.
- 04/15/2024
|
3 Buy Rated Stocks to Consider as Earnings Approach
- Several top-rated Zacks stocks are standing out before their first-quarter earnings report next week and here are three to consider.
- 04/12/2024
|
What's in Store for Abbott Laboratories (ABT) in Q1 Earnings?
- Abbott (ABT) is likely to have progressed with its initiative to commercialize several biosimilars in emerging markets.
- 04/12/2024
|
Ahead of Abbott (ABT) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
- Evaluate the expected performance of Abbott (ABT) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
- 04/12/2024
|
7 Healthcare Stocks to Keep Your Portfolio in Tip-Top Shape
- With rising concerns in the market potentially forcing a strategic shift, investors may want to consider healthcare stocks. No matter what happens, people need access to health-related products and services.
- 04/10/2024
|
Abbott (ABT) Rises Higher Than Market: Key Facts
- The latest trading day saw Abbott (ABT) settling at $112.44, representing a +1.74% change from its previous close.
- 04/09/2024
|
HAE vs. ABT: Which Stock Is the Better Value Option?
- Investors looking for stocks in the Medical - Products sector might want to consider either Haemonetics (HAE) or Abbott (ABT). But which of these two stocks is more attractive to value investors?
- 04/09/2024
|
Abbott (ABT) Faces Low Testing Demand, Currency Headwinds
- Abbott's (ABT) core laboratory diagnostics business is gaining strength on the continued success of the Alinity suite of diagnostics instruments, along with a broad test menu offering.
- 04/08/2024
|
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
- Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- 04/08/2024
|
Abbott (ABT) Receives FDA's Approval for the TriClip TEER System
- Abbott (ABT) receives FDA nod for TriClip, a first-of-its-kind device to repair a leaky tricuspid heart valve.
- 04/05/2024
|
Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?
- Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
- 04/05/2024
|
Abbott's (ABT) i-STAT TBI Cartridge Receives FDA Approval
- Abbott's (ABT) i-STAT Alinity instrument uses whole blood to help assess patients with a suspected mild traumatic brain injury or concussion.
- 04/02/2024
|
US FDA approves Abbott's heart valve repair device
- Abbott Laboratories said on Tuesday the U.S. FDA has approved its heart valve repair device designed for patients at risk of complications or death during open-heart surgeries.
- 04/02/2024
|
Abbott (ABT) Declines More Than Market: Some Information for Investors
- Abbott (ABT) concluded the recent trading session at $112.09, signifying a -1.38% move from its prior day's close.
- 04/01/2024
|
3 Strong Buy Healthcare Stocks to Add to Your Q2 Must-Watch List
- As the number of grey-haired people rises worldwide, investors need to notice the strong-buy healthcare stocks. The need for healthcare will grow as the number of people aged 60 years and older doubles by 2050, a situation never before witnessed in the world, thanks to smaller families and longer lifespans.
- 03/29/2024
|
Abbott Hosts Conference Call for First-Quarter Earnings
- ABBOTT PARK, Ill., March 27, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2024 financial results on Wednesday, April 17, before the market opens.
- 03/27/2024
|
Abbott's (ABT) Assert-IQ Cardiac Monitor Receives CE Mark
- Abbott's (ABT) Assert-IQ ICM enables regular monitoring for abnormal heart rhythms, as well as technologies to improve data management and workflow.
- 03/27/2024
|
Abbott (ABT) Increases Despite Market Slip: Here's What You Need to Know
- In the closing of the recent trading day, Abbott (ABT) stood at $111.50, denoting a +1.35% change from the preceding trading day.
- 03/26/2024
|
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
- Zacks.com users have recently been watching Abbott Laboratories (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- 03/26/2024
|
Winning Over Wall Street: 3 Stocks Earning Overwhelming Analyst Approval
- Seasoned investors typically pay close attention to “stocks with analyst approval,” a sign of potential success and resilience in the ever-volatile equity market landscape. Currently, we are in a period of rapid technological advancements in artificial intelligence (AI) and shifting economic paradigms amid expected interest rate cuts.
- 03/26/2024
|
Abbott (ABT) Expands in Canada With First Eterna SCS Use
- Abbott's (ABT) Eterna SCS system reduces pain without causing discomfort. It leverages the BurstDR stimulation technology.
- 03/25/2024
|
This is Jim Cramer's largest stock holding
- Jim Cramer is a highly polarizing figure on the investing scene. Somewhere between a financial expert and a prime-time TV personality, Cramer has built a reputation as a dynamic, boisterous, and controversial advisor to the average American investor.
- 03/25/2024
|
Want Decades of Passive Income? 2 Stocks to Buy Now.
- Johnson & Johnson and Abbott Laboratories have impressive track records of paying and growing their dividends. Both healthcare leaders have robust businesses and exciting growth opportunities.
- 03/22/2024
|
3 Stocks to Buy Right Now for the Coming Recession
- Inflation came in much hotter than expected in February. Core services inflation, which excludes housing, rose 0.5% from January following a 0.9% increase from December.
- 03/21/2024
|
3 Resilient Stocks to Protect Your Wealth During a Recession
- As the world economy teeters on the verge of instability, three titans have survived many financial storms and emerged stronger than ever from the waves of uncertainty. Here, recognizing these business titans' strategic acumen reveals a means to protect riches.
- 03/21/2024
|
Abbott (ABT) Stock Slides as Market Rises: Facts to Know Before You Trade
- Abbott (ABT) closed at $111.50 in the latest trading session, marking a -1.47% move from the prior day.
- 03/20/2024
|
Abbott (ABT) Exceeds Market Returns: Some Facts to Consider
- In the most recent trading session, Abbott (ABT) closed at $113.16, indicating a +0.64% shift from the previous trading day.
- 03/19/2024
|
Here's Why Investors Should Retain Abbott (ABT) Stock Now
- Investors are optimistic about Abbott (ABT), led by solid prospects in the Diagnostic business and robust adoption of FreeStyle Libre.
- 03/19/2024
|
Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?
- When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
- 03/19/2024
|
Abbott (ABT) is a Top-Ranked Momentum Stock: Should You Buy?
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 03/18/2024
|
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
- Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
- 03/15/2024
|
Medical Devices ETF Hits 52-Week High: Stocks to Watch
- Historically viewed as a defensive area, health care also boasts many growth aspects and benefits from advances in technology.
- 03/13/2024
|
Abbott (ABT) Ascends But Remains Behind Market: Some Facts to Note
- In the closing of the recent trading day, Abbott (ABT) stood at $120.76, denoting a +0.47% change from the preceding trading day.
- 03/12/2024
|
General Motors' executive vice president for software and services Mike Abbott to step down
- General Motors said on Tuesday that Mike Abbott will step down as executive vice president, software and services, due to health reasons.
- 03/12/2024
|
Abbott (ABT) Registers a Bigger Fall Than the Market: Important Facts to Note
- In the most recent trading session, Abbott (ABT) closed at $120.19, indicating a -0.64% shift from the previous trading day.
- 03/11/2024
|
3 Dividend Kings of Healthcare Stocks to Buy Hand Over Fist in March
- Johnson & Johnson's stellar fundamentals make it a no-brainer. Becton, Dickinson is an underrated compounder with decades of excellence.
- 03/11/2024
|
Abbott (ABT) to Reduce Childhood Malnutrition With New Pact
- Abbott's (ABT) latest partnership supports its sustainability goal of transforming care for malnutrition and improving the lives of 3 billion people per year by the decade's end.
- 03/07/2024
|
Is Abbott Laboratories a Top Dividend Growth Stock to Buy Now?
- Dividend growth stocks have a well-earned reputation for delivering above-average returns for long-term shareholders. Abbott Laboratories, a diversified healthcare company, sports one of the fastest dividend growth rates among large-cap stocks.
- 03/07/2024
|
Why Abbott (ABT) Dipped More Than Broader Market Today
- In the most recent trading session, Abbott (ABT) closed at $118.48, indicating a -1.3% shift from the previous trading day.
- 03/05/2024
|
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock
- Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- 03/04/2024
|
Ozempic Won't Sink This Medical Device Stock's Prospects -- Quite the Opposite
- Abbott's most important franchise works well in combination with weight-loss treatments. The company is also looking to address another problem these medicines create.
- 03/03/2024
|
Nearing Retirement? These Stocks Are as Cautious as They Come
- UnitedHealth is a central cog in U.S. healthcare. Johnson & Johnson is arguably the world's most financially secure company.
- 02/28/2024
|
Abbott Labs' Reversal Is Here - CGM Tailwinds In 2024
- Abbott Labs' Reversal Is Here - CGM Tailwinds In 2024
- 02/27/2024
|
3 Blue-Chip Stocks to Buy to Bolster Your Portfolio
- In the stock market, finding solid blue-chip stocks can lead to substantial portfolio growth. While the hype of flashy stocks often gets headlines, the steady performers driving constant returns truly boost portfolios.
- 02/26/2024
|
Could Abbott Laboratories Stock Help You Become a Millionaire?
- Abbott has delivered share price performance and passive income to investors for years. The company is diversified across healthcare businesses and sells many leading products.
- 02/26/2024
|
Abbott (ABT) Up 5.8% Since Last Earnings Report: Can It Continue?
- Abbott (ABT) reported earnings 30 days ago. What's next for the stock?
- 02/23/2024
|
Recession-Proof Riches: 7 Stocks to Buy for Bulletproof Portfolio Growth
- Investors in the vulnerable global economy constantly seek the Holy Grail: stocks immune to economic downturns. As the stock markets sway with economic and geopolitical uncertainty winds, finding those rare diamonds can feel like navigating a labyrinth blindfolded.
- 02/23/2024
|
Abbott (ABT) Increases Yet Falls Behind Market: What Investors Need to Know
- In the most recent trading session, Abbott (ABT) closed at $119.02, indicating a +0.98% shift from the previous trading day.
- 02/22/2024
|
What's Next For Abbott Stock After A 6% Rise This Year?
- Abbott (NYSE: ABT) reported its Q4 results last month, with revenues above and earnings aligning with the street estimates. The company reported revenue of $10.24 billion and earnings of $1.19 on a per-share and adjusted basis, compared to the consensus estimates of $10.19 billion and $1.19, respectively.
- 02/22/2024
|
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
- Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- 02/20/2024
|
Daily Dividend Report: Humana, Fedex, Honeywell, Coca-Cola, Abbott
- Humana announced today that its Board of Directors has declared a cash dividend to stockholders of $0.885 per share payable on April 26, 2024 to stockholders of record as of the close of business on March 29, 2024.
- 02/16/2024
|
Abbott's heart valve repair device gets FDA advisers' backing
- Advisers to the U.S. Food and Drug Administration on Tuesday backed an approval for Abbott Laboratories' heart valve repair device that is designed for patients who are at risk of complications or death during surgery.
- 02/13/2024
|
Abbott Laboratories says FDA independent panel votes to approve heart device
- Abbott Laboratories ABT, -1.06% said that a Food and Drug Administration panel voted in favor of the safety profile of its heart device TriClip.
- 02/13/2024
|
Abbott Laboratories Is the Latest Company to Get Involved in the Weight Loss Market. Here's How.
- Diabetes and obesity treatments including Ozempic, Wegovy, and Mounjaro are experiencing extraordinary demand. One unintended consequence of losing weight can be shedding muscle mass, which can be detrimental to overall health.
- 02/11/2024
|
3 Groundbreaking Healthcare Stocks to Buy for Robust Gains
- The health sector has two things to offer: new ideas and consistent returns. As a result, healthcare stocks will continue to be a good choice for investors looking for growth opportunities in 2024.
- 02/11/2024
|
How I Would Invest $1,000,000 And Live Of Dividends Forever
- Reaching retirement and having enough capital to build a dividend money machine are dreams shared by many. With life expectancy on the rise, high yield alone is no longer sufficient; we need to plan for both capital appreciation and dividend growth.
- 02/10/2024
|
US FDA staff raises no new concerns about Abbott's heart device
- The U.S. Food and Drug Administration (FDA) staff reviewers did not raise any new concerns on Friday over the safety and effectiveness of Abbott's heart valve repair device designed for patients who are at risk for surgery.
- 02/09/2024
|
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
- Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- 02/09/2024
|
7 Tremendous Dividend Stocks With Double-Digit 5-Year Growth Rates
- One mistake investors make when buying dividend stocks is chasing yield. Stocks with the highest yield could be a sign a company is struggling, which could put the yield at risk.
- 02/07/2024
|
HAE vs. ABT: Which Stock Is the Better Value Option?
- Investors looking for stocks in the Medical - Products sector might want to consider either Haemonetics (HAE) or Abbott (ABT). But which of these two stocks presents investors with the better value opportunity right now?
- 02/06/2024
|
2 Stocks to Buy Near Their 52-Week Highs
- Abbott Laboratories didn't perform well last year, but it still has bright prospects. Netflix reported strong earnings that point to plenty of growth potential ahead.
- 02/05/2024
|
2 Healthcare Dividend Kings to Buy and Hold Forever
- Abbott Laboratories and Johnson & Johnson have increased their payouts annually for 52 and 61 consecutive years, respectively. Both healthcare companies have long track records of important innovations and strong financial performances.
- 02/04/2024
|
Abbott Labs must face lawsuit over PediaSure height claims
- A judge has rejected Abbott Laboratories' effort to dismiss a New York City grandmother's lawsuit claiming it misled consumers into believing its PediaSure Grow & Gain nutrition drinks were "clinically proven" to help children grow taller.
- 02/02/2024
|
Could Abbott Labs Be the Next Big Winner in the Billion-Dollar Weight Loss Market?
- Novo Nordisk and Eli Lilly have generated billions of dollars in revenue selling weight loss drugs. Abbott Labs is launching a complementary product for those on the weight loss path.
- 02/02/2024
|
4 med tech stocks with improving prognosis for 2024
- Med tech stocks have been a mixed bag of results the last two years, with most moving within established trading ranges. The impact of COVID and its effect on procedure volumes were slow to dissipate, and the growth outlook was uncertain, leaving the market for their stock without a solid catalyst to drive it despite many trading at value levels and paying healthy dividends.
- 01/31/2024
|
Jim Cramer just bought Abbott stock: should you too?
- A near 2.0% post-earnings decline in Abbott Laboratories (NYSE: ABT) warrants an investment in the health care giant, says Jim Cramer. Cramer's bullish view on Abbott stock His Charitable Trust bought 275 shares of the medical devices company at $112 each on Monday.
- 01/29/2024
|
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
- Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
- 01/29/2024
|
Up Just 6% In 2023 Is Medtronic Stock A Better Pick Over Abbott?
- Given its better prospects, we believe Medtronic stock (NYSE: MDT) is a better pick than its peer, Abbott stock (NYSE: ABT). Abbott trades at a higher valuation multiple of 4.9x revenues vs.
- 01/29/2024
|
7 ‘AgeTech' Stocks to Profit From the Booming Longevity Market
- While it doesn't seem like it when you're young, aging happens to everyone and therefore, so-called AgeTech stocks should benefit from inevitability. A buzzword for age-related technology, this concept refers to a rapidly growing field focused on developing and applying innovative solutions to improve the lives of senior citizens.
- 01/28/2024
|
Is Abbott Laboratories (ABT) Stock Outpacing Its Medical Peers This Year?
- Here is how Abbott (ABT) and Akoya Biosciences (AKYA) have performed compared to their sector so far this year.
- 01/26/2024
|
Abbott: Strong R&D Pipeline Continues To Drive Growth; Reiterate 'Strong Buy'
- Abbott Laboratories' stock price has risen by 16.6% since October 2023, outperforming the index. The company achieved strong growth in FY23, excluding contributions from COVID testing businesses. Abbott Laboratories is providing guidance for 8-10% organic revenue growth in FY24, with a focus on overcoming challenges related to the pandemic.
- 01/26/2024
|
Abbott Laboratories on track for new highs in 2024
- Abbott Laboratories NYSE: ABT share price fell following its Q4 2023 results, but investors should be cheering the news. The decline is a response to a report that was largely as expected, with the expectation being healthcare industry normalization and return to growth.
- 01/25/2024
|
Once Slowed By Shutdown, Abbott Labs Says Baby Formula Franchise Back Leading U.S. Market
- Less than two years after a headline-grabbing shutdown of a baby formula plant in Michigan that fueled a national crisis, Abbott Laboratories has “reclaimed its previous market-leading position.”
- 01/24/2024
|
Abbott's (ABT) Q4 Earnings Match Estimates, Margins Rise
- Abbott (ABT) delivers better-than-expected revenues and in-line earnings for the fourth quarter of 2023.
- 01/24/2024
|
Q4 Earnings Roundup: ABT, GD, KMB & More
- A spot-check of early morning Q4 reports show some earnings misses and revenue beats; Tesla and others report after the close.
- 01/24/2024
|
Here's What Key Metrics Tell Us About Abbott (ABT) Q4 Earnings
- While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 01/24/2024
|
Abbott (ABT) Q4 Earnings Match Estimates
- Abbott (ABT) came out with quarterly earnings of $1.19 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.03 per share a year ago.
- 01/24/2024
|
Abbott Labs battles negative Covid-19 comparables but hits earnings targets
- Healthcare multinational Abbott Laboratories (NYSE:ABT) battled negative Covid-19-related comparables in the 2023 financial year, causing an 8.1% fall in group-wide revenues to $40.1 billion. However, organic revenues when excluding the impact of these comparables revealed steady double-digit top-line growth of 11.6%.
- 01/24/2024
|
Abbott reports solid results for its fiscal Q4
- Abbott Laboratories (NYSE: ABT) is trading down in premarket on Wednesday even though it reported solid results for its fiscal fourth quarter. Why is Abbott stock down on Wednesday?
- 01/24/2024
|
Abbott Laboratories Stock Is Down. Earnings, Sales Aren't the Problem.
- Abbott, a maker of healthcare products, posted fourth-quarter earnings in line with expectations, and beat sales estimates.
- 01/24/2024
|
Abbott's strong medical device sales helps meet quarterly profit expectations
- Abbott Laboratories on Wednesday reported a fourth-quarter profit that met Wall Street estimates as strong demand for medical devices offset lower-than-expected sales in its pharmaceuticals unit.
- 01/24/2024
|
7 Safe-Haven Stocks to Protect Your Portfolio During a Recession
- Why bother talking about safe-haven stocks for a recession when we already dodged that bullet last year? Tell me you haven't seen a Friday the 13th movie without telling me.
- 01/23/2024
|
Top Stocks to Watch as Earnings Approach
- Several expansive companies are expected to post stellar quarterly growth when they report Q4 results on Wednesday, January 24.
- 01/22/2024
|
Should You Buy Abbott Laboratories (ABT) Ahead of Earnings?
- Abbott Laboratories (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 01/22/2024
|
Seeking Clues to Abbott (ABT) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
- Beyond analysts' top -and-bottom-line estimates for Abbott (ABT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
- 01/19/2024
|
Abbott's (ABT) Innovations Aid, Macroeconomic Issues Stay
- Abbott (ABT) is successfully continuing the rollout of Alinity, the company's fully integrated and automated molecular diagnostics analyzer.
- 01/17/2024
|
What's in Store for Abbott Laboratories (ABT) in Q4 Earnings?
- Abbott Laboratories' (ABT) fourth-quarter 2023 results are likely to reflect solid base business momentum.
- 01/16/2024
|
Better Growth Stock: Abbott vs. AbbVie
- AbbVie launched about a decade ago as Abbott's spinoff of its pharmaceuticals business. Both companies have since lifted earnings into the triple digits.
- 01/16/2024
|
Abbott (ABT) Rises Higher Than Market: Key Facts
- The latest trading day saw Abbott (ABT) settling at $113.92, representing a +0.37% change from its previous close.
- 01/12/2024
|
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
- Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
- 01/12/2024
|
Final Trades: Uber, URNM, Abbott Labs and Vertex Pharma
- Brenda Vingiello, Sand Hill Global Advisors CIO, Bryn Talkington, Requisite Capital Management managing partner, Jim Lebenthal, Cerity Partners chief equity strategist, and Josh Brown, Ritholtz Wealth Management CEO, join CNBC's 'Halftime Report' to share their final trades.
- 01/11/2024
|
Abbott CEO Robert Ford: We had two objectives during COVID, help society and make company stronger
- Abbott CEO Robert Ford joins 'Mad Money' host Jim Cramer to talk lessons learned from the pandemic, quarterly earnings, weight loss drugs and more.
- 01/09/2024
|
Abbott (ABT) Advances While Market Declines: Some Information for Investors
- Abbott (ABT) closed at $112.73 in the latest trading session, marking a +0.29% move from the prior day.
- 01/09/2024
|
Abbott Laboratories (ABT) 42nd Annual J.P. Morgan Healthcare Conference Call Transcript
- Abbott Laboratories (ABT) 42nd Annual J.P. Morgan Healthcare Conference Call Transcript
- 01/09/2024
|
3 Dividend Growers Suited for Income Investors
- It's easy to understand why dividends are so cherished among investors, as they provide a passive income stream, help limit the impact of drawdowns in other positions, and allow for maximum returns through dividend reinvestment.
- 01/08/2024
|
Here's Why Investors Should Retain Abbott (ABT) Stock Now
- Investors are optimistic about Abbott (ABT) led by solid prospects in the Diagnostic business and raised guidance.
- 01/08/2024
|
Wearable Technology Market Gains Ground, 3 Stocks in Focus
- In the wearable medical devices industry, investors can keep a keen eye on stocks such as ABT, MDT and DXCM.
- 01/08/2024
|
7 Upcoming Dividend Increases, Including The 'Abbott's' And A Dividend King
- Seven stocks are expected to increase their dividends next week, including Hormel, Mastercard, Abbott Laboratories, and AbbVie.
- 01/04/2024
|
Could Abbott Laboratories Stock Help You Become a Millionaire?
- Abbott Labs has a long and successful track record of innovation and excellent performance. The company's dividend program should substantially contribute to its long-term stock returns.
- 01/03/2024
|
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
- Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- 01/01/2024
|
Investor Michael Farr is back with his top 10 stocks he's buying for 2024, and the tilt is defensive
- This year's list is a bit more defensive than in years past and has a focus on earnings growth.
- 12/28/2023
|
Abbott Laboratories: Another Healthy Dividend Hike From This Dividend King
- The most proven dividend growth stocks can be equivalent to a money tree for shareholders. Even as demand for its COVID-19 diagnostic tests continued to fall, Abbott Laboratories outpaced the analyst consensus in the third quarter. The company's interest coverage ratio through the first three quarters of 2023 was nearly 30.
- 12/28/2023
|
Silver Economy Successes: 3 Stocks Benefitting From an Aging Population
- Finding investment opportunities in tune with today's demographic trends can be challenging, but aging population stocks may be the solution. This market is booming in a world with an aging population, creating a special opportunity for investors to profit.
- 12/27/2023
|
Watch These 5 Stocks That Recently Hiked Dividends
- Investors may keep a tab on stocks like FULT, SFBS, MOS, ABT and ANDE, which have lately hiked their dividend payments.
- 12/27/2023
|
PETQ or ABT: Which Is the Better Value Stock Right Now?
- Investors looking for stocks in the Medical - Products sector might want to consider either PetIQ (PETQ) or Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks?
- 12/22/2023
|
29 Undervalued Dividend Aristocrats: December 2023
- The S&P 500 Dividend Aristocrats Index contains 67 dividend growth stocks called the Dividend Aristocrats.
- 12/22/2023
|
Better Growth Stock: AbbVie vs. Abbott Laboratories
- AbbVie is a top drugmaker that is putting its free cash flow to use lately with a couple of acquisitions. Abbott Labs has a broader, more diverse business that recently generated double-digit growth.
- 12/21/2023
|
Here's Why Abbott (ABT) Gained But Lagged the Market Today
- Abbott (ABT) reachead $108.42 at the closing of the latest trading day, reflecting a +0.33% change compared to its last close.
- 12/19/2023
|
Abbott (ABT) Rises Higher Than Market: Key Facts
- In the closing of the recent trading day, Abbott (ABT) stood at $108.06, denoting a +0.72% change from the preceding trading day.
- 12/18/2023
|
Abbott (ABT) Gains From Global Expansion Amid Macro Woes
- Abbott's (ABT) EPD business continues to witness low double-digit growth. It has successfully positioned itself as one of the best-positioned large healthcare companies in emerging markets.
- 12/18/2023
|
Dividend Income Update November 2023
- With the markets at or near all time highs, after a wild up and down 2023, I could find comfort in one thing, my dividends. As we all know, the market may move up and down irrationally and seemingly on a whim, while our dividends remain much more stable, reliable and predictable. Another four figures coming in a particular month is nothing to sneeze at. I'll definitely take it, as passive income always seems a little sweeter than active income.
- 12/15/2023
|
Abbott (ABT) Advances But Underperforms Market: Key Facts
- Abbott (ABT) concluded the recent trading session at $106.68, signifying a +0.43% move from its prior day's close.
- 12/12/2023
|
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
- Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
- 12/12/2023
|
2 Healthcare Stocks to Buy Hand Over Fist in December
- Abbott Labs has a strong brand name and solid growth avenues despite coronavirus-related issues. Intuitive Surgical's dominance in robotic-assisted surgery is an excellent sign for the company's future.
- 12/08/2023
|
Abbott (ABT) Advances While Market Declines: Some Information for Investors
- In the closing of the recent trading day, Abbott (ABT) stood at $104.94, denoting a +0.57% change from the preceding trading day.
- 12/06/2023
|
Abbott Laboratories: A 'Must-Have' In A Defensive Dividend Growth Portfolio
- In 2023, AI and the Magnificent 7 took the lead, leaving non-tech blue chip companies trailing behind in the rearview mirror. Abbott Laboratories had a difficult last three years, with its stock price trading sideways as sales driven by COVID-19 plummeted. Yet, Abbott operates a recession-proof business model with long-term tailwinds, its core business growing at double digits.
- 12/03/2023
|
Abbott (ABT) Rises Higher Than Market: Key Facts
- Abbott (ABT) closed the most recent trading day at $104.29, moving +0.64% from the previous trading session.
- 11/30/2023
|
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
- Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
- 11/28/2023
|
Here's Why Investors Should Retain Abbott (ABT) Stock Now
- Investors are optimistic about Abbott (ABT) driven by expansion in the global market and raised guidance.
- 11/27/2023
|
Abbott Laboratories: One Of The Safest Dividend Growth Stocks On The Market
- Abbott Laboratories is a stable investment in challenging times, with an AA- credit rating and a history of surviving economic downturns. ABT has a well-diversified healthcare portfolio, including diagnostics, medical devices, and pharmaceuticals, positioning it to address evolving healthcare challenges. Despite a temporary stock dip, ABT has shown robust financial performance with impressive growth across segments, reflecting resilience and sales expansion.
- 11/25/2023
|
PETQ vs. ABT: Which Stock Should Value Investors Buy Now?
- Investors with an interest in Medical - Products stocks have likely encountered both PetIQ (PETQ) and Abbott (ABT). But which of these two stocks offers value investors a better bang for their buck right now?
- 11/20/2023
|
Ozempic Might Be Helping Abbott Laboratories and DexCom Stock. Here's How.
- Ozempic could lead to patients needing to buy fewer interventions for diabetes. It could also do the same for certain cardiovascular interventions.
- 11/20/2023
|
Abbott rumored to endorse Trump during border visit
- Rep. Carlos Gimenez, R-Fla., discusses former President Donald Trump's upcoming trip to Texas on 'The Evening Edit.
- 11/17/2023
|
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
- Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- 11/15/2023
|
Who's afraid of Ozempic? From restaurants to package makers, companies work to calm investors' GLP-1 jitters.
- That's the message from many corporate executives who have lately been peppered with questions about how Wegovy, Ozempic and other drugs widely used for weight loss may impact their bottom line.
- 11/10/2023
|
15 stocks with the closest US government connections
- Quiver Quantitative, the pioneering company behind an alternative data platform designed for retail investors, has been actively tracking stock market trades made by US Congress members and other political figures. Some of the trades have been notably controversial, mainly due to their timing or because they violated federal laws.
- 11/09/2023
|
Abbott India's Q2 profit climbs on strong sales
- Abbott India , the local unit of U.S. healthcare firm Abbott Laboratories , reported a 17.7% rise in second-quarter profit on Thursday, driven by strong sales in its mainstay pharmaceuticals segment.
- 11/09/2023
|
2 Medical Device Companies Experiencing Strong Demand Even as Weight-Loss Drugs Rise in Popularity
- The rise of weight-loss treatments has some investors worried about demand for certain medical devices. Yet, DexCom and Abbott Labs still see strong sales for their continuous glucose monitoring devices.
- 11/08/2023
|
3 Dividend Kings to Buy for Royal Returns
- Investing in the stock market is a journey of both patience and foresight. Dividend kings reign supreme in this realm, offering high-yield dividends and long-term investment opportunities.
- 11/06/2023
|
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
- Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
- 11/03/2023
|
1 Stock Down 15% This Year to Buy and Hold Forever
- Abbott Labs' sales have fluctuated in recent years, but its underlying business is solid. Its most important unit should continue performing well despite competitive pressures.
- 11/02/2023
|
Abbott Labs Vs. Thermo Fisher: Which Is The Better Healthcare Stock?
- Thermo Fisher and Abbott are two of our key Healthcare holdings in our fund, and both are among our top 10 holdings overall. Abbott and Thermo Fisher focus on different industries which are Healthcare Equipment and Life Science Tools respectively. Both show strong revenue growth compared to the market average growth rate which indicates that both companies exhibit competitive advantages within their respective main markets.
- 11/01/2023
|
FDA issues warning letter to Abbott for probiotic products for infants
- The U.S. Food and Drug Administration said on Thursday it has issued a warning letter to Abbott Laboratories for the company's probiotic products sold under the brand Similac Probiotic Tri-Blend for use in hospitalized preterm infants.
- 10/26/2023
|
ZBH or ABT: Which Is the Better Value Stock Right Now?
- Investors looking for stocks in the Medical - Products sector might want to consider either Zimmer Biomet (ZBH) or Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks?
- 10/25/2023
|
5 Stocks to Watch on Solid Revenues in Last Reported Quarter
- We have narrowed our search to five U.S. corporate behemoths. These are: JPM, UNH, PG, ABT, FCX.
- 10/25/2023
|
Are These 3 Dividend Aristocrats Undervalued Hidden Gems?
- If you look at MarketBeat's list of dividend aristocrats, you'll see a select group of publicly traded companies that have an outstanding track record of consistently increasing their dividend payouts for at least 25 consecutive years.
- 10/25/2023
|
Abbott Laboratories May Soon Launch a Game-Changing New Device in the U.S.
- Abbott Laboratories' business has underwhelmed investors in 2023, as testing numbers are down big. Growth in its medical devices was the only bright spot in the company's recent earnings report.
- 10/24/2023
|
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock
- Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
- 10/23/2023
|
The Value Deepens for Medtech Stocks: Reversal Imminent
- Results from Johnson & Johnson NYSE: JNJ and Abbott Laboratories NYSE: ABT foreshadow good news for MedTech investors. Both companies outperformed on the top and bottom lines, driven by broad strength in their MedTech units.
- 10/23/2023
|
Abbott Labs: Fear Is In The Air - That's Why I'm Bullish
- Abbott Laboratories reported solid growth across all segments in its third-quarter results, excluding its COVID diagnostics portfolio. The company's medical devices business, which includes its Diabetes Care portfolio, grew almost 29% in Q3 despite fears of competition from GLP-1 drugs.
- 10/20/2023
|
7 Blue-Chip Stocks to Buy on the Dip
- While there are many ways to position yourself in the market during this ambiguous juncture, one of the most straightforward approaches involves targeting blue-chip stocks to buy on the dip. By definition, blue chips represent industry stalwarts with strong financial backbones.
- 10/19/2023
|
Abbott Earnings Show Obesity Drug Worries Are Overblown
- CEO Robert Ford said more users of its glucose monitoring system were using the device while also taking new obesity drugs.
- 10/19/2023
|
'We don't see' weight-loss drugs impacting medical devices' sales, says Abbott CEO Robert Ford
- Robert Ford, Abbott chairman and CEO, joins 'Closing Bell Overtime' to talk Q3 earnings, the impact of weight loss drugs on their product and more.
- 10/18/2023
|
Abbott (ABT) Q3 Earnings and Revenues Surpass, Margins Dip
- Abbott (ABT) reports solid underlying base business performance in the third quarter of 2023.
- 10/18/2023
|
Geopolitical Conflicts in Middle-East in Focus
- Geopolitical Conflicts in Middle-East in Focus.
- 10/18/2023
|
Abbott Laboratories 3Q earnings top estimates on strong medical devices sales growth
- Abbott Laboratories (NYSE:ABT) shares rose after the healthcare technology company posted a third quarter earnings beat and provided strong full-year guidance. While revenue decreased 2.8% year-over-year to $10.1 billion due to the expected decline in COVID-19 testing-related sales, it topped Street expectations of $9.8 billion.
- 10/18/2023
|
Abbott (ABT) Beats Q3 Earnings and Revenue Estimates
- Abbott (ABT) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $1.10 per share. This compares to earnings of $1.15 per share a year ago.
- 10/18/2023
|
Oversold and Overextended, Abbott Laboratories is a Great Buy
- Abbott Laboratories NYSE: ABT share price has trended lower for nearly 2 years, but that trend is over. The impact of COVID on sales and the post-COVID letdown were cause enough for the market to sell, but not now; the market is oversold and overextended with normalization at hand.
- 10/18/2023
|
Abbott Raises Outlook, Boosted By 'Whopping' Growth Of Diabetes Device
- Abbott stock rose moderately Wednesday after the company beat third-quarter expectations and raised the midpoint of its earnings view.
- 10/18/2023
|
Abbott Stock Is Rising. Earnings Beat and Guidance Was Strong.
- Healthcare-products firm Abbott beat third-quarter estimates despite a drop in sales of Covid-19 testing kits. It raised the midpoint of earnings guidance for the year.
- 10/18/2023
|
Abbott Labs shares rise as company beats earnings estimates, raises full-year guidance
- Abbott Laboratories shares ABT, -0.04% climbed 2.5% premarket on Wednesday after the healthcare products company posted a better-than-expected third-quarter profit and raised its earnings guidance for the full year. The company reported third quarter net income of $1.436 billion, or 82 cents per share, versus $1.435 billion, or 81 cents per share, in the year earlier period.
- 10/18/2023
|
Abbott beats profit estimates on strong sales of devices, diagnostics
- Abbott Laboratories on Wednesday tightened its profit forecast for the year after beating estimates for third-quarter earnings due to strong demand for its medical devices and diagnostics products.
- 10/18/2023
|
Should You Buy Abbott (ABT) Ahead of Earnings?
- Abbott (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 10/16/2023
|
Which Is A Better Pick – Abbott Stock Or Amgen?
- There is more to the comparison, and in the sections below, we discuss why we believe ABT will offer better returns than AMGN in the next three years.
- 10/16/2023
|
Will Abbott (ABT) Beat Estimates Again in Its Next Earnings Report?
- Abbott (ABT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 10/13/2023
|
My Top Buy Dividend King And Dividend Aristocrat
- My Top Buy Dividend King And Dividend Aristocrat
- 10/13/2023
|
3 Reasons to Buy Abbott Laboratories Stock
- Abbott Laboratories' diabetes care business looks highly promising. The company's diversified operations provide some safety and stability.
- 10/11/2023
|
As Covid testing business drops, Abbott searches for new line of business with consumer wearables
- Abbott is working to bring a new glucose-tracking wearable called Lingo to U.S. consumers next year
- 10/10/2023
|
What's in Store for Abbott Laboratories (ABT) in Q3 Earnings?
- Abbott Laboratories' (ABT) third-quarter 2023 results are likely to reflect solid underlying base business organic sales growth.
- 10/10/2023
|
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
- Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- 10/09/2023
|
HLN vs. ABT: Which Stock Is the Better Value Option?
- Investors interested in stocks from the Medical - Products sector have probably already heard of Haleon PLC Sponsored ADR (HLN) and Abbott (ABT). But which of these two stocks is more attractive to value investors?
- 10/06/2023
|
(ABT) Ascends While Market Falls: Some Facts to Note
- Abbott (ABT) closed at $96.20 in the latest trading session, marking a +0.58% move from the prior day.
- 10/05/2023
|
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
- These three companies have a proven ability to develop innovative products in the healthcare field. All three have performed poorly on the market over the past year, but their prospects remain intact.
- 10/01/2023
|
Final Trades: Abbott Labs, Yields & more
- The "Halftime Report" traders give their top picks to watch for the second half.
- 09/28/2023
|
Abbott (ABT) Rides on Nutrition Recovery Amid Low Testing Sales
- Abbott's (ABT) Nutrition business has started showing signs of recovery since the beginning of 2023.
- 09/28/2023
|
After Plunging -8.5% in 4 Weeks, Here's Why the Trend Might Reverse for Abbott (ABT)
- The heavy selling pressure might have exhausted for Abbott (ABT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- 09/28/2023
|
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
- Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- 09/27/2023
|
Here's Why Investors Should Invest in Abbott (ABT) Stock Now
- Investors are optimistic about Abbott (ABT) on strong growth in the Diagnostics business and upbeat guidance.
- 09/26/2023
|
5 Dividend Aristocrats to Buy as Things Look Dicey for Wall Street
- As stocks are subjected to bouts of volatility, place bets on dividend aristocrats like Caterpillar (CAT), Abbott Laboratories (ABT), McDonald's (MCD), Aflac (AFL) and Automatic Data Processing (ADP) for steady income.
- 09/26/2023
|
2 Stocks to Benefit from the Aging Population
- While the direction of the stock markets is unpredictable, the growth of the aging population is entirely predictable. Along with an aging population come additional healthcare, beauty and wellness needs.
- 09/26/2023
|
Abbott (ABT) Closes Acquisition Deal of Bigfoot Biomedical
- Abbott's (ABT) footprint in the diabetes care market is increased by the Bigfoot Biomedical acquisition.
- 09/25/2023
|
3 Best Stocks to Buy in September and Hold Forever
- Kenvue is poised to make its mark as a great business with a new name. Abbott Labs has long-term upside in key healthcare end markets.
- 09/24/2023
|
Abbott Stock: Bear vs. Bull
- The company has grown revenue for more than a decade. However, 2023 has been a challenge as Covid testing ebbs.
- 09/23/2023
|
Abbott India warns of potential laxative syrup shortages amid production halt
- Abbott Laboratories' Indian unit has cautioned about potential shortages of two popular laxative syrups, Cremaffin and Duphalac, due to a production halt in India's Goa state.
- 09/22/2023
|
Abbott India warns of laxatives shortage in tussle with Goa regulator
- Abbott Laboratories' Indian unit has warned of potential supply shortages of two popular laxative syrups after production was prohibited in India's Goa state, where drug inspectors have found lapses at a company factory, a letter shows.
- 09/22/2023
|
All You Need to Know About Abbott (ABT) Rating Upgrade to Buy
- Abbott (ABT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 09/20/2023
|
Abbott (ABT) Broadens Electrophysiology Footprint With TactiFlex
- The successful deployment of Abbott's (ABT) TactiFlex Ablation Catheter, Sensor Enabled in Canada broadens the company's global footprint in the electrophysiology space.
- 09/20/2023
|
Abbott (ABT) Unveils Connected Diabetes App With New Pact
- Abbott's (ABT) FreeStyle Libre portfolio is the world's top sensor-based CGM system, changing the lives of over 5 million people.
- 09/20/2023
|
Abbott Laboratories: Buy This Fairly Valued Dividend King For Consistently Rising Income
- Abbott's adjusted diluted EPS payout ratio is going to expand significantly from the mid-30% range in 2022 to the mid-40% range in 2023. Reduced demand for COVID-19 testing saw the healthcare company's revenue and adjusted diluted EPS shrink in the first half of 2023. Abbott's interest coverage ratio was just shy of 30 through the first six months of 2023.
- 09/17/2023
|
2 Dividend Kings to Buy on the Dip and Hold Forever
- Abbott Laboratories and AbbVie used to be one and the same company. Both have raised their payouts for 51 years in a row, making them Dividend Kings.
- 09/15/2023
|
Could Abbott Laboratories Stock Help You Become a Millionaire?
- For an investment to reach $1 million, you need to consider how much you're willing to invest and for how long. Abbott Laboratories is a top healthcare company that has grown to a valuation of nearly $180 billion.
- 09/15/2023
|
Goa state warns Abbott India on antacid license suspension
- India's Goa state has warned the local unit of Abbott Laboratories it plans to suspend the manufacturing license of its popular antacid medicine after inspectors flagged contamination risks and sanitization issues at its factory, government documents show.
- 09/14/2023
|
Is Abbott Laboratories a Buy?
- Abbott Laboratories isn't a rapidly growing stock. But the steady growth of its dividend can add up over time.
- 09/12/2023
|
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
- Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- 09/11/2023
|
September Rally? 3 Healthcare Stocks to Buy Before Liftoff.
- With inflation taking center stage once again, it's becoming clear that consumers are prioritizing wants and needs. One of those “non-discretionary” expenses is healthcare, which makes it a good time to look for healthcare stocks to buy.
- 09/08/2023
|
The 3 Best Pharma Stocks to Buy Now: September 2023
- The pharmaceutical sector will always be a sector in constant evolution and growth. As technology advances, the companies that make life in this sector will always be applying it, as well as implementing new processes, new combinations, and new formulas, always with the aim of being able to make medicines and treatments much more effective and efficient for all of us.
- 09/08/2023
|
Abbott (ABT) to Advance Diabetes Care With New Acquisition
- Abbott's (ABT) recent deal will enable it to create more interconnected solutions to improve the personalization and accuracy of diabetes control.
- 09/06/2023
|
Is Abbott Stock A Better Healthcare Pick Over Thermo Fisher Scientific?
- There is more to the comparison, and in the sections below, we discuss why we believe that TMO will offer better returns than ABT in the next three years.
- 09/06/2023
|
Down 10.3%, Is Abbott Laboratories Stock a Buy on the Dip?
- Shares of Abbott Laboratories have fallen by more than 10% from the high point they reached in July. The company has a remarkable track record of 50 consecutive years of annual dividend raises.
- 09/05/2023
|
Abbott's (ABT) New Positive Data Favors OCT in Stent Implantation
- Abbott's (ABT) latest late-breaking data reflects OCT's potential to improve clinical practice related to stent placement.
- 09/04/2023
|
Abbott's (ABT) Libre Gains Momentum Amid Low Testing Sales
- Banking on the successful execution of Abbott's (ABT) branded generic operating model, EPD is well positioned for sustained growth in many of the growing pharmaceutical markets.
- 08/31/2023
|
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
- Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- 08/29/2023
|
U.S. Credit Rating Concerns? Here Are 3 Stocks to Protect Your Portfolio
- Fear is back in the air. On August 8, 2023, Moody's rating agency downgraded central U.S. banks due to weaker profits and increased funding risks.
- 08/24/2023
|
Which Is A Better Buy – Boston Scientific Stock Or Abbott?
- Sharpe is a measure of return per unit of risk, and high-performance portfolios can provide the best of both worlds.
- 08/24/2023
|
Want Growing Passive Income? This Dividend King Could Be a Smart Buy
- Abbott Labs is positioned to recover from sharply lower demand for its COVID-19 tests. Other products like its FreeStyle Libre continuous glucose monitor should help rev up results.
- 08/23/2023
|
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
- Abbott Laboratories is positioned to profit from important growth opportunities. Intuitive Surgical has only begun to tap the market for robotic-aided surgery.
- 08/19/2023
|
Down 4% to 17%, These Monster Dividend Stocks Could Be Picking Up Steam
- Altria is aiming to have its smoke-free portfolio bringing in $5 billion in revenue by 2028. 3M has increased its yearly dividend for 65 straight years.
- 08/19/2023
|
Abbott (ABT) Gains in Core Diagnostics With FDA Nod for Alinity H
- Abbott's (ABT) Alinity h-series not only delivers technological innovation but also addresses the realistic challenges faced by modern healthcare systems.
- 08/15/2023
|
2 Blue Chip Dividend Stocks That Are Top Buys in August
- Blue chip dividend stocks can be outstanding picks for investors with a long-term outlook. Abbott Laboratories and Bristol Myers Squibb are two top-shelf pharma stocks that stand out from the crowd.
- 08/14/2023
|
Here's Why Investors Should Retain Abbott (ABT) Stock Now
- Investors are optimistic about Abbott (ABT) on its strategic expansion in the global market and recovery within the Nutrition segment.
- 08/14/2023
|
Abbott (ABT) EPD Arm Grows, Low Testing Sales Play Spoilsport
- Banking on the successful execution of Abbott's (ABT) branded generic operating model, EPD is well positioned for sustained growth in many of the growing pharmaceutical markets.
- 08/14/2023
|
2 Best Healthcare Stocks to Buy Right Now
- Abbott Laboratories and Humana are both leaders in their respective industries with respectable growth potential. The two companies each pay safe and growing dividends to shareholders.
- 08/14/2023
|
Avricore Health says HealthTab inks reseller deal with Abbott to support UK expansion
- Avricore Health (TSX-V:AVCR, OTC:AVCRF) Inc has announced the signing of a reseller agreement between HealthTab Inc, the company's point-of-care testing solution, and Abbott Rapid Dx UK & Ireland. The pharmacy service innovator said the agreement provides a foundation for HealthTab to purchase and distribute the Afinion 2 and associated tests for diabetes and heart disease screening in community pharmacies in the UK.
- 08/08/2023
|
2 Top Stocks to Buy in August and Hold Forever
- Both of these companies are proven innovators in a necessary industry. Regeneron has two major products and a solid pipeline to drive excellent results.
- 08/06/2023
|
Does Abbott Laboratories' Dividend Make It a Buy?
- Abbott Labs is one of the most consistent dividend stocks you'll find. It can afford to keep hiking its payout for the foreseeable future.
- 08/04/2023
|
Abbott Labs Vs AbbVie: Which One Is The Best Investment Choice?
- Abbott Labs spun off AbbVie in 2013. AbbVie has lost patent protection on its largest selling product Humira. AbbVie has better financial metrics and dividends.
- 08/03/2023
|
Two Dividend Aristocrats With Unappreciated AI Upside
- Artificial Intelligence (AI) is generating a lot of hype on Wall Street, with investors eager to capitalize on its potential. Companies that have been utilizing AI for years are well-positioned to benefit from its commercial success and heightened interest. Mature companies with data-centric business models, such as Abbott Laboratories and S&P Global, could see significant upside from AI.
- 08/03/2023
|
4 Medical Product Stocks to Buy Amid Recovering Prospects
- Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. ABT, SYK, ZBH and HAE are well poised to gain from the favorable factors.
- 07/31/2023
|
Abbott: This Dividend King Is Ready For Takeoff
- Healthcare investing provides opportunities with wide moats and long-term potential in companies like Abbott Laboratories. ABT's four major segments, including Medical Devices and Diagnostic Products, address key health issues and show impressive organic sales growth. With a positive earnings outlook and attractive valuation, ABT offers the potential for long-term outperforming returns in the healthcare industry.
- 07/31/2023
|
Magnetar Financial LLC Reduces Stake in MedTech Acquisition Corp
- On July 25, 2023, Magnetar Financial LLC (Trades, Portfolio), a renowned investment firm, reduced its stake in MedTech Acquisition Corp ( MTACU , Financial). This article provides an in-depth analysis of the transaction, the profiles of both the firm and the traded company, and the potential implications for value investors.
- 07/27/2023
|
3 Ultrareliable Dividend Stocks to Buy and Hold for Decades
- Now that Johnson & Johnson no longer sells consumer goods, it's poised to grow, along with sales of pharmaceuticals and medical technology. Medtronic's dominance in the medical device industry has allowed it to raise its dividend payout for 46 consecutive years.
- 07/24/2023
|
Abbott Laboratories 2Q profit tops expectations driven by strong medical devices sales
- Abbott Laboratories (NYSE:ABT) shares surged on Thursday after the company posted a second-quarter earnings beat driven by strong demand for its medical devices as surgery volumes increase. Its adjusted earnings per share of $1.08 topped the Street's expectation of $1.05.
- 07/20/2023
|
Abbott Laboratories (ABT) Q2 2023 Earnings Call Transcript
- Abbott Laboratories (NYSE:ABT ) Q2 2023 Earnings Conference Call July 20, 2023 9:30 AM ET Company Participants Mike Comilla - Vice President, Investor Relations Robert Ford - Chairman and Chief Executive Officer Bob Funck - Executive Vice President, Finance and Chief Financial Officer Conference Call Participants Joshua Jennings - TD Cowen Larry Biegelsen - Wells Fargo Danielle Antalffy - UBS Vijay Kumar - Evercore ISI Joanne Wuensch - Citi Marie Thibault - BTIG Matt Miksic - Barclays Jayson Bedford - Raymond James Operator Good morning and thank you for standing by. Welcome to Abbott's Second Quarter 2023 Earnings Conference Call.
- 07/20/2023
|
Abbott (ABT) Q2 Earnings & Revenues Beat Estimates, Down Y/Y
- Abbott Laboratories ABT reported second-quarter 2023 adjusted earnings of $1.08 per share, which topped the Zacks Consensus Estimate by 3.8%. However, the adjusted figure declined from the prior-year quarter's levels by 24.5%.
- 07/20/2023
|
Stock movers July 20, 2022: Johnson & Johnson, Kenvue, and Abbott Labs
- Johnson & Johnson, Kenvue, and Abbott Labs posted second quarter results that topped analyst estimates. Yahoo Finance Live anchors break down the market reaction to the report.
- 07/20/2023
|
Abbott Laboratories Has the Prescription for Higher Share Prices
- Abbott Laboratories NYSE: ABT is a tale of two stories. The first is its recovery from the COVID-19 boost and bubble.
- 07/20/2023
|
Abbott (ABT) Q2 Earnings and Revenues Surpass Estimates
- Abbott (ABT) came out with quarterly earnings of $1.08 per share, beating the Zacks Consensus Estimate of $1.04 per share. This compares to earnings of $1.43 per share a year ago.
- 07/20/2023
|
Abbott Labs' stock up 1.6% premarket after earnings fall but still top analyst estimates
- Abbott Laboratories' stock ABT, +0.31% rose 1.6% in premarket trade Thursday, after the diagnostics and medical-device company posted earnings that were lower than a year ago but ahead of analyst estimates. The company had net income of $1.375 billion, or 78 cents a share, for the quarter, down from $2.018 billion, or $1.14 a share, in the year-earlier period.
- 07/20/2023
|
Abbott beats quarterly profit estimates on demand for medical devices
- Abbott Laboratories on Thursday reported second-quarter profit above expectations, due to recovery in surgical procedure volumes and demand for its diabetes care devices.
- 07/20/2023
|
Our Dividend Growth Portfolio Continues To Outpace The S&P 500
- In 2015, I purchased 15 of the largest cap U.S. dividend achievers, which have continued to outpace the S&P 500. The portfolio was designed to provide greater protection during recessions and severe bear markets, and began to pull away from the S&P 500 after the world changed in 2020. The portfolio is 55% U.S. stocks and 45% Canadian stocks, with modest allocations to bonds, cash, gold and bitcoin, and a few thematic plays in the electric vehicle and battery space.
- 07/19/2023
|
2 Medical Stocks to Buy as Earnings Approach
- Among the broader healthcare space, Abbott Laboratories (ABT) and Intuitive Surgical (ISRG) are two medical stocks that will highlight this week's earnings lineup.
- 07/18/2023
|
10 Dividend Growth Stocks For July 2023
- The article presents a monthly series of 10 top-ranked dividend growth stocks for further research and potential investment. The stocks are ranked based on quality scores, with tie-breaking metrics including dividend safety scores, credit ratings, and forward dividend yield. The top three stocks for this month are Visa, UnitedHealth, and Intercontinental Exchange. The article also provides key metrics and fair value estimates for each stock, and suggests that Tractor Supply Company passes all selection criteria for adding new positions to the author's DivGro portfolio.
- 07/15/2023
|
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
- Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- 07/14/2023
|
5 Stocks to Buy Ahead of Q2 Earnings Next Week
- We have narrowed our search to five companies that are set to declare second-quarter earnings results next week. These are: GPC, ABT, AN, SNA, PPG.
- 07/13/2023
|
ABT vs. LMAT: Which Stock Should Value Investors Buy Now?
- Investors interested in Medical - Products stocks are likely familiar with Abbott (ABT) and LeMaitre Vascular (LMAT). But which of these two stocks offers value investors a better bang for their buck right now?
- 07/12/2023
|
Lower Testing Demand To Weigh On Abbott's Q2?
- Abbott will see a decline in sales given the forex headwinds and lower Covid-19-related testing demand.
- 07/12/2023
|
Abbott (ABT) Gets FDA Approval for AVEIR DR Leadless Pacemaker
- Abbott (ABT) receives FDA approval for the AVEIR DR leadless pacemaker system, featuring the proprietary i2i technology.
- 07/06/2023
|
Will Abbott (ABT) Beat Estimates Again in Its Next Earnings Report?
- Abbott (ABT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 07/05/2023
|
Abbott Laboratories Is A Hold Due To Its High Valuation
- I analyzed Abbott Laboratories, a healthcare company with a diversified portfolio that includes pharmaceuticals, diagnostic products, nutritional products, and medical devices. I believe Abbott has potential growth opportunities in diabetes care and cardiovascular diseases, with significant worldwide exposure allowing for increased sales in various markets. However, the company faces risks such as declining demand for Covid tests, competition, and a high valuation. In my opinion, shares of Abbott Laboratories are HOLD due to their high valuation. The shares would be attractive at a P/E ratio of 16-17 or a P/E ratio of 19 once the company returns to its growth path.
- 06/29/2023
|
Abbott (ABT) EPD Sales Aid Growth Amid Currency Headwind
- Abbott (ABT) continues to make good progress, increasing manufacturing production and recovering market share in the Nutrition business.
- 06/27/2023
|
Here's Why Investors Should Retain Abbott (ABT) Stock Now
- Investors are optimistic about Abbott (ABT) on continued growth in Diabetes business and upbeat guidance.
- 06/26/2023
|
Abbott (ABT) FreeStyle Libre 2 Gets Reimbursement in France
- Abbott's (ABT) FreeStyle Libre increased reimbursement makes it possible for more people in France with diabetes to use the recent CGM technology.
- 06/23/2023
|
Abbott Laboratories: Offers Promising Buying Opportunity (Technical Analysis)
- Abbott Laboratories: Offers Promising Buying Opportunity (Technical Analysis)
- 06/23/2023
|
Abbott (ABT) Just Overtook the 50-Day Moving Average
- Abbott (ABT) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ABT broke out above the 50-day moving average, suggesting a short-term bullish trend.
- 06/23/2023
|
Will Abbott Stock Rebound To Its 2022 Highs?
- The stock has gained 10% since September 2022 compared to the S&P 500, which gained about 23% during this period.
- 06/21/2023
|
3 Passive Income Stocks to Hold for the Next 20 Years
- Abbott has a solid diagnostics and medical-devices portfolio and ranks as a Dividend King. Nike is a sports apparel and footwear leader that has increased its dividend for the past 15 years.
- 06/20/2023
|
Dividend Income Update May 2023
- Without rehashing the wild ride we experienced in the market so far in 2023, I could find comfort in one thing, my dividends. Hitting the elusive four-digit mark in May has been a welcome sign for me on my dividend growth journey. In May 2022 I brought in $862.43 and this May I have seen a year over year increase of 23.8%.
- 06/19/2023
|
Abbott (ABT) EPD Sales Gain Traction, Margin Pressure Lingers
- Abbott (ABT) continues to make good progress in Nutrition, increasing manufacturing production and recovering market share in this business.
- 06/12/2023
|
Abbott (ABT) Is Considered a Good Investment by Brokers: Is That True?
- The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
- 06/07/2023
|
2 Dividend Kings Down 12% and 14% You'll Regret Not Buying on The Dip
- Abbott Labs and Johnson & Johnson have raised their payouts for 51 and 60 consecutive years, respectively. Both companies have solid businesses and a proven ability to be successful in the tricky healthcare industry.
- 06/04/2023
|
Abbott accuses one of its former scientists of trade-secrets theft in US court
- Healthcare company Abbott Laboratories on Tuesday sued one of its former scientists, accusing him in U.S. court of "secretly downloading" sensitive corporate files containing competitive information about nutrition products.
- 05/31/2023
|
Abbott (ABT) Reports Upbeat Cardiomems Sensor Study Result
- Abbott's (ABT) MONITOR-HF is the third randomized, controlled trial that will provide significant health benefits to indicated heart failure patients.
- 05/30/2023
|
Buy Alert: 3 Undervalued High-Yield Gems For Your Retirement
- This article discusses three high-yielding stocks for retirees and income-oriented investors: ONEOK, AbbVie, and Realty Income. ONEOK is a cyclical income play with a 6.5% yield, AbbVie offers a high-quality healthcare yield of 4.2%, and Realty Income provides steady and reliable dividend growth with a 5.2% yield.
- 05/26/2023
|
How Dexcom and Abbott are moving beyond diabetes with blood sugar monitoring
- CNBC spoke with both Abbott and Dexcom about the technology inside continuous glucose monitors and how they see the technology expanding.
- 05/26/2023
|
Medical technology is a good space for cover in recession times, says Mizuho's Anthony Petrone
- Anthony Petrone, senior medical devices analyst at Mizuho, joins 'The Exchange' to discuss medical technology gaining share, the bull case for Medtronic, and how medication advancements could impact the medtech sector.
- 05/24/2023
|
Abbott (ABT) Unveils Late-Breaking Data on Leadless Pacemaker
- Abbott (ABT) study analyzes primary safety and efficacy endpoints in the first 300 people enrolled across 55 centers in the United States, Canada and Europe.
- 05/24/2023
|
FTC Investigates Abbott For Alleged Collusion in Federal Baby Formula Contract Bids
- Abbott, the nation's largest maker of infant formula, is being investigated by the Federal Trade Commission for potentially anti-competitive federal nutrition program bids.
- 05/24/2023
|
10 A-Rated Dividend Aristocrats For The Ultimate High-Yield SWAN Portfolio
- The debt ceiling crisis is coming down to the wire. We're possibly already out of time to prevent default and just don't know it. UBS estimates a short default could create a 20% bear market and a one-month default could lead to a 44% crash.
- 05/24/2023
|
Abbott, other formula makers face FTC investigation for collusion - WSJ
- The U.S. Federal Trade Commission is investigating whether baby-formula makers colluded on bids for attractive state contracts, the Wall Street Journal reported on Wednesday.
- 05/24/2023
|
Abbott Laboratories: A Mixed, Yet Expensive Bag
- Abbott Laboratories is suffering from a reversal of pandemic trends and its own issues around pediatric nutrition. This creates a tough setup for 2023, as valuations remain demanding.
- 05/22/2023
|
Judge tosses some claims in Abbott baby formula litigation
- Abbott Laboratories persuaded a federal judge to dismiss some claims in nationwide litigation over recalled baby formula.
- 05/22/2023
|
Abbott (ABT) Expands in Electrophysiology With New FDA Nod
- Abbott (ABT) notes that using TactiFlex catheter can lead to reduced procedure times and better safety compared to the company's previous generation catheters.
- 05/22/2023
|
Abbott's (ABT) New Pact to Advance Clinical Trials Diversity
- Abbott's (ABT) latest additions to Diversity in Clinical Trials effort expand upon the alliances, awards and the emphasis on diverse participation in its own clinical trials.
- 05/15/2023
|
Which Healthcare Stock Is A Better Pick: Abbott Or This Robotic Products Company?
- There is more to the comparison, and in the sections below, we discuss why we believe ISRG stock will offer higher returns than ABT stock in the next three years.
- 05/15/2023
|
Investing for the Long-Term? Here are 7 Must-Have Dividend Stocks
- Warren Buffett is credited with saying that his preferred length of time for owning a stock is forever. To give credit where credit is due, the Oracle of Omaha does put his money where his mouth is.
- 05/14/2023
|
Abbott (ABT) EPD Business Grows Strong, Macro Issues Stay
- Abbott (ABT) continues to make good progress, increasing manufacturing production and recovering market share in the Nutrition business.
- 05/08/2023
|
3 Dividend Stock Warning Signs That Could Portend Trouble
- Sharply rising payout ratios and negative payout ratios are both big red flags. The slowing or pausing of annual dividend growth is a major warning sign.
- 05/06/2023
|
Only 2 Companies Are AAA Rated As U.S. Risks Being A Deadbeat
- Lawmakers are playing chicken with the debt ceiling. Luckily there are still two U.S. S&P 500 companies left with AAA credit ratings.
- 05/03/2023
|
3 Dividend Aristocrats To Help Beat Stagflation
- High Inflation combined with low economic growth creates a period of stagflation, but these stocks can still outperform. All 3 of these dividend stocks have paid a growing dividend for 25+ CONSECUTIVE years.
- 05/02/2023
|
3 Stocks to Buy Before They Soar to New Heights in 2023
- Many stocks are recovering from the losses they endured last year, with some looking ready to break out and test new highs. Many of the top stocks to buy in down markets have led the way higher in 2023.
- 05/01/2023
|
Earn Double-Digit Income With Options (May 2023)
- We explain why selling cash-covered puts and covered calls are relatively safe choices for earning a high income. We will discuss how to formulate an options income strategy that's sustainable and repeatable.
- 04/29/2023
|
Got $1,000? 2 Top Dividend Stocks to Buy Now
- Abbott and Target are both Dividend Kings, so they've shown that increasing dividends is important to them. These stocks also have what it takes to deliver earnings growth over time.
- 04/28/2023
|
7 Healthcare Stocks With Huge Return Potential for Long-Term Investors
- Healthcare stocks are one of the best bets out there. The U.S. spends more on healthcare than any other country.
- 04/27/2023
|
NUVA vs. ABT: Which Stock Is the Better Value Option?
- Investors looking for stocks in the Medical - Products sector might want to consider either NuVasive (NUVA) or Abbott (ABT). But which of these two stocks is more attractive to value investors?
- 04/25/2023
|
Is Abbott Laboratories Stock a Buy for Dividend Investors?
- Abbott Laboratories' financial results were negatively impacted by a sharp drop in COVID-19 test sales in Q1. The company's market-beating dividend is well covered.
- 04/25/2023
|
Abbott Remains A Top Pick For Dividend Investors
- Abbott Remains A Top Pick For Dividend Investors.
- 04/24/2023
|
Is Abbott Laboratories Still a Good Dividend Stock to Buy?
- After climbing around 18% over the past month, shares of Abbott Laboratories now offer an uninspiring 1.8% dividend yield. Abbott has increased its payout by an impressive 82% over the past five years.
- 04/23/2023
|
Abbott Labs shares pop as revenue, earnings defy steep drop in Covid test sales
- Abbott Laboratories said Covid-related headwinds may actually be easing.
- 04/19/2023
|
Cramer's Mad Dash: Abbott's a clear winner
- CNBC's Jim Cramer delivers his daily Mad Dash.
- 04/19/2023
|
8 Defensive Plays as Healthcare Stocks Stumble
- Healthcare stocks have sputtered this year after performing well in 2022. A Barron's screen has identified stocks that are poised to outperform for the rest of the year.
- 04/19/2023
|
Diversified Abbott Laboratories Could Reverse And Move Higher
- It is no surprise that Abbott Laboratories (NYSE: ABT) produce a solid quarter. Med-tech companies like Intuitive Surgical (NASDAQ: ISRG), Boston Scientific (NYSE: BSX) and DexCom (NASDAQ: DXCM) have seen an increase in analyst interest driven by results and outlook.
- 04/19/2023
|
Abbott (ABT) Beats Q1 Earnings and Revenue Estimates
- Abbott (ABT) came out with quarterly earnings of $1.03 per share, beating the Zacks Consensus Estimate of $0.98 per share. This compares to earnings of $1.73 per share a year ago.
- 04/19/2023
|
Abbott Laboratories weathers Covid-19 test slowdown to report forecast topping 1Q profit
- Abbott Laboratories (NYSE:ABT)' first quarter earnings topped expectations with growth in business segments such as medical devices offsetting a sharp decline in Covid-19 test sales, sending its shares higher in pre-market trading. The Chicago-based medical products company posted adjusted earnings per share of $1.03, above the consensus expectation per FactSet of $0.99.
- 04/19/2023
|
Abbott Labs Shakes Off Covid Test Decline To Top First-Quarter Estimates
- Abbott Laboratories reported better-than-expected first-quarter sales despite a slowdown from its Covid test segment. ABT stock jumped.
- 04/19/2023
|
Abbott Labs' Sales, Earnings Defy Slowdown in Covid-19 Tests. Stock Rises.
- The company beat analysts' expectations with first-quarter earnings of $1.03 a share on sales of $9.75 billion.
- 04/19/2023
|
Abbott Labs stock up 2% premarket after earnings beat despite declining COVID testing sales
- Abbott Laboratories stock ABT, -0.35% rose 2% in premarket trade Wednesday, after the diagnostics and medical device company beat earnings estimates for the first quarter, although declining sales of COVID tests continued to weigh. The company posted net income of $1.318 billion, or 75 cents a share, down from $2.447 billion, or $1.37 a share, in the year-earlier period.
- 04/19/2023
|
Final Trades: JPMorgan, Abbott Labs, UnitedHealth & more
- The "Halftime Report" traders give their top picks to watch for the second half.
- 04/17/2023
|
Abbott (ABT) Gets FDA Clearance for FreeStyle Libre 3 Reader
- Abbott (ABT) receives the FDA clearance for a standalone reader to be used for the FreeStyle Libre 3 iCGM system.
- 04/17/2023
|
What To Expect From Abbott's Q1?
- Abbott will see a decline in sales given the forex headwinds and lower Covid-19-related testing demand.
- 04/13/2023
|
What's in Store for Abbott Laboratories (ABT) in Q1 Earnings?
- Abbott Laboratories' (ABT) Established Pharmaceuticals Division (EPD) and Diabetes arm are boosting business in recent months.
- 04/12/2023
|
Stay away from low quality high dividend payers, says Washington Crossing 's Chad Morganlander
- Gina Sanchez, chief market strategist at Lido Advisors, and Chad Morganlander, senior portfolio manager with Washington Crossing Advisors, joins 'The Exchange' to discuss defensive but expensive dividend stocks, finding cheap stocks with great dividend outlooks, and strategies for selecting dividend payers.
- 04/11/2023
|
My 12 Best Dividend Kings For April 2023
- The 49 Dividend Kings collectively lost 1 basis point in March but retained a positive year-to-date return. The 12 best dividend kings selected for March, based on forecasted growth and valuation, underperformed the average dividend king return by 32 bps.
- 04/10/2023
|
My Dividend Growth Portfolio March Update: Still Accumulating Cash
- The portfolio remains at record high levels of cash holdings, which is fine for the first time in a long time, cash is providing a decent return. Income growth is projected at 7.9% for the year, up from last month. This was primarily due to including an estimated return on cash.
- 04/10/2023
|
Dividend Champion, Contender, And Challenger Highlights: Week Of April 9
- A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends.
- 04/09/2023
|
3 No-Brainer Medical Device Stocks to Buy Right Now
- Edwards Lifesciences' state-of-the-art heart valves have a big growth runway. Abbott Laboratories has received several encouraging FDA approvals recently.
- 04/06/2023
|
3 Discounted Dividend Stocks With Combined 150+ Years Of Dividend Growth
- All three of these dividend stocks have paid a growing dividend for more than 25 years each
- 04/06/2023
|
My Dividend Growth Portfolio - Q1 2023 Summary
- In 2015, I started publishing updates regarding my dividend growth portfolio, and I keep doing so every quarter. This is part of being transparent with my readers, so they can see what I hold and its correlation with my writing.
- 04/06/2023
|
3 Dividend-Growth Stocks to Buy in April That Can Crush Inflation
- CVS Health is famous for its retail business, but it's just a small part of its increasingly profitable operation. UnitedHealth Group is a health insurance benefits manager that provides more of the benefits it's paid to manage.
- 04/02/2023
|
6 April Dividend Kings To Buy, 5 To Watch
- "There is only one-criterion to be included among the Dividend Kings: A publicly-traded company must increase its total fiscal-year dividend payout for a minimum of 50 consecutive years." - Dogs of the Dow. The 47 Dividend Kings screened as of March 27, 2023, represented eight of 11 Morningstar Sectors. Broker targeted top 10 net gainers ranged 21.65%-59.78% topped by VFC and GRC.
- 03/31/2023
|
Abbott's (ABT) Epic Max Tissue Valve Receives FDA Approval
- Abbott's (ABT) Epic Max design optimizes patient blood flow and has a low profile that makes future cardiac interventions simpler.
- 03/31/2023
|
3 Healthcare Stocks to Watch As the Industry Evolves
- In 2022, healthcare stocks surpassed the S&P 500. But in 2023, they are not doing so well.
- 03/31/2023
|
My Best Dividend Aristocrats For April 2023
- NOBL gave up a big chunk of its January gains in February, finishing the month down 2.36%. March has seen the ETF tumble some more as it's down 1.88% through 3/29. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term.
- 03/30/2023
|
8 Defensive Dividend Stars That Could Help You Retire Rich
- Most people are far behind on their retirement goals - often without realizing it. In this article, I present conservative dividend growth investing as a suitable way to achieve long-term financial goals with subdued risks (getting rich slowly).
- 03/30/2023
|
Selecting Dividend Aristocrats Using SCHD Methodology - Mounting A Comeback
- I propose leveraging the stock selection criteria from the underlying index of SCHD to build a portfolio with a subset of Dividend Aristocrats. I am tracking two portfolios built using this process and comparing the results to NOBL and SCHD.
- 03/28/2023
|
2 Dividend Stocks Down 11% to 22% to Buy and Hold Forever
- Pfizer is in the process of pumping out new products to help replace its coronavirus lineup. Abbott has a diversified business centered around its highly successful medical devices unit.
- 03/28/2023
|
Abbott's (ABT) CardioMEMS Favors Heart Failure Management
- Abbott (ABT) announces key findings from meta-analysis, which shows remote pressure monitoring to be a life-extending option among heart failure patients.
- 03/27/2023
|
Wall Street Analysts See Abbott (ABT) as a Buy: Should You Invest?
- According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic.
- 03/24/2023
|
Here's Why You Should Retain Abbott (ABT) Stock for Now
- Investors are optimistic about Abbott (ABT) on continued growth in the core Diagnostics arm.
- 03/22/2023
|
Abbott Labs: Steadily Getting Back To Normal
- Abbott has had a crazy couple of years, with a formula recall and a COVID testing boom. Through this year, most of that should start to normalize, and the Libre 3 launch and growth in the diabetes market should remain a long-term tailwind for the company.
- 03/20/2023
|
What Is Driving Growth For Abbott Stock?
- After a 10% fall year-to-date, at the current levels, Abbott stock (NYSE: ABT) has room for growth, in our view.
- 03/20/2023
|
Abbott Laboratories: A Dividend King At A Discount
- In this article, we dive into Abbott Laboratories, one of the few dividend kings with a dividend growth track record of at least 50 consecutive annual hikes. The company comes with a decent dividend yield and sustainable dividend growth backed by a wide-moat business model.
- 03/20/2023
|
Readers Revealed 21 Ideal February Dividend Dogs
- Prior to February 28, 2023, readers mentioned 38 equities in recent comments on Arnold articles. Some bad-news investments (rogues) mixed with (mostly) favorites. Thus, these are ReFa/Ro. Ten analyst-target-estimated TOP-NET-GAIN Re/Fa/Ro: ABT, MMM, PFE, CCAP, ACRE, CS, VFC, REFI, BRSP, and MITT, averaged 64.47% net gains from data collected 3/14/23.
- 03/17/2023
|
Abbott (ABT) Diabetes Arm Growth Robust Amid Macroeconomic Woes
- Abbott (ABT) currently forecasts total organic sales growth, excluding the impact of COVID testing-related sales, to be in the high-single digits in 2023.
- 03/17/2023
|
Healthcare Stocks With at Least 30 Years of Dividend Increases
- While it is not the only factor to consider, the annual dividend can solidify whether a stock will benefit you financially. And among the many industry sectors to invest in, healthcare can be one of the most stable, especially regarding the dividend yield.
- 03/14/2023
|
DivHut Portfolio Update: February 2023
- The system is clearly broken and has been for a while; however, I could find comfort in one thing, my dividends. These days, there are no shortages of accidental high yielding stocks but look at real cash on hand when viewing balance sheets.
- 03/14/2023
|
Abbott (ABT) to Pair CGM Sensors & AID System on FDA Clearance
- Abbott Laboratories (ABT) receives FDA clearance for the integration of its iCGM system sensors with automated insulin delivery (AID) systems.
- 03/13/2023
|
2 Top Dividend Stocks You Can Buy and Hold Forever
- PepsiCo and Abbott Laboratories both possess tremendous brand power. The two companies should continue to reward shareholders with rising dividends.
- 03/09/2023
|
My 12 Best Dividend Kings For March 2023
- The 49 Dividend Kings started the new year on a positive note but cooled off in February, collectively losing 2.06%. The 11 best dividend kings selected for February, based on forecasted growth and valuation, outperformed the average dividend king return by 19 bps.
- 03/08/2023
|
Abbott (ABT) Gets FDA Nod for Alinity I Laboratory Test
- Abbott's (ABT) Alinity i TBI lab test provides a new reliable result in 18 minutes to support clinicians in quickly assessing concussion and triaging patients.
- 03/08/2023
|
Abbott (ABT) Reveals Favorable Data on Tricuspid Regurgitation
- Abbott Laboratories (ABT) demonstrates the superiority of the TriClip device in treating patients with severe, symptomatic tricuspid regurgitation.
- 03/08/2023
|
3 Value Stocks on Sale Now
- Growth stocks have clearly led the market thus far in 2023, but will that continue?
- 03/07/2023
|
Abbott (ABT) Makes Progress in the TAVI Space With Navitor
- Results from Abbott's (ABT) PORTICO study support Navitor's recent FDA approval to treat patients with severe aortic stenosis who are at high or extreme risk for open-heart surgery.
- 03/07/2023
|
Abbott's (ABT) MitraClip Device Shows Favorable Outcome
- Abbott's (ABT) landmark COAPT trial demonstrated that MitraClip is safe and effective and can reduce the hospitalization rate.
- 03/07/2023
|
Dexcom Pummeled On A New FDA Clearance For Key Rival Abbott Laboratories
- Dexcom stock toppled Monday after the FDA cleared Abbott Laboratories to pair its body-worn glucose monitors with automated insulin pumps. The post Dexcom Pummeled On A New FDA Clearance For Key Rival Abbott Laboratories appeared first on Investor's Business Daily.
- 03/06/2023
|
2 Top Dividend Kings to Buy for the Long Haul
- These aren't just dividend plays, either.
- 03/04/2023
|
Apple cloud chief Abbott to step down - Bloomberg News
- Apple Inc's head of cloud services Michael Abbott is leaving the company, joining a growing list of senior officials who have departed the iPhone maker recently, Bloomberg News reported on Friday.
- 03/03/2023
|
Lucira Stock Jumps over 250% on FDA Approval, Beware Chapter 11
- Lucira Health Inc. (NASDAQ: LHDX) shares spiked up 264% to close at $0.52 on a massive 278 million shares traded on the announcement of FDA approval for its combination at-home COVID-19 and a flu test. The over-the-counter (OTC) 30-minute at-home rapid test can detect influenza A and B and the SARS-CoV-2 virus using nasal swabs.
- 03/01/2023
|
March Dividend Kings: 5 Buys, 4 To Watch
- "There is only one-criterion to be included among the Dividend Kings: a publicly-traded company must increase its total fiscal-year dividend-payout for a minimum of 50 consecutive years."--Dogs of the Dow. The 47 Dividend Kings screened as of February 24, 2023, represented eight of eleven Morningstar Sectors. Broker targeted-top-ten net-gainers ranged 15.54%-31.75% topped-by NFG & VFC.
- 02/28/2023
|
Why Abbott Laboratories Stock Bumped Higher Today
- The company's specialized heart care products appear to prove their value in clinical testing.
- 02/28/2023
|
Should Abbott and DexCom Investors Be Worried About Apple's Latest News?
- The continuous glucose monitoring market could heat up.
- 02/28/2023
|
Dividend Stocks To Buy Now? 3 For Your Watchlist
- Dividend stocks to watch this week.
- 02/27/2023
|
My Best Dividend Aristocrats For March 2023
- NOBL started the year off with a gain of 3.23% in January; it is thus far not faring as well in February, but the ETF is still positive year-to-date. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term.
- 02/25/2023
|
Why Is Abbott (ABT) Down 7.7% Since Last Earnings Report?
- Abbott (ABT) reported earnings 30 days ago. What's next for the stock?
- 02/24/2023
|
Better Buy: Abbott Laboratories or DexCom Stock?
- Both stocks should benefit from the growth in diabetes care.
- 02/24/2023
|
Is Abbott Stock A Better Pick Over This Pharmaceuticals Bellwether?
- Both stocks are trading at a similar valuation of a little over 4x trailing revenues.
- 02/24/2023
|
Selecting Dividend Aristocrats Using SCHD Methodology - Falling Behind
- I propose leveraging the stock selection criteria from the underlying index of SCHD to build a portfolio with a subset of Dividend Aristocrats. I am tracking two portfolios built using this process and comparing the results to NOBL and SCHD.
- 02/22/2023
|
Why Abbott Laboratories Stock Sank Today
- The company's glucose monitoring business might come under some serious pressure.
- 02/22/2023
|
Here's Why You Should Retain Abbott (ABT) Stock for Now
- Investors are optimistic about Abbott (ABT) owing to continued growth in the Diabetes business.
- 02/20/2023
|
3 Top Dividend Kings to Buy for the Long Haul
- These companies have more than 150 years of dividend growth between them.
- 02/20/2023
|
Abbott Laboratories under SEC and FTC investigation over baby-formula business
- The Securities and Exchange Commission and Federal Trade Commission are investigating Abbott Laboratories' baby-formula business, the company said.
- 02/17/2023
|
Abbott Baby-Formula Business Under Investigation By SEC, FTC
- The SEC's enforcement division sent a subpoena to Abbott in December requesting information about its powder infant-formula business and related public disclosures, the company said Friday in a securities filing.
- 02/17/2023
|
How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula
- A new study published in Science Translational Medicine could introduce a profitable opportunity for makers of seizure drug medications. The discovery has immense medical implications, of course, but it could lead to a windfall for investors, particularly those holding Abbott Laboratories (NYSE: ABT) and AbbVie, Inc (NYSE: ABBV) shares.
- 02/17/2023
|
Abbott Acquires Cardiovascular Systems: Key Takeaways For Investors
- Abbott Laboratories expands its cardiovascular pipeline with the relatively small acquisition of Cardiovascular Systems, Inc. Cardiovascular Systems investors get a way out of a cash-burning stock at a decent price. The timing of the deal is opportunistic for Abbott.
- 02/15/2023
|
Similac maker Abbott could face criminal penalties of up to $500,000 per offense in DOJ probe of factory conditions amid the baby formula shortage
- "It's a layup for a misdemeanor charge," a food safety attorney told Crain's Chicago, though a felony would be harder for investigators to prove.
- 02/15/2023
|
Which Healthcare Stock Is a Better Pick in 2023?
- Investor sentiment has improved this year on expectations of less-aggressive interest rate hikes by the Federal Reserve to tame inflation. However, the ongoing macro uncertainty continues to create confusion about which sectors or companies to invest in.
- 02/14/2023
|
Will Abbott Laboratories Remain A Top Dividend Aristocrat Stock Going Forward?
- ABT has been growing its dividends for OVER half a century and is one of only 37 US stocks to do so. We examine if ABT has ample elbow room to service the dividend.
- 02/14/2023
|
Candy? Flowers? These Top Stocks Offer You Something Even Sweeter
- These stocks may reward you over time.
- 02/14/2023
|
Abbott (ABT) to Expand Vascular Device Line With New Buyout
- Abbott's (ABT) latest deal will help gain access to Cardiovascular System's leading atherectomy device to treat vascular disease.
- 02/13/2023
|
Dividend Champion, Contender, And Challenger Highlights: Week Of February 12
- A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends.
- 02/12/2023
|
The Dividend Aristocrats Ranked By Quality Scores
- The annual rebalancing and subsequent changes to the S&P 500 Dividend Aristocrats Index have produced a new list of 67 dividend growth stocks called the Dividend Aristocrats. I rank the Dividend Aristocrats using Quality Snapshots, an elegant and effective system for assessing the quality of dividend growth stocks.
- 02/11/2023
|
Compounders And Dividends: February 2023 Watch List Update
- Three companies have been removed from my watchlist and added to the active portfolio. I added four new companies to my watchlist.
- 02/11/2023
|
Abbott Buying Cardiovascular Systems: Details (ABT)
- Abbott (NYSE: ABT) is buying Cardiovascular Systems (CSI). These are the details.
- 02/10/2023
|
Cardiovascular Systems shares jump after deal to be bought by Abbott for $890 million
- Cardiovascular Systems CSII, -1.99% shares rose 47% to $19.58 in early premarket trade after Abbott ABT, -1.60% agreed to buy the company for $890 million, or $20 per share. CSI is a leader in devices for atherectomy, a minimally invasive treatment for plaque build-up in arteries.
- 02/09/2023
|
3 Dividend Stocks That Will Hold Up No Matter the Market Conditions
- These stocks could boost your portfolio in bear markets and bull markets.
- 02/08/2023
|
Baby Formula Blues Hit Abbott Laboratories Stock Hard in 2022. Can It Rebound in 2023?
- The healthcare stock fell 22% last year.
- 02/07/2023
|
Is This Dividend King a Buy for Income Investors?
- This healthcare company has one of the most established payouts in its sector.
- 02/07/2023
|
2 Beaten-Down Stocks With Stable Dividends to Buy In 2023
- You can bet the farm on these companies' dividends.
- 02/04/2023
|
3 Unstoppable Dividend Stocks to Buy in February
- All three belong to the elite group of stocks known as Dividend Kings.
- 02/04/2023
|
ZBH vs. ABT: Which Stock Is the Better Value Option?
- ZBH vs. ABT: Which Stock Is the Better Value Option?
- 02/01/2023
|
2 Top Dividend Growth Stocks to Buy in February
- They don't offer the highest yields, but these strongly profitable businesses are poised to raise their payouts at a blistering pace.
- 02/01/2023
|
5 Top Stocks to Buy Now
- This eclectic mix of stocks will help diversify your portfolio.
- 01/31/2023
|
The 4% DGI Core Portfolio: 2022 Year-End Review
- We present the 2022 year-end review of our eight-year-old Passive DGI-Core Portfolio. We consider this portfolio and strategy as the foundation of our overall portfolio. We will provide updates on changes, additional investments, dividends collected, and an overall 2022 performance.
- 01/28/2023
|
Is Abbott Laboratories a Good Dividend Stock to Buy Now?
- At least four Wall Street banks recently raised their price targets for the healthcare giant.
- 01/28/2023
|
Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?
- Johnson & Johnson (NYSE: JNJ) and Abbott Laboratories (NYSE: ABT) are 2 of the more attractive Dividend Kings for today's market. They offer relatively high yields and at least some value while projecting growth in 2023.
- 01/27/2023
|
Abbott's Sales and Earnings Are Sinking: Should Investors Worry?
- There's more to the story than the negative trends for Abbott's top and bottom lines.
- 01/26/2023
|
3 Must-Have Dividend Stocks For 2023
- Dividend growth investing keeps the eye on growth, but makes sure there's some immediate return. These 3 stocks are must-haves for DGI enthusiasts. I look at the companies' story, dividends, growth, and current valuation compared to their history.
- 01/26/2023
|
Why Abbott Laboratories Stock Got Whacked on Wednesday
- Double beats for its latest quarter couldn't keep the bears away from the company's shares on Hump Day.
- 01/25/2023
|
Abbott Laboratories (ABT) Q4 2022 Earnings Call Transcript
- Abbott Laboratories (NYSE:ABT ) Q4 2022 Earnings Conference Call January 25, 2023 9:00 AM ET Company Participants Scott Leinenweber - Vice President, Investor Relations Robert Ford - Chairman and Chief Executive Officer Bob Funck - Executive Vice President, Finance and Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Josh Jennings - Cowen Joanne Wuensch - Citibank Vijay Kumar - Evercore ISI Travis Steed - Bank of America Matt Miksic - Barclays Operator Good morning and thank you for standing by. Welcome to Abbott's Fourth Quarter 2022 Earnings Conference Call.
- 01/25/2023
|
Abbott's (ABT) Q4 Earnings Beat Estimates, Margins Down
- The downside can be attributed to a manufacturing disruption during 2022 of certain infant formula products at Abbott's (ABT) Sturgis, MI facility.
- 01/25/2023
|
Abbott Laboratories tops Q4 earnings
- Yahoo Finance's Anjalee Khemlani joins the Live show to break down fourth-quarter earnings for Abbott Laboratories.
- 01/25/2023
|
Abbott (ABT) Q4 Earnings and Revenues Top Estimates
- Abbott (ABT) delivered earnings and revenue surprises of 14.44% and 6.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 01/25/2023
|
Abbott beats earnings, revenue expectations in Q4
- Abbott Laboratories ABT had better-than-expected earnings and revenue in the fourth quarter of 2022, though headwinds from its baby formula business and declining COVID-19 test sales are still weighing on the company's performance. Abbott had a profit of $1.0 billion, or 59 cents per share, in the fourth quarter of 2022, down from $1.9 billion, or $1.11 per share, in the same quarter of 2021.
- 01/25/2023
|
Earnings Exchange: KMB, ABT & MSFT
- David Katz, Matrix Asset Advisors CIO, joins ‘The Exchange' to discuss a few stocks ahead of earnings, including Kimberly-Clark, Abbott and Microsoft.
- 01/24/2023
|
The Dividend Kings Ranked By Quality Score
- Dividend Kings have an astounding track record of 50 or more years of higher dividend payouts. I rank the Dividend Kings using Quality Snapshots, a simple yet elegant system for assessing the quality of dividend growth stocks.
- 01/24/2023
|
3 Irresistible Dividend Kings
- I'm starting this article with a theoretical background explaining the benefits that come with high-quality dividends. We dive into empirical evidence supporting a wide variety of dividend strategies. The theme of this article is dividend kings, which are stocks that have hiked their dividends for at least 50 consecutive years.
- 01/24/2023
|
Selecting Dividend Aristocrats Using SCHD Methodology - Slow And Steady
- I propose leveraging the stock selection criteria from the underlying index of SCHD to build a portfolio with a subset of Dividend Aristocrats. I am tracking two portfolios built using this process and comparing the results to NOBL and SCHD.
- 01/23/2023
|
Final Trades: Abbott Labs, GE Healthcare, Viper Energy and more
- The "Halftime Report" traders give their top picks to watch for the second half.
- 01/23/2023
|
Sec. Yellen dismisses $1 trillion coin, DOJ investigates Abbott, banks work on digital wallet
- Yahoo Finance anchor Julie Hyman reports the latest notable business headlines include Janet Yellen's dismissal of a $1 trillion coin, the Justice Department investigating Abbott Lab in Michigan, and big banks working on a new digital wallet that links with debit and credit cards.
- 01/23/2023
|
Abbott's (ABT) New FDA Approval to Improve Patient Outcome
- Abbott's (ABT) latest regulatory clearance is expected to improve the treatment of high-risk patients with aortic stenosis.
- 01/23/2023
|
Abbott Laboratories Draws DOJ Scrutiny Before Earnings
- Abbott Laboratories (NYSE:ABT) is under the U.S. Department of Justice's (DOJ) microscope, after the Wall Street Journal reported the DOJ's consumer-protection branch is conducting a criminal investigation into the baby formula supplier's Michigan plant.
- 01/23/2023
|
Want Safe and Growing Passive Income? Buy These 2 Dividend Kings In 2023
- It doesn't get any safer for income investors than Dividend Kings.
- 01/23/2023
|
Ranking The Diversified Healthcare Giants
- The Top Six Healthcare Products and Service companies are some of the most popular investments in the market. However, they offer varying financial profiles.
- 01/22/2023
|
Abbott Under Federal Investigation Over Baby Formula—Here's How The Pharmaceutical Giant Got Here
- The FDA found multiple unsanitary conditions at Abbott's plant in Michigan last year, following its recall of its baby formula, prompting a nationwide shortage.
- 01/21/2023
|
Abbott faces U.S. criminal probe over baby formula -WSJ
- Abbott Laboratories' Michigan plant, which was at the center of the U.S. baby formula shortage last year, is being investigated by the Justice Department, the Wall Street Journal reported on Friday.
- 01/20/2023
|
Abbott facing criminal investigation over baby-formula plant operations
- The Justice Department is investigating conduct at the Abbott Laboratories infant-formula plant in Sturgis, Mich., that led to its shutdown last year and worsened a nationwide formula shortage, people familiar with the matter said.
- 01/20/2023
|
Abbott Under Criminal Investigation Over Baby Formula
- Federal prosecutors are probing conduct at Abbott's baby-formula plant in Michigan, which the company temporarily shutdown last year after a potentially deadly bacteria was found
- 01/20/2023
|
Why Abbott (ABT) is Poised to Beat Earnings Estimates Again
- Abbott (ABT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 01/20/2023
|
3 Top Passive-Income Stocks to Own in 2023
- These stocks can add safety and growth to your portfolio.
- 01/19/2023
|
10 Biggest Companies Reporting Earnings in the 4th Week of Jan 2023
- The fourth quarter earnings season is always the most important because it reveals the full year performance of the companies as well.
- 01/18/2023
|
My Dividend Growth Portfolio - Q4 2022 Summary
- In 2015, I started publishing updates regarding my dividend growth portfolio, and I keep doing so every quarter. This is part of being transparent with my readers, so they can see what I hold and its correlation with my writing.
- 01/18/2023
|
What's in Store for Abbott Laboratories (ABT) in Q4 Earnings?
- Within Abbott's (ABT) Established Pharmaceuticals Division (EPD), new product launches across key markets have been majorly boosting business in recent months.
- 01/17/2023
|
Final Trades: Abbott Labs, SL Green, Zoetis & more
- The "Halftime Report" traders give their top picks to watch for the second half.
- 01/11/2023
|
Abbott Laboratories (ABT) 41st Annual J.P. Morgan Healthcare Conference (Transcript)
- Abbott Laboratories (NYSE:ABT ) 41st Annual J.P. Morgan Healthcare Conference January 10, 2023 12:00 PM ET Company Participants Robert Ford - Chairman and Chief Executive Officer Conference Call Participants Robbie Marcus - J.P.
- 01/10/2023
|
Abbott's (ABT) New Launch to Boost Blood Donation Experience
- Abbott's (ABT) mixed reality offers donors an innovative, immersive digital experience while giving blood.
- 01/09/2023
|
3 Reliable Dividend Stocks You Can Buy With $600
- With products and services that many of us can't live without, these businesses are poised to deliver steadily rising dividend payouts.
- 01/09/2023
|
Dividend Champion, Contender, And Challenger Highlights: Week Of January 8
- A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends.
- 01/08/2023
|
8 Upcoming Dividend Increases, Including A Dividend King
- All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. They have an average increase of 7.4% and a median increase of 6.1%.
- 01/05/2023
|
Abbott Hosts Conference Call for Fourth-Quarter Earnings
- ABBOTT PARK, Ill., Jan. 4, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its fourth-quarter 2022 financial results on Wednesday, Jan. 25, 2023, before the market opens.
- 01/04/2023
|
Beat the Dow Jones With This Unstoppable Dividend Stock
- This drugmaker is accustomed to outperforming the broader market.
- 01/03/2023
|
BlackRock, Kimberly-Clark Among 13 Companies To Start 2023 With Annual Dividend Increases
- There were several double-digit boosts in December, with Mastercard and Eli Lilly leading the way with 16% and 15% increases, respectively. Abbott Labs began its second half-century of dividend growth with an 8.5% increase.
- 01/02/2023
|
My Dividend Growth Portfolio - Final 2022 Recap
- 2022 was another fantastic year for dividend growth, with my income increasing by over 13%. I recount every sale made during the year and the replacement purchases.
- 01/02/2023
|
Abbott: Wait For A Better Entry Point
- The number of children and teenagers in the United States diagnosed with type 2 diabetes could rise by as much as 675% by 2060, which boosts the market. The dividend per share has risen steadily at 7.2% per year, and management is shareholder-friendly by buying back shares, further boosting the dividend per share.
- 01/01/2023
|
2023 Dividend Growth Portfolio Review And Look Ahead
- Review of the current holdings and sectors in the portfolio, and how it has changed over the years. Income projections for 2023, and potential pitfalls.
- 01/01/2023
|
100 Best Stocks Of 2022: Oil Stocks And Medicals Shine
- Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business Daily.
- 12/30/2022
|
Selecting Dividend Aristocrats Using SCHD's Methodology - Initial Results
- I propose leveraging the stock selection criteria from the underlying index of SCHD to build a portfolio with a subset of Dividend Aristocrats. I am tracking two portfolios built using this process and comparing the results to NOBL and SCHD.
- 12/29/2022
|
Abbott (ABT) to Upgrade PHCs Across India With New Pact
- Abbott's (ABT) HWC program is likely to benefit more than 2.5 million people from under-resourced communities annually.
- 12/28/2022
|
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
- Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
- 12/27/2022
|
3 Stocks on Santa's Nice List to Buy Before 2023
- These stocks each offer something Santa would like.
- 12/24/2022
|
Pick Either Abbott Stock Or Its Industry Peer – Both Are Likely To Offer Similar Returns
- We believe that Abbott stock and Medtronic stock in the medical devices industry will likely give similar returns over the next three years. Although Abbott is trading at a higher valuation of 4.2x trailing revenues, compared to 3.
- 12/21/2022
|
What Stocks To Buy Today? 3 Dividend Aristocrats To Watch
- Are these dividend aristocrats on your radar right now?
- 12/20/2022
|
Here's Why You Should Retain Abbott (ABT) Stock for Now
- Investors continue to be optimistic about Abbott (ABT) owing to the strength in its Diabetes business and product launches.
- 12/20/2022
|
Abbott to Present at J.P. Morgan Healthcare Conference
- ABBOTT PARK, Ill., Dec. 20, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the 41st Annual J.P.
- 12/20/2022
|
1 Passive Income Stock to Buy Today, and 1 to Avoid for Now
- Rising interest rates don't affect all passive income stocks equally.
- 12/18/2022
|
2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year
- These stocks look cheap -- especially considering their long-term potential.
- 12/18/2022
|
Want $250 in Passive Income? Buy These 2 Dividend Kings and Wait
- These companies will work hard to grow your base of passive income.
- 12/16/2022
|
2 Top Dividend Stocks to Buy Hand Over Fist Before 2023
- These stocks will bring you income -- no matter what the market is doing.
- 12/16/2022
|
Why Abbott Laboratories Topped the Market on Tuesday
- Bullish momentum behind the big pharmaceutical company was aided by a glowing new analyst note.
- 12/13/2022
|
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock
- Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- 12/12/2022
|
Abbott's 8% Dividend Hike Defies Disappointing Results
- Following several years of steady growth, Abbott Laboratories ( ABT , Financial) reported disappointing results for the third quarter of 2022, causing investors to worry that further declines could be in store for the stock. Medical device sales were down sharply, adding to already-negative investor sentiment from an infant formula recall and production halt earlier this year due to an FDA inspection that found Cronobacter sakazakii bacteria, which can be deadly to infants, in several areas of the company's Sturgis, Michigan facility.
- 12/09/2022
|
Abbott Labs boosts dividend by more than 8%
- Abbott Laboratories ABT, +1.13% said Friday morning that it would be raising its dividend to 51 cents a share. The increase amounts to a 8.5% bump relative to the company's prior quarterly dividend of 47 cents a share.
- 12/09/2022
|
2 Dividend Aristocrats to Buy for 2023
- You can count on these dividend stocks to continue raising their payouts for years to come.
- 12/07/2022
|
Is Trending Stock Abbott Laboratories (ABT) a Buy Now?
- Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- 11/28/2022
|
Is This Stock-Split Stock a Buy For 2023?
- Don't buy this company's shares for its recent stock split.
- 11/26/2022
|
This Robotic Surgical Company Is Likely To Offer Better Returns Over Abbott Stock
- We believe Intuitive Surgical stock is currently a better pick than Abbott stock, given its better prospects. Although Abbott is trading at a comparatively lower valuation of 4.1x trailing revenues vs. 15.2x for Intuitive Surgical, this gap in the valuation is justified mainly given the latter's superior revenue growth and lower financial risk, as discussed below.
- 11/25/2022
|
2 Unbeatable Dividend Stocks Billionaires Keep Buying in a Bear Market
- Some of the world's most successful investors made big bets on these dividend payers recently.
- 11/25/2022
|
Abbott Laboratories: Good Execution And Attractive Valuation
- Abbott is a market leader in medical device businesses such as vascular care and diabetes care. It also leads in the in-vitro diagnostic market. The likely decline of COVID testing heavily impacted the share price.
- 11/24/2022
|
Good Stocks To Invest In Now? 3 Dividend Aristocrats Stocks For Your List
- Check out these three dividend aristocrats in the stock market this week.
- 11/22/2022
|
Want Passive Income in 2023? Buy These Dividend Kings
- These stocks offer you a gift: recurrent income just for owning them.
- 11/22/2022
|
4 Growth Stocks To Buy As Inflation Cools
- Inflation cooled more than expected recently. It could be the first sign of a different rate environment and a bullish stock market. These four stocks should profit either way due to their strong growth, profitable cash flows, and shareholder returns.
- 11/21/2022
|
Abbott Laboratories: Prepare For A Tough 2023
- The stock of Abbott Labs is down 18%+ over the past 12 months and has significantly underperformed the broad healthcare sector. This is likely not what investors expected - typically a healthcare stock like Abbott would outperform during an inflationary bear market.
- 11/21/2022
|
Abbott (ABT) Up 7.7% Since Last Earnings Report: Can It Continue?
- Abbott (ABT) reported earnings 30 days ago. What's next for the stock?
- 11/18/2022
|
Is Most-Watched Stock Abbott Laboratories (ABT) Worth Betting on Now?
- Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
- 11/15/2022
|
7 No-Brainer Blue-Chip Stocks to Buy for 2023 and Beyond
- While it's tempting to target the flavors of the week during a market correction, investors ought to spare some time for no-brainer blue-chip stocks to buy for 2023 and beyond. Indeed, the broader market and economic dynamics encourage retail investors to think about value and stability over growth.
- 11/12/2022
|
Better Buy: Johnson & Johnson vs. Abbott Laboratories
- These two healthcare giants are among the safest stocks investors can buy right now.
- 11/10/2022
|
3 Top Healthcare Stocks Defying the Bear Market
- These healthcare companies haven't been slowed by macroeconomic conditions.
- 11/10/2022
|
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
- Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
- 11/04/2022
|
3 Dividend-Paying Stocks to Buy in November and Hold Forever
- Adding these stocks to your portfolio could lead to a lifetime of passive income.
- 11/02/2022
|
This Groundbreaking Device Just Keeps Winning for Abbott Labs
- Its continuous glucose monitor has proven immensely effective in helping type 2 diabetes patients.
- 11/01/2022
|
These Are Stan Moss' Top 10 Holdings
- Stan C. Moss is CEO at the investment management firm Polen Capital, one of the largest hedge funds based on assets under management.
- 10/31/2022
|
Is This Dividend King a Buy Near Its 52-Week Low?
- Shares of this medical device and diagnostics stock have slumped in 2022.
- 10/28/2022
|
My Best Dividend Aristocrats For November 2022
- NOBL fell 9.15% in September, which brings the Funds return for the year to a loss of 17.47%. Thus far this month, through October 24th, the dividend aristocrat ETF is up 6.04%, bringing its year-to-date return to -12.49%.
- 10/26/2022
|
Inflation is dominating the conversation on earnings calls. Here's what execs are saying
- One thing's clear at the start of the corporate earnings season: Inflation is still a hot topic for companies.
- 10/24/2022
|
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
- Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
- 10/24/2022
|
Is Abbott Laboratories Still a Good Dividend Stock to Buy?
- Third-quarter results were less than encouraging on the surface, but what do they say about the road ahead for Abbott Laboratories?
- 10/22/2022
|
Abbott's (ABT) Q3 Earnings Top Estimates, 2022 EPS View Up (Revised)
- Abbott's (ABT) Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
- 10/20/2022
|
Abbott (ABT) Q3 Earnings and Revenues Surpass Estimates
- Abbott (ABT) delivered earnings and revenue surprises of 26.37% and 8.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 10/19/2022
|
Abbott CEO provides update on progress as baby formula shortage persists
- Abbott Laboratories CEO Robert Ford says the company replaced leadership at its troubled Michigan facility and is building a new infant formula plant.
- 10/19/2022
|
3 Stocks Set to Soar From 52-Week Lows
- The stock market remains near 52-week lows, and it might be the time to start looking for stocks to buy at a discount. Following September's inflation figures, things don't appear to change soon.
- 10/19/2022
|
Abbott has ‘levers to pull' in its medical businesses, analyst says
- RBC Capital Analyst Shagun Singh Chadha joins Yahoo Finance Live anchor AKiko Fujita to discuss Abbott earnings and growth in its business segments including COVID testing, baby formula, and nutrition.
- 10/19/2022
|
Abbott Names New Leadership at Troubled Baby-Formula Plant
- The company, which had halted production at the Sturgis, Mich., plant earlier in the year, also said it will spend $500 million to build a new formula plant.
- 10/19/2022
|
Abbott Laboratories predicts COVID-19 will be endemic this winter
- Is the billion-dollar COVID-19 testing sales boom over?
- 10/19/2022
|
Why Abbott Laboratories Stock Is Slumping Today
- A potential drop-off in COVID-19 testing sales is weighing on the healthcare giant's shares today.
- 10/19/2022
|
Rapid Covid Tests Can't Keep Abbott Healthy Forever
- While Abbott Laboratories beat analysts' expectations due to demand for Covid-19 at-home tests, a decline by its medical-device business and broader headwinds helped send its shares down.
- 10/19/2022
|
Abbott Laboratories (ABT) Q3 2022 Earnings Call Transcript
- Abbott Laboratories (NYSE:ABT ) Q3 2022 Earnings Conference Call October 19, 2022 9:00 AM ET Company Participants Scott Leinenweber - Vice President, Investor Relations, Licensing and Acquisition Robert Ford - Chairman and CEO Bob Funck - Executive Vice President, Finance and CFO Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Joanne Wuensch - Citibank Josh Jennings - Cowen Vijay Kumar - Evercore ISI Travis Steed - Bank of America Operator Good morning and thank you for standing by. Welcome to Abbott's Third Quarter 2022 Earnings Conference Call.
- 10/19/2022
|
Abbott Labs Reports Narrower-Than-Expected Quarterly Declines, And Shares Topple
- Abbott Laboratories reported better-than-expected third-quarter declines and raised its earnings guidance. But ABT stock tumbled.
- 10/19/2022
|
Abbott Raises Guidance but Says Quarterly Sales Hit by Baby Formula Shortage
- Abbott says sales of medical devices rose more than 11% in the third quarter.
- 10/19/2022
|
Abbott attributes Q3 sales decline to baby formula shortage, less COVID-19 testing
- Abbott Laboratories ABT, +1.41% said Wednesday that it had earnings of $1.4 billion, or $1.15 per share, in the third quarter of 2022, compared with $2.1 billion, or $1.40, in the same quarter a year ago. Adjusted earnings per share were $1.15, against a FactSet consensus of 94 cents.
- 10/19/2022
|
Abbott raises 2022 profit forecast for second time
- Abbott Laboratories on Wednesday raised its annual earnings forecast for the second time, citing strong demand for medical devices and pharmaceutical products.
- 10/19/2022
|
3 Dividend Stocks to Buy Now for a Lifetime of Passive Income
- These ultra-reliable businesses could deliver quarterly payments that steadily grow throughout your retirement.
- 10/17/2022
|
Penny Stocks & The Stock Market This Week: What To Watch Now
- Trading penny stocks right now? Here's what to watch in the stock market this week October 17, 2022 to October 21, 2022.
- 10/16/2022
|
Abbott is recalling baby formula again after discovering faulty bottle caps on Similac products produced at Ohio facility
- The news comes after a February recall on formula that prompted a widespread shortage and national crisis as parents struggled to feed their children.
- 10/15/2022
|
3 Beaten-Down Stocks to Buy and Hold
- These stocks could be ready for big bounces.
- 10/15/2022
|
Abbott Issues New Baby Formula Recall
- Abbott, the baby formula manufacturer, said Friday it's recalling some lots of its "ready-to-feed" liquid products and formulas in 2-ounce containers. A "small percentage" of the bottles may not have been sealed properly, Abbott said.
- 10/14/2022
|
What's in Store for Abbott Laboratories (ABT) in Q3 Earnings?
- Going by the industry-wide trend so far, logistical challenges and increasing unit costs might have weighed on the corporate profitability of Abbott (ABT) in Q3.
- 10/13/2022
|
Why Abbott (ABT) Could Beat Earnings Estimates Again
- Abbott (ABT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 10/13/2022
|
Why the Bear Market May Not Be Over Anytime Soon
- Are investors better off waiting until next year to buy stocks?
- 10/13/2022
|
Will Abbott Stock Rise After Its Q3 Results?
- Supply chain disruptions, forex headwinds, and a decline in Covid-19-related demand will likely weigh on the company's performance.
- 10/12/2022
|
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
- Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- 10/11/2022
|
Better Bear-Market Buy: Abbott Laboratories vs. AbbVie Stock
- It's parent vs. child in this bear-market matchup.
- 10/11/2022
|
3 Diabetes Care Stocks That Could Help Set You Up for Life
- These companies are three of the leading manufacturers of continuous glucose monitoring systems.
- 10/09/2022
|
2 Top Healthcare Stocks to Buy Right Now
- Healthcare is about as sticky of a business model as you'll find.
- 10/08/2022
|
3 Dividend Stocks to Buy In October and Hold Forever
- The payouts these companies distribute every quarter could surge over the next several years.
- 10/05/2022
|
Here's Why This Dividend King Is a Buy
- Shares of this drugmaker have far outpaced the S&P 500 index in 2022.
- 10/01/2022
|
This CGM Device Maker Is Likely To Outperform Abbott Stock
- There is more to the comparison, and in the sections below, we discuss why we believe DXCM stock will offer better returns than ABT stock in the next three years.
- 09/29/2022
|
7 Vaccine Stocks to Sell ASAP Now That the ‘Pandemic's Over'
- As people acclimatize to the new normal, it's time to look at some vaccine stocks to sell. Instead of relying primarily on vaccines and antiviral drugs, the government let people manage infections.
- 09/27/2022
|
2 Growth Stocks Down 14% to 28% to Buy and Hold Forever
- These stocks have already made plenty of investors a lot richer. They aren't done.
- 09/26/2022
|
Abbott (ABT) Reports Favorable Findings From RELIEF Study
- The latest data from the RELIEF Study suggests a lower rate of hospitalizations from serious diabetes-related events with Abbott's (ABT) FreeStyle Libre system.
- 09/22/2022
|
3 Stocks You Can Keep Forever
- They tend to grow steadily and without interruption over the long term.
- 09/17/2022
|
Stock Market Sell-Off: 2 Reliable Dividend Stocks to Buy On the Dip
- It will take more than high interest rates or a recession to stop these stocks from outperforming over the long run.
- 09/16/2022
|
3 Unstoppable Dividend Stocks to Buy in September
- These stocks offer more than just dividends.
- 09/13/2022
|
2 Dividend Aristocrats to Buy for Passive Income That Could Outperform the Market
- This pair of Midwestern companies have outperformed in recent years, and their futures look brighter than ever.
- 09/12/2022
|
Pick Either Johnson & Johnson Stock Or This Healthcare Company – Both Are Likely To Offer Similar Returns
- We believe that healthcare companies Abbott stock (NYSE: ABT) and Johnson & Johnson stock (NYSE: JNJ) are likely to offer similar returns over the next three years.
- 09/12/2022
|
3 Beaten-Down Stocks to Buy Right Now
- These solid businesses look like bargains today.
- 09/11/2022
|
How recovery shape informs defensive stock buys
- Gina Sanchez, chief market strategist at Lido Advisors, joins 'The Exchange' to discuss her recommendations for three buys and a bail. Her picks include Abbot, Microsoft, and Tesla, with weariness around Bitcoin.
- 09/09/2022
|
Here's Why Investors Should Retain Abbott (ABT) Stock Now
- Strong results across the EPD, diagnostics and medical devices businesses are driving Abbott's (ABT) top line.
- 09/09/2022
|
Why Abbot Stock Was a Winner Today
- Investors were clearly impressed by data showing the benefits of a device that treats a heart condition in infants.
- 09/08/2022
|
Abbott (ABT) Debuts Amplatzer Talisman System in Europe
- Abbott's (ABT) Amplatzer Talisman PFO Occlusion System will enable doctors across Europe to treat people experiencing a patent foramen ovale-associated stroke.
- 09/08/2022
|
Abbott Rebuffs Calls For Raising Assault Weapon Purchase Age To 21
- Uvalde officials have urged Abbott to call a special legislative session to pass tougher gun laws, a move polling suggests the vast majority of Texans support.
- 08/31/2022
|
Abbott restarts Similac infant formula production at Michigan facility
- Abbott Laboratories has restarted production of its Similac infant formula at the plant in Sturgis, Michigan at the center of the U.S. baby formula shortage.
- 08/27/2022
|
Abbott Stock And Its Sector Peer Likely To Offer Similar Returns
- We think healthcare companies Abbott stock (NYSE: ABT) and Baxter stock (NYSE: BAX) may offer similar returns over the next few years. Although BAX is trading at a comparatively lower valuation of 2.2x trailing revenues than 3.4x for Abbott, this gap in the valuation is justified given.
- 08/25/2022
|
Abbott (ABT) to Offer New Treatment Option for Chronic Pain
- Abbott's (ABT) Proclaim Plus SCS system with FlexBurst360 therapy will cater to the changing needs of patients with chronic pain.
- 08/24/2022
|
The 'Halftime Report' investment committee offers its dividend picks
- Favorite dividend stock picks right now. With CNBC's Frank Holland the the 'Halftime Report' investment committee, Rob Sechan, Kevin O'Leary, Richard Saperstein and Shannon Saccocia
- 08/19/2022
|
Abbott (ABT) Down 0.7% Since Last Earnings Report: Can It Rebound?
- Abbott (ABT) reported earnings 30 days ago. What's next for the stock?
- 08/19/2022
|
3 Top Dividend Kings to Buy for the Long Haul
- You'll need to hold these stocks for many years to get the full benefit of their consistent dividend growth.
- 08/18/2022
|
Here is a Simple 4 Stock Portfolio that Can Outperform the Market
- Diversification is the edge for any portfolio. Rising inflation is impacting discretionary consumer spending as households try to stretch their wallets.
- 08/15/2022
|
Should Dividend Investors Add This Stock to Their Portfolios?
- This Dividend King pays shareholders a market-beating dividend.
- 08/14/2022
|
Abbott to add 1,000 jobs in $450 million Irish investment
- U.S. healthcare company Abbott Laboratories plans to hire 1,000 more people in Ireland in one of the biggest job announcements this year in the country's booming multinational sector, state investment agency IDA Ireland said on Friday.
- 08/12/2022
|
2 Dividend Kings That Have Hiked Their Payouts by More Than 50% in 5 Years
- These companies aren't stingy when it comes to making rate hikes.
- 08/11/2022
|
Abbott Laboratories' Dividend Strength Is Top Notch
- Dividend Aristocrat Abbott Laboratories is one of our favorite healthcare names. Abbott's dividend increases in recent years have been quite substantial, and the company yields a very nice 1.7% at the time of this writing.
- 08/10/2022
|
Should You Really Care About This Company's Short-Term Success?
- Abbott Laboratories' growth looks much less impressive after removing sales from COVID-19 diagnostics.
- 08/05/2022
|
Abbott Laboratories: A Lesser Johnson & Johnson?
- Similar to JNJ, ABT is a broadly diversified medical device and healthcare company. It has received much attention for its strong performance during the COVID-19 pandemic. ABT stock is down 20% from its all-time high, and one can rightly question whether ABT is a useful addition to a dividend growth portfolio.
- 08/04/2022
|
Abbott Laboratories: An Excellent Wealth Compounder You'll Want To Own
- ABT is a diversified healthcare company with strong growth prospects, an impressive track record of shareholder returns, and a fortress balance sheet. The company is moving past its infant formula recall, and has promising new products that should drive meaningful growth.
- 08/04/2022
|
Use These To Find Your Stock's Support and Resistance Levels
- A stock is a trading and investing instrument representative of an underlying business but surprisingly gets too often misunderstood in a bear market.
- 08/01/2022
|
3 Dividend Aristocrats to Buy in August
- These stocks have reliable dividends and strong underlying businesses.
- 07/31/2022
|
7 Blue-Chip Stocks to Buy Before the Bull Market Returns
- The bear market is firmly in place so long as the economy worsens. The incoming recession is a necessary headwind.
- 07/29/2022
|
7 Large-Cap Stocks to Buy on the Dip
- Following this year's sell-off, seasoned investors are increasingly hunting for large-cap stocks to buy on the dip. For instance, the S&P 500 index and Dow Jones Industrial Average have lost 185 and 13% so far in 2022.
- 07/27/2022
|
Why a Product Recall Won't Change This Company's Prospects
- This company's business won't fail that easily.
- 07/27/2022
|
Is Abbott Laboratories stock a ‘buy' after market-beating Q2 results?
- Abbott Laboratories (NYSE: ABT) down more than 20% for the year is an opportunity to buy a quality name at a deep discount, says Brenda Vingiello. She's the Chief Investment Officer at Sand Hill Global Advisors.
- 07/21/2022
|
Final Trades: Boeing, Invitation Homes, Abbott Labs & more
- The "Halftime Report" traders give their top picks to watch for the second half.
- 07/21/2022
|
Abbott is now aiming to recover the baby-formula market share that it lost
- Abbott Laboratories ABT, -1.35% is focused on recovering its position in the baby-formula market in the U.S. following the recall that required the intervention of the Biden administration to ensure that parents were able to feed their babies.
- 07/20/2022
|
A Debt-Free and Fairly Valued Medical Devices Company
- LeMaitre Vascular Inc. ( LMAT , Financial) has been on a roll—it has generated robust financial results and metrics that produced a high GF Score. But the share price has been in a slump.
- 07/20/2022
|
Abbott earnings top estimates as baby formula losses offset by COVID test sales
- Yahoo Finance medical reporter Anjalee Khemlani breaks down second-quarter earnings for Abbott Laboratories.
- 07/20/2022
|
Abbot Laboratories Stock Lower on Disappointing Forecast
- Abbott Laboratories (NYSE:ABT) is down 1.7% to trade at $107.79 at last glance, despite the company's strong second-quarter earnings and revenue, both of which beat estimates.
- 07/20/2022
|
Abbott Laboratories (ABT) CEO Robert Ford on Q2 2022 Results - Earnings Call Transcript
- Abbott Laboratories (NYSE:ABT ) Q2 2022 Earnings Conference Call July 20, 2022 9:00 AM ET Company Participants Scott Leinenweber - Vice President, Investor Relations, Licensing & Acquisition Robert Ford - Chairman & Chief Executive Officer Bob Funck - Executive Vice President, Finance & Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Joshua Jennings - Cowen Larry Biegelsen - Wells Fargo Joanne Wuensch - Citi Vijay Kumar - Evercore ISI Travis Steed - Bank of America Jayson Bedford - Raymond James Operator Good morning and thank you for standing by. Welcome to Abbott's Second Quarter 2022 Earnings Conference Call.
- 07/20/2022
|
Abbott (ABT) Q2 Earnings and Revenues Top Estimates
- Abbott (ABT) delivered earnings and revenue surprises of 31.19% and 8.67%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 07/20/2022
|
Abbott Lifts Annual Profit Guidance On Higher COVID-19 Test Sales
- Abbott Laboratories (NYSE: ABT) has reported Q2 FY22 adjusted EPS of $1.43, up 22.2% Y/Y, better than the consensus of $1.12. Q2 sales of $11.3 billion increased 10.1% on a reported basis and 14.3% on an organic basis, beating the consensus of $10.29 billion.
- 07/20/2022
|
What's Going On With Abbott Stock Today?
- Abbott Laboratories (NYSE: ABT) shares are trading lower Wednesday after the company reported financial results. Abbott said second-quarter revenue increased 10.1% year-over-year to $11.3 billion, which beat the estimate of $10.29 billion, according to data from Benzinga Pro.
- 07/20/2022
|
Abbott Laboratories shares fall in premarket despite second-quarter earnings beat
- Shares of Abbott Laboratories ABT, +2.72% fell 2.85% to $106.8 in premarket trading Wednesday although the company beat second-quarter earnings and sales estimates, fueled by sales of its COVID-19 tests. In the second quarter of 2022 Abbott reported earnings of $2.018 billion, or $1.14 per share, compared to earnings of $1.189 billion, or 66 cents a share, in the same period last year.
- 07/20/2022
|
Abbott raises 2022 profit forecast
- Abbott Laboratories on Wednesday raised its annual earnings forecast following strong demand for its medical devices and diagnostics products.
- 07/20/2022
|
3 Healthcare Stocks That Could Help Set You Up for Life
- These players are trading at bargain prices today.
- 07/19/2022
|
3 Dividend Growth Stocks You Can Buy Now and Hold Forever
- Recession or no recession, these well-established businesses are going to keep on growing.
- 07/19/2022
|
Abbott Labs Stock Can Be a Recession Hedge for Your Portfolio
- Diversified global medical science products maker Abbott (NYSE: ABT) stock is down a modest (-11.5%) on the year. Abbott provides full lifecycle health and medical products from baby formula to nutrition supplement products, chronic disease treatments and medical devices to generic pharmaceuticals
- 07/18/2022
|
3 Dividend Growth Stocks to Buy in July
- These three stocks have a lot in common.
- 07/17/2022
|
10 Dividend Growth Stocks For July 2022
- This monthly series ranks a selection of dividend growth stocks in Dividend Radar and presents the ten top-ranked stocks for consideration. To rank stocks, I use DVK Quality Snapshots to obtain quality scores, sort them in descending order, and break ties with additional metrics.
- 07/16/2022
|
3 Dividend Stocks That Should Pay You the Rest of Your Life
- These companies should provide steadily rising income to shareholders in the decades to come.
- 07/16/2022
|
Want to Get Richer? 5 Best Stocks to Buy Now and Hold Forever
- Health and wealth; it doesn't get much better than that.
- 07/16/2022
|
Abbott expects to start shipping EleCare infant formula next week
- Abbott Laboratories said on Friday it expects to begin releasing EleCare formula next week from its recently reopened Sturgis plant, which has been at the center of a baby formula shortage in the United States.
- 07/15/2022
|
Will Abbott Stock Rise After Its Q2 Results?
- A rise in the number of procedures performed will likely aid the company's medical devices sales, offsetting any decline in the diagnostics business, given that the segment benefited from higher Covid-19 testing in the prior-year quarter.
- 07/15/2022
|
My 11 Best Dividend Kings For July 2022
- The 44 Dividend Kings finished June in the red, collectively losing 5.39%. Last month, the 11 best dividend kings based on forecasted growth and valuation underperformed the average dividend king return by 152 bps.
- 07/14/2022
|
Abbott (ABT) Receives FDA's Breakthrough Device Designation For Exploring Deep Brain Stimulation To Manage Severe Depression
- Abbott (NYSE: ABT) announced that the FDA has granted Breakthrough Device Designation to investigate the use of its deep brain stimulation (DBS) system in treatment-resistant depression (TRD), which is a form of major depressive disorder (MDD). These are the details.
- 07/12/2022
|
4 Undervalued Names With Very High GF Scores
- Investors looking for stocks that could potentially outperform are encouraged to consider the GF Score at the top of each summary page.
- 07/10/2022
|
Abbott's troubled baby formula factory back in business
- Production is again underway at the Abbott Labs facility in Michigan which was shutdown twice this year amid the baby formula crisis.
- 07/09/2022
|
Abbott says it has reopened Michigan baby formula plant
- Abbott Laboratories has reopened its Sturgis, Michigan baby formula plant, which was shut last month due to heavy rains, a company spokesperson told Reuters on Saturday.
- 07/09/2022
|
3 Stalwart Stocks That Could Be Safer Than Amazon
- These businesses operate on a large scale but with a narrower focus than Amazon.
- 07/08/2022
|
Should You Buy Abbott Stock At $110?
- This marks an outperformance compared to some of its peers, with Medtronic stock rising around 1%, Boston Scientific stock up 9%, Stryker stock seeing a 30% growth, and the S&P 500 index rising 54% over the same period.
- 07/08/2022
|
Abbott: Successfully Handled The Infant Formula Crisis
- Abbott was caught in a middle of the infant formula crisis. 92% of the market is occupied by three companies, the closure of the plant in Michigan led to disastrous consequences.
- 07/04/2022
|
Abbott Finds Support Around $100
- Abbott has declined for roughly six consecutive months, falling about 40% from its late 2021 peak. Abbott seemed to bounce off of the $100 per share price on the last leg down, and that may end up being extreme support in the near term.
- 06/30/2022
|
ESLOY or ABT: Which Is the Better Value Stock Right Now?
- ESLOY vs. ABT: Which Stock Is the Better Value Option?
- 06/29/2022
|
Strength Seen in Abbott (ABT): Can Its 3.1% Jump Turn into More Strength?
- Abbott (ABT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
- 06/27/2022
|
Malcolm Ethridge: Invest in Iron Mountain, Abbott Labs, Microsoft
- Malcolm Ethridge, Executive Vice President at CIC Wealth, joins Worldwide Exchange to break down his top stock picks.
- 06/24/2022
|
FDA probes 5th infant illness tied to Abbott formula, former Nikola CEO charged with wire fraud
- Yahoo Finance anchor Julie Hyman reports some of the day's notable business headlines including the FDA investigating the death of an infant who consumed formula by Abbott Laboratories, Tesla CEO Elon Musk calling his factories “gigantic money furnaces” as firestorms surround the company, and former Nikola Motors CEO Trevor Milton being charged with wire fraud.
- 06/23/2022
|
FDA Probes Another Infant Death Given Abbott Formula, Less Than Month After Troubled Plant Reopens
- Problems for Abbott Laboratories' (NYSE: ABT) Sturgis plant in Michigan for baby formula powder refuse to subside. The FDA was recently notified of another infant's death who was given formula made at Abbott's Sturgis facility.
- 06/23/2022
|
7 ‘Strong Buy' Dividend Aristocrats Are Safe-Haven Stocks to Own During a Recession
- The market received the proverbial haymaker from the Federal Reserve last week, when the central bank raised interest rates by 75 basis points, the largest increase since November of 1994.
- 06/21/2022
|
3 Oversold Health Care Stocks Set for a Rebound
- With so much carnage in the stock market right now, investors are rushing to the exits trying to preserve what gains they have left. In a market-wide sell-off, stocks of all stripes get sold off, regardless of quality.
- 06/20/2022
|
Best Health Care Stocks To Buy Now? 3 To Watch
- Check out these health care stocks this holiday-shortened week.
- 06/20/2022
|
Finally, a Reasonable Price For This Healthcare Blue Chip
- Abbott Laboratories is a blue chip worth scooping up when it goes on sale.
- 06/20/2022
|
2 Top Healthcare Stocks Near 52-Week Lows to Buy
- These two businesses are stronger than ever, but their stock prices are at their lowest points in at least a year.
- 06/19/2022
|
3 Dividend Stocks to Double Up on Right Now
- They're profitable, growing, hiking their payouts, and surviving the bear market without breaking a sweat.
- 06/18/2022
|
Stock Market Drop: 3 Cheap Healthcare Stocks to Buy Right Now
- Declines in the market make now the time to go bargain hunting.
- 06/18/2022
|
Abbott baby formula factor down after storm, Revlon files for bankruptcy, WWE probes CEO settlement
- Yahoo Finance's Julie Hyman breaks down leading business headlines on the baby formula shortage, Revlon, and the WWE.
- 06/16/2022
|
Abbott pauses baby formula production in Michigan after heavy rains
- (Reuters) -Abbott Laboratories said on Wednesday it has stopped production of its EleCare specialty formula after severe storms in southwestern Michigan flooded areas of its plant in Sturgis, Michigan.
- 06/16/2022
|
What led to the U.S. baby formula shortage − and how officials are trying to prevent it from happening again
- In addition to a factory shutdown, America's strict formula import regulations and a nutritional program for low-income families may have contributed to the disaster.
- 06/15/2022
|
Baby formula shortage: Abbott to import formula from Spain this summer
- Abbott Laboratories announced Tuesday it will begin importing baby formula from a manufacturing facility in Spain to the U.S. to ease domestic shortages.
- 06/14/2022
|
ESLOY vs. ABT: Which Stock Is the Better Value Option?
- ESLOY vs. ABT: Which Stock Is the Better Value Option?
- 06/13/2022
|
7 Monkeypox Stocks That May Take Off in Q2
- SIGA Technologies (SIGA) may lead on the list of monkeypox stocks that could soar, but Bavarian Nordic seems to be leading the sales race. The post 7 Monkeypox Stocks That May Take Off in Q2 appeared first on InvestorPlace.
- 06/09/2022
|
Abbott Labs reportedly aware of problems at baby-formula factory in Michigan months earlier than known
- STURGIS, Mich. — Abbott Laboratories was alerted to allegations concerning problems at an infant-formula plant months earlier than previously publicly known, according to a government official, a person familiar with the matter and documents viewed by the Wall Street Journal.
- 06/08/2022
|
Abbott restarts shut-down factory, Icahn drops pregnant pig proxy fight with McDonald's and Kroger
- Abbott Nutrition has restarted its shut-down baby formula factory out of Michigan, Carl Icahn has dropped his pregnant pig proxy fight with McDonald's and Kroger, and Google will pay an Australian politician for ‘defamatory' YouTube videos.
- 06/06/2022
|
Abbott (ABT) FreeStyle Libre 3 System's Study Outcome Favorable
- Abbott's (ABT) FreeStyle Libre 3 system is the first and only 14-day CGM system with an overall MARD of 7.9%.
- 06/06/2022
|
Abbott labs reopening shuttered Michigan baby formula plant
- Abbott Laboratories has finally reopened the Sturgis, Michigan facility that was shuttered by the Food and Drug Administration in February.
- 06/04/2022
|
Abbott Nutrition restarts baby formula production in reopened Michigan plant
- Abbott Nutrition has resumed baby formula production at its Sturgis, Michigan, plant, in a move that aims to address a nationwide shortage.
- 06/04/2022
|
Abbott Nutrition resumes production of baby formula at Michigan facility following contamination
- "We will ramp production as quickly as we can while meeting all requirements," Abbott said, noting it will take three weeks to hit store shelves.
- 06/04/2022
|
Abbott Today Restarted Baby Formula Production At Michigan Plant
- Abbott Laboratories Saturday restarted infant formula production at its Sturgis, Mich., facility after meeting initial requirements agreed to with the U.S. Food and Drug Administration as part of an earlier consent decree with the agency.
- 06/04/2022
|
Abbott reopens baby formula plant in Michigan
- Abbott Laboratories said on Saturday that it has reopened its baby formula production plant in Sturgis, Michigan, taking a step toward alleviating an acute nationwide shortage that has sent parents scrambling for supplies.
- 06/04/2022
|
3 Top Dividend Kings to Buy for the Long Haul
- A bear market can test investors' patience, but these companies can help you survive.
- 05/28/2022
|
ESLOY vs. ABT: Which Stock Should Value Investors Buy Now?
- ESLOY vs. ABT: Which Stock Is the Better Value Option?
- 05/27/2022
|
Baby formula shortage hearing spotlights Abbott plant conditions, FDA oversight
- Yahoo Finance's Anjalee Khemlani reports the latest on the baby formula shortage.
- 05/26/2022
|
Abbott (ABT) to Commence Limited Release of EleCare Soon
- Abbott's (ABT) release of limited quantities of EleCare branded specialty formulas to be free of charge to children in need.
- 05/26/2022
|
Baby formula crisis: Products from closed plant won't hit shelves until at least mid-July, Abbott says
- Baby formula from Abbott Nutrition's shuttered manufacturing facility will not hit shelves until mid-July, an official says.
- 05/25/2022
|
House lawmakers take on baby-formula shortage: ‘We expect answers from the FDA, Abbott'
- Democratic and Republican lawmakers on Wednesday were putting a spotlight on makers of baby formula, the Biden administration, and industry experts due to an ongoing shortage, with two House hearings taking place on Capitol Hill.
- 05/25/2022
|
Abbott to restart production of EleCare formula on June 4
- Abbott Laboratories ABT, -1.10% said Tuesday it plans to restart manufacturing formula at its plant in Sturgis, Mich., on June 4, and it will prioritize production of EleCare, a hypoallergenic, amino acid-based formula.
- 05/25/2022
|
Abbott (ABT) Transcatheter Valve Devices' Study Data Favorable
- Abbott's (ABT) study data presented at EuroPCR 2022 reinforces the company's commitment to offering structural heart solutions, supported by clinical evidence that exceeds existing standards of care.
- 05/24/2022
|
The Wall Street Journal: Abbott CEO apologizes for baby formula shortage, promises production ramp-up
- Abbott Laboratories Chief Executive Robert Ford apologized Saturday for his company's role in the nationwide shortage of baby formula and promised production will ramp up again in June.
- 05/22/2022
|
'We're sorry' for U.S. baby formula shortage, Abbott CEO Ford says in Washington Post op-ed
- The apology by Abbott's CEO came after President Joe Biden signed a new law to deal with the baby formula shortage.
- 05/21/2022
|
What Could the Baby Formula Shortage Mean for Abbott Laboratories?
- There are more stormy waters ahead, but they might not be a problem in the end.
- 05/21/2022
|
Abbott Is A Great Company, But Its Price Makes It Unattractive
- Abbott is dealing with some significant pressure due to the baby formula shortage. The shares of Abbott are trading for a price 22% lower than the 52 weeks high.
- 05/20/2022
|
Abbott (ABT) Down 8.9% Since Last Earnings Report: Can It Rebound?
- Abbott (ABT) reported earnings 30 days ago. What's next for the stock?
- 05/20/2022
|
Abbott completes India recall of baby formula products imported from U.S
- Abbott Laboratories' India unit has completed a recall of baby formula products that were manufactured at the company's troubled Michigan facility in the United States, a spokesperson for the company said on Friday.
- 05/20/2022
|
Abbott baby formula plant on track to reopen within 1-2 weeks -FDA commissioner
- Abbott Laboratories and the U.S. Food and Drug Administration are on track to reopen the company's Sturgis, Michigan, baby formula manufacturing plant within one or two weeks, FDA Commissioner Robert Califf said on Thursday.
- 05/19/2022
|
What price will the supply chain pay for resiliency?
- At one time, a factory in Denmark run by pharmaceutical firm Novo Nordisk A/S (ADR: NVO) made half of the world's supply of insulin. Vowing to never run short of a product that people's lives depended upon, Novo kept a five-year supply in the deep freeze.
- 05/18/2022
|
Senate panel investigates Abbott tax practices after contamination shut down baby formula plant
|
ABT Stock Climbs as Abbott Reaches a Baby Formula Deal With the FDA
- ABT stock is climbing on reports that Abbott has reached a deal to restart baby formula production at its Sturgis, Michigan plant. The post ABT Stock Climbs as Abbott Reaches a Baby Formula Deal With the FDA appeared first on InvestorPlace.
- 05/17/2022
|
How the Infant Formula Recall Will Impact Abbott's Revenue
- Big losses in the company's offerings for tiny people might not be as bad as they seem.
- 05/17/2022
|
FDA and Abbott Nutrition reach deal to restart production of baby formula amid nationwide shortage
- Abbott said it could reopen its factory within two weeks, and then it would take six to eight more weeks for the products to reach stores.
- 05/16/2022
|
FDA reaches agreement with Abbott that could re-open formula plant
- CNBC's Valerie Castro joins Shep Smith to report on the nationwide baby formula shortage and the agreement reached with the FDA on a pathway to re-open the baby formula plant.
- 05/16/2022
|
Abbott Strikes Deal With FDA To Reopen Baby Formula Plant At Center Of National Shortage
- It could take more than 10 weeks for Abbott Laboratories' baby formula to reappear on store shelves, the company said.
- 05/16/2022
|
Abbott, FDA reach deal to resume making baby formula at U.S. plant amid shortage
- Abbott Laboratories and the Food and Drug Administration reached a deal Monday to restart production of baby formula at a U.S. plant that has been shut down amid a recall of the product, which contributed to a nationwide shortage of formula.
- 05/16/2022
|
Abbott reaches agreement with FDA to reopen baby formula plant to ease nationwide shortage
|
Explainer-What happened with Abbott baby formula that worsened a U.S. shortage?
- Abbott Laboratories, the biggest U.S. supplier of powder infant formula including Similac, initiated a recall and closed its Sturgis, Michigan, manufacturing plant earlier this year after reports of serious bacterial infections in four infants.
- 05/16/2022
|
Here's Why Investors Should Retain Abbott (ABT) Stock Now
- Strong performance across the Diabetes Care and EPD businesses is driving the top line for Abbott (ABT).
- 05/16/2022
|
Baby formula shortage has Abbott leaning on Ireland, Ohio factories
- Abbott Nutrition said Friday it has bolstered production at its baby formula manufacturing plants in Ireland and Michigan in an effort to ease the shortages exacerbated by the shutdown of its
- 05/13/2022
|
Abbott to extend baby formula rebates until at least Aug. 31
- Abbott Laboratories ABT, +1.40% said Friday that it will pay rebates for other infant formula products similar to Similac through August as a result of the current formula shortage caused in part by a recall at its plant in Michigan. The company has infant formula contracts with the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC).
- 05/13/2022
|
U.S. CDC closes investigation on Abbott's infant formula
- The U.S. Centers for Disease Control and Prevention (CDC) has closed its investigation on Abbott Laboratories' infant formula, with no additional cases of infections, according to a notice on the U.S. Food and Drug Administration website.
- 05/13/2022
|
3 Dividend Stocks You Can Buy and Hold for Decades
- You can really think long term with these great dividend stocks.
- 05/13/2022
|
Baby Formula Shortage: How Safety Concerns At An Abbott Facility Fueled A Crisis
- A whistleblower report released last month showed a former Abbott employee brought concerns about the facility months before the FDA issued a recall.
- 05/12/2022
|
Abbott says it will be at least two months before baby formula from shuttered plant hits shelves
- Abbott Nutrition, a major U.S. formula manufacturer, says it will be at least two months before baby formula made at its closed Sturgis, Michigan, plant will hit stores shelves after it reopens "subject to FDA approval."
- 05/11/2022
|
Abbott could restart infant formula production at Michigan plant
- Abbott Laboratories said on Wednesday it could restart production of infant formula at its troubled Michigan facility within two weeks.
- 05/11/2022
|
As a shortage worsens, Abbott says it can get baby formula back on store shelves in June
- Abbott Laboratories ABT, -0.42% said it can restart production of its baby formulas at a plant in Michigan within two weeks if U.S. regulators allow it to do so.
- 05/11/2022
|
3 Medical Product Stocks Set to Beat on Earnings This Season
- Medical product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how CGC, HAE and ALC are poised ahead of their earnings releases.
- 05/09/2022
|
What's Next for Abbott Laboratories' Stock?
- There are choppy waters ahead, but plenty of opportunity on the horizon.
- 05/07/2022
|
Abbott: Solid Conviction Pick
- Abbott's Q1 2022 earnings support a strong buy thesis for this perennial outperformer, with all segments save nutrition performing at peak levels. Abbott's new product pipeline has provided epic pandemic performance as it continues to produce and refresh Abbott's revenues.
- 05/06/2022
|
Better Dividend King: Johnson & Johnson vs. Abbott Laboratories
- Where's the safer place to park your money?
- 05/05/2022
|
The 5 Best Healthcare Stocks To Own Right Now
- People will always need medical treatment regardless of what is going on with the economy, which makes stocks in the healthcare sector consistently reliable investments.
- 04/28/2022
|
Here's the Worst News for Abbott Right Now (and Why Investors Shouldn't Worry)
- There's some sunshine around the dark cloud.
- 04/26/2022
|
3 Medical Product Stocks Poised to Beat This Earnings Season
- Medical product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how ALC, ZBH and CSII are poised ahead of their earnings releases.
- 04/25/2022
|
21 Bold Words from Abbott's CEO About the Future of Its COVID Tests
- Will sales plummet once the coronavirus shifts from being a pandemic-level threat to an endemic illness?
- 04/23/2022
|
Abbot tops first-quarter EPS by $0.26
- Abbot (NYSE: ABT) records a first-quarter EPS of $1.73, beating analyst estimates of $1.47 by 25 cents. The company recorded a first-quarter revenue of about $11.9 billion, which also topped the $11.02 billon consensus estimate.
- 04/22/2022
|
This Medical Devices Company Is A Better Pick Over Abbott Stock
- We think that Stryker Corp. stock (NYSE: SYK) currently is a better pick compared to its industry peer, Abbott stock (NYSE: ABT), despite it being the more expensive of the two, trading at 6.1x trailing revenues compared to 5.1x for Abbott.
- 04/22/2022
|
7 Stocks to Buy If You Think Inflation Is Topping Out
- Some analysts believe that the market may have seen peak inflation. Here are seven stocks to buy if inflation is at, or near, its peak The post 7 Stocks to Buy If You Think Inflation Is Topping Out appeared first on InvestorPlace.
- 04/22/2022
|
Abbott Laboratories reports a 14% YoY increase in Q1 sales
- Abbott Laboratories reported its financial results for the first quarter on Wednesday. Here's what you should know.
- 04/20/2022
|
Abbott predicts fewer sales of COVID-19 tests in 2022 but says the business of at-home tests isn't going away
- Abbott Laboratories, the maker of the popular rapid BinaxNow COVID-19 test, made $3.3 billion in revenue from its COVID-19 tests in the first three months of the year, far surpassing the $2.5 billion in COVID-19 tests that the company predicted it would sell over the entirety of 2022.
- 04/20/2022
|
Abbott Laboratories (ABT) CEO Robert Ford on Q1 2022 Results - Earnings Call Transcript
- Abbott Laboratories (NYSE:ABT ) Q1 2022 Earnings Conference Call April 20, 2022 9:00 AM ET Company Participants Scott Leinenweber - Vice President, Investor Relations, Licensing and Acquisition Robert Ford - Chairman and Chief Executive Officer Bob Funck - Executive Vice President Finance and Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Vijay Kumar - Evercore ISI Josh Jennings - Cowen and Company Larry Biegelsen - Wells Fargo Joanne Wuensch - Citigroup Travis Steed - Bank of America Matt Miksic - Credit Suisse Operator Good morning, and thank you for standing by. Welcome to Abbott's First Quarter 2022 Earnings Conference Call.
- 04/20/2022
|
Abbott's (ABT) Q1 Earnings and Revenues Exceed Estimates
- Within Adult Nutrition, Abbott (ABT) gains from the strong performance of Ensure and Glucerna brands in Q1.
- 04/20/2022
|
Highly Valued Abbot Laboratories Could Move Lower
- Abbott Laboratories (NYSE: ABT) is not in danger of losing its business but we have some concerns its share price could fall. Not only is it a highly-valued stock compared to peers but its current revenue and earnings are based largely on COVID-19.
- 04/20/2022
|
Abbott Clocks Q1 COVID-19 Test Sales Of $3.3B, Reaffirms FY22 EPS Outlook
- Abbott Laboratories (NYSE: ABT) has reported Q1 FY22 adjusted EPS of $1.73, up 31.1% Y/Y, better than the consensus of $1.47 and the management guidance of $1.50. Q1 sales of $11.9 billion increased 13.8% on a reported basis and 17.5% on an organic basis, beating the consensus of $11.02.
- 04/20/2022
|
Abbott reported $3.3 billion in sales of COVID-19 tests in the first quarter
- Shares of Abbott Laboratories ABT, +3.17% were down 2.0% in premarket trading on Wednesday though the company beat earnings and revenue expectations in the first quarter of 2022, driven in large part by more than $3 billion in sales of its COVID-19 tests. Abbott had earnings of $2.4 billion, or $1.37 per share, in the first quarter of 2022, up from $1.8 billion, or $1.00 per share, in the same quarter a year ago.
- 04/20/2022
|
Abbott reports 36% rise in quarterly profit on Omicron-driven testing demand
- Abbott Laboratories reported a 36% rise in quarterly profit on Wednesday, boosted by an Omicron-led demand for its COVID-19 test kits and a recovery in elective procedures, which boosted demand for its medical devices.The company's net earnings rose to $2.45 billion, or $1.37 per share, in the first quarter ended March 31, from $1.8 billion, or $1 per share, a year earlier.
- 04/20/2022
|
Why Abbott (ABT) Could Beat Earnings Estimates Again
- Abbott (ABT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 04/19/2022
|
Earnings Previews: Abbott Labs, Baker Hughes, Procter & Gamble
- Before markets opened on Monday, Bank of America reported first-quarter results that beat both revenue and profit estimates, and shares traded up about 1%.
- 04/18/2022
|
What's in Store for Abbott Laboratories (ABT) in Q1 Earnings?
- Excluding COVID testing sales, Abbott's (ABT) worldwide Diagnostic sales are expected to have demonstrated strong growth in Q1 on the continuous rollout of Alinity, Abbott's suite of diagnostic instruments.
- 04/18/2022
|
O'Rourke accuses Abbott of ‘spiking inflation,' ‘killing businesses' with now-repealed truck inspection policy
- Texas Democratic gubernatorial candidate Beto O'Rourke on Sunday accused Republican Gov. Greg Abbott of "spiking inflation" with his now-repealed truck inspection policy that clogged traffic at the Texas-Mexico border.
- 04/17/2022
|
2 Top Healthcare Stocks to Buy Right Now
- These stocks operate in different parts of the global healthcare industry.
- 04/16/2022
|
3 Top Dividend Kings to Buy for the Long Haul
- These three companies bring more to the table than an ever-increasing dividend.
- 04/15/2022
|
3 Best Life Sciences Stocks to Buy Now
- Thinking about digging into immunization stocks? Let's look more broadly, into life sciences stocks.
- 04/08/2022
|
Upcoming Ex-Dividend Dates: April 8-20, 2022
- Upcoming Ex-Dividend Dates: April 8-20, 2022
- 04/07/2022
|
Abbott (ABT) Aveir VR Leadless Pacemaker Receives FDA Nod
- Abbott's (ABT) Aveir VR is a leadless pacemaker designed to treat patients with slow heart rhythms in the United States.
- 04/05/2022
|
5 Top Health Care Stocks To Watch In The Stock Market Today
- Are these health care stocks on your watchlist right now?
- 04/03/2022
|
Here's Why Abbott's a Great Buy Even if COVID Testing Revenue Falls
- This company's other businesses are booming.
- 04/02/2022
|
Abbott's Bright Future In Connected Tech
- Abbott's base operations are hitting on all cylinders.
- 03/23/2022
|
Want to Beat the Market? 2 Stocks to Buy and Hold Forever
- Patience is the key to earning above-average returns.
- 03/22/2022
|
Here's Why You Should Retain Abbott (ABT) Stock for Now
- Investors are optimistic about Abbott (ABT) backed by its progress in the diabetes business.
- 03/21/2022
|
Abbott: Back Where We Were 12 Months Ago Is Not A Bad Place To Be
- I predicted Abbott would have a sensational year in 2021 thanks to COVID test revenues and set a price target of >$160.
- 03/17/2022
|
Abbott (ABT) Gains But Lags Market: What You Should Know
- In the latest trading session, Abbott (ABT) closed at $117.48, marking a +1.7% move from the previous day.
- 03/15/2022
|
3 Supercharged Dividend Stocks to Buy if There's a Stock Market Sell-Off
- They have the products that keep customers coming back again and again forever.
- 03/11/2022
|
Abbott (ABT) Gains But Lags Market: What You Should Know
- In the latest trading session, Abbott (ABT) closed at $118.39, marking a +1.96% move from the previous day.
- 03/09/2022
|
IHI: A Standout Performer With Equally Strong Future Growth Prospects
- IHI: A Standout Performer With Equally Strong Future Growth Prospects
- 03/05/2022
|
This Healthcare Company Is A Better Pick Over Abbott Stock
- We think that Thermo Fisher Scientific stock (NYSE: TMO) currently is a better pick compared to Abbott Labs stock (NYSE: ABT), with a similar market capitalization in the healthcare sector, despite its comparatively expensive valuation.
- 03/04/2022
|
Abbott (ABT) Gains But Lags Market: What You Should Know
- In the latest trading session, Abbott (ABT) closed at $120.36, marking a +1.85% move from the previous day.
- 03/02/2022
|
Best Time In Years To Buy These Core Dividend Growth Stocks
- The Russian invasion of Ukraine seems to have set off a reinvigorated bout of volatility in the markets.
- 02/25/2022
|
Should You Buy Abbott Stock After Its Recent Fall?
- This can largely be attributed to its recent voluntary recall of three types of baby formula - Similac, Alimentum, and EleCare - all manufactured in its Sturgis plant and with an expiration of April 1 or later.
- 02/24/2022
|
Abbott (ABT) COVID Testing Sales Surge, FX Headwind Stays
- Abbott (ABT) registers strong growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care.
- 02/23/2022
|
Want to Get Richer? 5 Best Stocks to Buy Now and Hold Forever
- These stocks will take your wealth to the next level while letting you sleep well at night.
- 02/22/2022
|
Abbott (ABT) Gets FDA Approval for CardioMEMS HF System
- Abbott's (ABT) CardioMEMS HF System will enable physicians to monitor for early warning signs of worsening heart failure before it progresses to a later stage.
- 02/22/2022
|
Is Now the Time to Buy This Blue-Chip Healthcare Stock?
- Abbott Laboratories recently became a Dividend King.
- 02/21/2022
|
Riding The Stock Waves: Update On The Medical Devices Sector
- Riding The Stock Waves: Update On The Medical Devices Sector
- 02/21/2022
|
China warns consumers not to use Abbott formula products
- China Customs has warned consumers from buying and eating infant and baby products of Abbott Laboratories, according to said in a post issued on Sunday on its website.
- 02/21/2022
|
Abbott recalls Similac, other baby formulas after 4 reported illnesses
- The FDA is urging consumers not to purchase or use certain Similac, Alimentum or EleCare powdered infant formulas produced at Abbott Nutrition's Sturgis, Michigan, facility while it investigates four cases of Cronobacter sakazakii and salmonella Newport infections in Ohio, Texas and Minnesota.
- 02/18/2022
|
Abbott Recalls Baby Formula Manufactured At Michigan facility
- Abbott Laboratories (NYSE: ABT) recalls powdered baby formulas, including Similac, made at a Michigan facility after four consumers complained about bacterial infections in infants who consumed the products. The complaints were related to Cronobacter sakazakii bacteria or Salmonella Newport.
- 02/18/2022
|
Abbott Labs Recalls Infant Formulas Amid FDA Warning
- The FDA is investigating consumer complaints that four babies became sick with bacteria infections after consuming products from Michigan plant
- 02/18/2022
|
Abbott recalls certain Similac baby formula made at Michigan facility
- Abbott Laboratories said on Thursday it was recalling powdered baby formulas, including Similac, made at a Michigan facility after four consumers complained about bacterial infections in infants who consumed the products.
- 02/17/2022
|
Abbott recalls some Similac, other powder baby formulas due to Salmonella, Cronobacter complaints
- Abbott Laboratories ABT, -2.51% said late Thursday it is voluntarily recalling powder baby formulas, including its best-selling Similac, made in one plant in Michigan after it received four consumer complaints related to the bacteria Cronobacter sakazakii or Salmonella Newport in infants who had consumed powder infant formula made in the factory. "During testing in our Sturgis, Mich.
- 02/17/2022
|
10 Health Care Stocks Warren Buffett Owns That Offer Safety and Dependable Dividends
- If any investor has stood the test of time, it is Warren Buffett, and with good reason.
- 02/14/2022
|
Why This Healthcare Giant Expects Decreased Covid Profits in 2022
- Abbott may soon be returning to its pre-pandemic days.
- 02/11/2022
|
The Vanguard Health Care Fund's Top 5 Trades
- The Vanguard Health Care Fund (Trades, Portfolio) released its fourth-quarter 2021 portfolio earlier this week.
- 02/10/2022
|
Here's Why You Should Retain Abbott (ABT) Stock For Now
- Investors continue to be optimistic about Abbott (ABT) owing to the strength in its diagnostics business.
- 02/10/2022
|
My Best Dividend Kings For February 2022
- The 36 Dividend Kings started 2022 on a sour note losing 3.88% during January. The 8 best dividend kings based on forecasted growth and valuation trailed the average dividend king return by 129 bps in January.
- 02/09/2022
|
Diamond Hill Capital Makes New Tech Bets, Sells Charles Schwab
- Diamond Hill Capital (Trades, Portfolio) recently disclosed its 13F portfolio updates for the fourth quarter of 2021, which ended on Dec. 31.
- 02/08/2022
|
3 Medical Products Stocks Poised to Beat This Earnings Season
- The Medical Products companies' Q4 results are likely to reflect base business recovery. Let's see how BAX, HSIC, and XRAY are poised ahead of their earnings releases.
- 02/07/2022
|
Abbott Stock is an Oversold Play
- Diversified global medical science products maker Abbott (NYSE: ABT) stock has sold off with the benchmark indexes in a throw the baby out with the bath water type reaction.
- 02/07/2022
|
The Coming Sell-Off May Be Huge: 5 Dividend Aristocrats to Buy Now for Safety and Income
- It was nice while it lasted, but the dumpster fire that was the quarterly earnings report from Meta Platforms (known for years as Facebook) may have lit the fuse for a continuation of the selling we saw almost the entire month of January.
- 02/04/2022
|
Abbott's (ABT) Diabetes Arm Booms, Neuromodulation Sales Soft
- Even though COVID-19 case rates are surging in the United States and other geographies, Abbott is seeing growth in its consumer-facing businesses like nutrition, EPD and diabetes care.
- 02/02/2022
|
Abbott Hedges Grid Bets As EU Advances Controversial Green Investment Plan
- Texas Governor Greg Abbott warned Texans that he could not guarantee they would not lose power in a looming winter storm, as officials at the EU advanced a plan to qualify nuclear and natural gas power plants as sustainable investments as they face a potential energy crisis of their own making.
- 02/02/2022
|
Eaton Vance Worldwide Health Sciences Fund Dumps Medtronic, Boosts Abbott Labs
- The Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) disclosed its portfolio for the fourth quarter of 2021 earlier this week.
- 01/28/2022
|
5 Top Health Care Stocks To Watch Before February 2022
- Should investors be paying more attention to these health care stocks?
- 01/27/2022
|
Abbott Lab's Sales Jumped 24.5% in 2021
- On Wednesday, Abbott Laboratories ( ABT , Financial) reported its earnings results for the fourth quarter and full year of 2021.
- 01/27/2022
|
Institutions Cap Gains In Abbot Laboratories
- As has become the theme of 1st quarter trading, it looks like institutional activity capped the gains in Abbot Laboratories (NYSE: ABT) but the bottom may already be in sight for shareholders. While the institutional activity shifted in favor of the bears in the 3rd and 4th quarters of 2021 the tide seems to be turning again.
- 01/27/2022
|
Annual Forecast Weighs On Healthcare Name
- Abbot Laboratories (ABT) announced better-than-expected fourth-quarter earnings results ahead of the open today.
- 01/26/2022
|
Cramer's Investing Club: We believe the market is wrong on core holding Abbott's future potential
- Abbott management, known for under promising and over delivering, will do better than Wall Street thinks.
- 01/26/2022
|
Abbott Laboratories (ABT) CEO Robert Ford on Q4 2021 Results - Earnings Call Transcript
- Abbott Laboratories (ABT) CEO Robert Ford on Q4 2021 Results - Earnings Call Transcript
- 01/26/2022
|
Abbott's (ABT) Q4 Earnings and Revenues Beat Estimates
- Abbott's (ABT) COVID-19 testing-related sales in Q4 increased on demand for BinaxNOW, Panbio and ID NOW rapid testing platforms.
- 01/26/2022
|
Stocks Gain as Tech Rallies and Investors Await Fed Rate Decision
- U.S. stocks are moving higher, led by tech, after another volatile trading day ahead of a Fed announcement about the future of monetary policy.
- 01/26/2022
|
Abbott (ABT) Q4 Earnings and Revenues Surpass Estimates
- Abbott (ABT) delivered earnings and revenue surprises of 11.86% and 8.52%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 01/26/2022
|
Abbott Beats Earnings Expectations. The Stock is Down.
- Shares of the maker of a leading Covid-19 at-home antigen test were down slightly in premarket trading Wednesday.
- 01/26/2022
|
Abbott Posts $2.3B In COVID-19 Test Sales In Q4; Issues FY22 Outlook
- Abbott Laboratories (NYSE: ABT) has reported Q4 FY21 adjusted EPS of $1.32, down from $1.45 a year ago but better than the consensus of $1.21. Q4 sales of $11.5 billion increased 7.2% on a reported basis and 7.7% on an organic basis, beating the consensus of $10.71 billion.
- 01/26/2022
|
Abbott sold $2.3 billion in COVID-19 tests in the fourth quarter
- Shares of Abbott Laboratories ABT, -0.44% were down 0.8% in premarket trading on Wednesday. The company beat expectations for both earnings and revenue in the fourth quarter, bolstered by more than $2 billion in sales of its COVID-19 tests during the quarter's omicron surge.
- 01/26/2022
|
S&P 500 Corrects Ahead Of Fed Meeting: Let's Check The Technicals
- It's been a crazy start to what is expected to be the most pivotal week of Q1 market action.
- 01/25/2022
|
Abbott Laboratories Can be a Port in the Market Storm
- First the bad news. Abbott Laboratories (NYSE:ABT) reports earnings tomorrow and there is growing sentiment that it will miss on either the top line or bottom line or both.
- 01/25/2022
|
Will Abbott Stock Rise After Its Q4 Results?
- Abbott is scheduled to report its Q4 2021 results on Wednesday, January 26, and we expect it to be below the consensus estimates. A rise in Covid-19 cases in Q4 due to the spread of the Omicron variant likely aided Covid-19 testing demand for the company, bolstering its diagnostics business.
- 01/25/2022
|
Earnings Previews: Abbott Labs, AT&T, Boeing, Freeport-McMoRan
- We have well and truly arrived at the December-quarter earnings reporting season. Hundreds of results are due out this week, including those from the two largest U.S.
- 01/24/2022
|
Earnings Outlook: Abbott's share price soared as COVID-19 testing demand surged. Here's what that may mean for the company's fourth-quarter earnings
- Abbott Laboratories Inc.'s ABT, -3.59% stock hit a 10-year high of $141.46 on Dec. 27 at the same time that people across the U.S. were scrambling to find COVID-19 tests due to the rapidly spreading omicron variant.
- 01/24/2022
|
Is a Surprise Coming for Abbott (ABT) This Earnings Season?
- Abbott (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 01/24/2022
|
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
- Both of these healthcare stalwarts offer dividends and double-digit revenue growth
- 01/22/2022
|
Abbott Laboratories: Shelter Your Capital With This SWAN Stock
- Abbott Laboratories has a moat-worthy business and is set to benefit from demographic tailwinds. It's benefiting from cost savings and management continues the company's track record of innovation.
- 01/22/2022
|
3 Things About Abbott Laboratories That Smart Investors Know
- It isn't a stock for the impatient.
- 01/21/2022
|
Rise in COVID-19 Test Demand to Boost Abbott (ABT) Q4 Earnings
- With the latest surge in COVID infections due to the more contagious Omicron variant, Abbott (ABT) is expected to report sequentially stronger diagnostics results for the fourth quarter.
- 01/21/2022
|
Final Trades: Bank of America, Abbott Labs, Starbucks & more
- The "Halftime Report" traders give their top picks to watch for the second half.
- 01/20/2022
|
Why Has Abbott Stock Dropped In January And Is A Rebound Likely?
- Abbott Laboratories has seen its shares come down in recent weeks. Interest rate movements and COVID themes played a role in that. Despite the recent decline, shares aren't especially cheap. ABT still trades at a somewhat elevated valuation relative to its expected growth.
- 01/20/2022
|
3 Dividend Stocks to Buy and Hold Forever
- Investors wanting dividends to fortify their portfolio should consider dividend stocks that deliver outsized payments to shareholders. The post 3 Dividend Stocks to Buy and Hold Forever appeared first on InvestorPlace.
- 01/19/2022
|
Abbott's (ABT) Organic Base Sales Grow Amid COVID Case Surge
- Even though COVID-19 case rates are surging, Abbott (ABT) is registering growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care.
- 01/18/2022
|
Will Demand for Rapid COVID-19 Tests Help Abbott Laboratories Beat the Market in 2022?
- It didn't work out that way in 2021.
- 01/16/2022
|
Abbott (ABT) Gets FDA Nod for New Cardiac Mapping System
- Abbott's (ABT) EnSite X EP System with EnSite Omnipolar Technology offers a 360-degree view of the heart, regardless of catheter orientation, for cardiac mapping without compromise.
- 01/14/2022
|
3 Reasons to Buy This Newly Minted Dividend King
- Abbott Laboratories recently joined the ranks of dividend payer royalty.
- 01/13/2022
|
FDA Clears Abbott's Latest EnSite Heart Mapping Platform
- Abbott Laboratories (NYSE: ABT) has scored clearance from the FDA for its latest 3D cardiac mapping platform, designed to help physicians target abnormal heart rhythms. The EnSite X EP system threads a catheter into the heart to chart out the regions of the cardiac muscle where unsteady electric pulses can cause irregular heartbeats and then guides surgeons in treating those areas with ablation procedures.
- 01/12/2022
|
Upcoming Ex-Dividend Dates: January 13-26, 2022
- Upcoming Ex-Dividend Dates: January 13-26, 2022
- 01/12/2022
|
Abbott (ABT) Gains But Lags Market: What You Should Know
- In the latest trading session, Abbott (ABT) closed at $135.70, marking a +0.33% move from the previous day.
- 01/11/2022
|
How to Analyze Dividend Stocks
- For many investors, dividends are an integral part of investing. Some investors will only buy companies with dividends, and some will only buy companies with high dividend yields compared to the rest of the market.
- 01/11/2022
|
Why Abbott (ABT) Could Beat Earnings Estimates Again
- Abbott (ABT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 01/11/2022
|
Omicron-specific vaccines are ‘already priced into COVID stocks': Jefferies Managing Director
- Jefferies Managing Director Michael Yee joins Yahoo Finance Live's Julie Hyman and Brian Sozzi to discuss the biotech sector, outlook for M&A activity, and the outlook for COVID-19 stocks.
- 01/11/2022
|
Abbott Laboratories (ABT) CEO Robert Ford Presents at JPMorgan 40th Annual Healthcare Brokers Conference (Transcript)
- Abbott Laboratories (ABT) CEO Robert Ford Presents at JPMorgan 40th Annual Healthcare Brokers Conference (Transcript)
- 01/11/2022
|
Abbott Labs CEO expects strong COVID-19 testing demand in near term
- Abbott Laboratories Chief Executive Officer Robert Ford said on Tuesday demand for COVID-19 testing has surged globally and that sales of its tests should stay strong in the near term.
- 01/11/2022
|
3 Top Stock Trades for the Week of Jan. 10, 2022
- Sellers continue to push their advantage making it necessary to play defense to win. Here are three top stock trades for the new week.
- 01/10/2022
|
Abbott Labs rips ‘bad actors' reselling COVID tests above retail price
- Over-the-counter COVID-19 tests are in high demand as the Omicron variant drives a record surge in daily infections.
- 01/07/2022
|
10 Upcoming Dividend Increases Including The 'Abbotts'
- All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. They have an average increase of 7.1% and a median increase of 7.2%. I've tracked 21 increases in 2022.
- 01/06/2022
|
Abbott's (ABT) Proclaim XR SCS Gets FDA Nod for New MRI Label
- The latest FDA approval is set to augment Abbott's (ABT) Neuromodulation arm, which is having a hard time amid the COVID spell due to its elective nature of business.
- 01/05/2022
|
Upcoming Ex-Dividend Dates: January 6-17, 2022
- We provide a summary of upcoming ex-dividend dates in a quick reference table. The table includes relevant data and key statistics as well as the next payout and pay date.
- 01/05/2022
|
Abbott Hosts Conference Call for Fourth-Quarter Earnings
- ABBOTT PARK, Ill., Jan. 4, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its fourth-quarter 2021 financial results on Wednesday, Jan. 26, 2022, before the market opens.
- 01/04/2022
|
Abbott (ABT) Stock Sinks As Market Gains: What You Should Know
- In the latest trading session, Abbott (ABT) closed at $139.04, marking a -1.21% move from the previous day.
- 01/03/2022
|
Here's Why You Should Invest in Abbott (ABT) Stock Right Now
- Riding on current business growth and bullish near-term prospects, Abbott (ABT) is worth investing in for now.
- 12/31/2021
|
5 Dividend Stocks To Watch In 2022
- Could these dividend stocks be big winners in the new year?
- 12/30/2021
|
3 Dividend Kings That Are Yielding More Than 3%
- You don't need to sacrifice a good yield for safety.
- 12/30/2021
|
Abbott (ABT) Diagnostic and Nutrition Arms Grow Worldwide
- Abbott (ABT) registers strong growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care.
- 12/29/2021
|
Abbott (ABT) Scales to a 52-Week High: What's Driving It?
- Strength in Diabetes Care and Diagnostics businesses is driving Abbott's (ABT) top line.
- 12/28/2021
|
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
- Their products are indispensible, and their continued growth is nearly guaranteed.
- 12/28/2021
|
3 Dividend Stocks to Buy If the Market Crashes in 2022
- The next crash is always around the corner, so get ready.
- 12/26/2021
|
Abbott (ABT) Gains But Lags Market: What You Should Know
- Abbott (ABT) closed at $135.27 in the latest trading session, marking a +0.21% move from the prior day.
- 12/21/2021
|
Best Long Term Stocks To Buy? 4 Health Care Stocks For Your Watchlist
- Could these health care stocks be worth looking out for as the new year approaches?
- 12/21/2021
|
COVID Testing Kit Makers Respond To Biden's Call For 500 Million Free At-Home Tests
- President Joe Biden announced his administration's strategy for curbing the spread of the omicron variant of the coronavirus includes ordering 500 million at-home tests to ship free to Americans. What Happened: During a Tuesday afternoon speech, Biden said omicron will cause breakthrough infections among vaccinated Americans in “potentially in large numbers,” although the cases are unlikely to be severe, he added.
- 12/21/2021
|
3 Reasons Why Abbott (ABT) Is a Great Growth Stock
- Abbott (ABT) possesses solid growth attributes, which could help it handily outperform the market.
- 12/21/2021
|
ABT or RMD: Which Is the Better Value Stock Right Now?
- ABT vs. RMD: Which Stock Is the Better Value Option?
- 12/21/2021
|
Is Abbott (ABT) Stock Outpacing Its Medical Peers This Year?
- Here is how Abbott (ABT) and Organogenesis (ORGO) have performed compared to their sector so far this year.
- 12/21/2021
|
Abbott to Present at J.P. Morgan Healthcare Conference
- ABBOTT PARK, Ill., Dec. 21, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) will present virtually at the 40th Annual J.P.
- 12/21/2021
|
3 Great Stocks to Buy With the Omicron Variant Spreading Like Wildfire
- Bad news related to COVID-19 could be good news for these stocks.
- 12/21/2021
|
My Dividend Growth Portfolio Final 2021 Recap - Record Growth And A New Position Established
- Total income will finish 2021 at $13,662, an increase of 13.9% over the previous year.
- 12/20/2021
|
3 COVID Stocks That Will Pay You Rich Dividends in 2022
- Here's why you might want to own Pfizer, Merck, or Abbott Labs next year.
- 12/16/2021
|
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
- Abbott (ABT) closed the most recent trading day at $135.56, moving +1.97% from the previous trading session.
- 12/15/2021
|
Abbott Laboratories Stock (ABT): Why It Increased
- The stock price of Abbott Laboratories (NYSE: ABT) increased by 1.39% in the previous trading session. This is why it happened.
- 12/12/2021
|
CVS, Abbot, and Other Companies That Raised Their Dividends This Week
- Zoetis, Pentair, Johnson Controls International, and Abbott Laboratories were among the many companies that declared dividend increases this week.
- 12/12/2021
|
3 Healthcare Stocks for Long-Term Dividend Growth
- When selecting dividend stocks to buy, investors are faced with a variety of choices. However, we like healthcare stocks for many reasons, particularly given inherent recession resilience and long-term earnings growth.
- 12/10/2021
|
My Dividend Growth Portfolio November Update: 27 Holdings, 7 Buys, 4 Sells
- The portfolio generated $1,067 in dividends during the month, an improvement over August. YTD, I've received $12,700. I closed out my positions in REM, DIS, MLPA, and SPYD.
- 12/09/2021
|
Abbott (ABT) Stock Sinks As Market Gains: What You Should Know
- Abbott (ABT) closed at $132.37 in the latest trading session, marking a -0.04% move from the prior day.
- 12/08/2021
|
Abbott: Detection Is Still Key To Limit Infection Amid Covid Mutations
- Abbott's Covid test kits which have enabled the company to rapidly overcome mid-2020 revenue lows are now essential tools in limiting infection rates throughout the world.
- 12/08/2021
|
3 Stocks to Capitalize on the Buoyant Medical Products Industry
- Despite the COVID-19 pandemic induced challenges, rising demand for IVD coupled with dependence on AI & Robotics should lend support to the Zacks Medical-Products industry. ABT, BIO and HRC are well-poised to gain from the prospects.
- 12/07/2021
|
6 Dividend Increases Expected In December 2021
- 6 Dividend Increases Expected In December 2021
- 12/07/2021
|
5 ‘Strong Buy' Blue Chip Stocks With Dividend Hikes Expected This Week
- After years of a low interest rate environment, many investors have turned to equities not only for the growth potential but also for solid and dependable dividends, which help to provide an income stream.
- 12/06/2021
|
7 Stocks to Buy to Give Your Portfolio a Booster Shot
- With the omicron variant of Covid-19 already touching down in the U.S., here are the stocks to buy to inoculate your portfolio. The post 7 Stocks to Buy to Give Your Portfolio a Booster Shot appeared first on InvestorPlace.
- 12/06/2021
|
Chantico Global CEO invests in Thermo Fisher, Abbott Labs due to ongoing pandemic
- Chantico Global CEO Gina Sanchez joins the 'Halftime Report' to discuss where she's investing in the markets as the pandemic drags on.
- 12/03/2021
|
Abbott (ABT) Nutrition Sales Strong Amid Spike in COVID Cases
- Abbott (ABT) is registering strong growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care.
- 12/03/2021
|
Abbott (ABT) Gains But Lags Market: What You Should Know
- In the latest trading session, Abbott (ABT) closed at $128.38, marking a +1.29% move from the previous day.
- 12/02/2021
|
4 MedTech Dividend Stocks in Focus on Amid Omicron Variant Panic
- Abbott Laboratories (ABT), West Pharmaceuticals Services (WST), Baxter International (BAX) and Chemed Corporation (CHE) are high-yield dividend stocks with sustainable business models.
- 12/02/2021
|
5 Health Care Dividend Aristocrats to Buy for 2022 as Yields Plunge Once Again
- Just when you thought it was starting to look safer, yet another COVID-19 variant comes around.
- 12/01/2021
|
Abbott: Vaccinate Your Portfolio With A Pandemic-Resistant Dividend Aristocrat
- Abbott's Q3, 2021 exemplified its pandemic resistance. Abbott's COVID-19 testing has grown to a major contributor for Abbott, counterbalancing the pandemic challenges elsewhere in its business.
- 11/30/2021
|
Here's Why You Should Retain Abbott (ABT) Stock For Now
- Investors are optimistic about Abbott (ABT) owing to strong third-quarter results and bullish 2021 outlook.
- 11/26/2021
|
3 Stocks Likely To Drop Huge Dividend Hikes In December
- We've just hit the best time of the year to roll out one of our most potent dividend “hacks.”
- 11/24/2021
|
1 To Buy Out Of 37 Billionaire Holdings In November
- Kiplinger Investing publishes opportune source-lists for investors online. Two recent billionaires stock-lists by Dan Burrows were published 6/1/21 and 9/9/21. 20 of the 37 billionaire-held stocks pay dividends. As of 11/21/21, the top-ten ranged 1.28%-5.77% by annual yield and ranged 18.52%-56.53% per broker-estimated price-target upsides.
- 11/23/2021
|
Rapid Covid-19 tests in high demand ahead of Thanksgiving
- CNBC's Meg Tirrell joins 'Squawk Box' to report on the increased demand for Covid-19 tests ahead of the Thanksgiving holiday.
- 11/23/2021
|
Abbott Laboratories: Momentum Has Returned
- After Abbott Laboratories ( ABT , Financial) reported its second-quarter earnings results late last July, the stock fell as leadership had lowered its guidance. The stock had been on the upswing as it looked like the company was going to produce its best year ever, so the downward revised guidance spooked investors.
- 11/18/2021
|
Abbott (ABT) Introduces New Next-Generation Infant Formula
- Abbott's (ABT) Similac 360 Total Care contains five different HMOs, similar to human breast milk, to support the health and development of an infant.
- 11/17/2021
|
This Pharma Stock Appears To Be A Better Pick Over Abbott Labs
- We think that Eli Lilly stock currently is a better pick compared to Abbott Labs stock with similar market capitalization in the healthcare sector, despite Eli Lilly being the more expensive of the two. LLY stock trades at about 9.5x trailing revenues, compared to 5.5x for ABT stock.
- 11/17/2021
|
Better Buy: DexCom or Abbott Labs?
- Abbott's the heavyweight, and DexCom is the formidable challenger.
- 11/17/2021
|
Abbott (ABT) Scales to a 52-Week High: What's Driving It?
- Strong performance by the Diabetes Care and Diagnostics businesses is driving the top line for Abbott (ABT).
- 11/16/2021
|
Abbott (ABT) Aveir System Meets Primary Pivotal Trial Endpoints
- Abbott's (ABT) Aveir pacing system has the potential to advance treatment for patients who need a pacemaker but where physicians are concerned about more invasive surgery.
- 11/15/2021
|
2 Dividend Aristocrats That Could Announce Generous Rate Hikes in December
- Buy now to take advantage of what will likely be higher yields to come.
- 11/11/2021
|
Why Abbott (ABT) is a Top Momentum Stock for the Long-Term
- Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 11/10/2021
|
Best Stocks To Buy Today? 4 Dividend Stocks To Check Out
- Dividend stocks could be worth paying attention to as the Federal Reserve may look to pull back its monetary support.
- 11/03/2021
|
4 Medical Products Stocks Poised to Beat This Earnings Season
- Amid concerns surrounding growing COVID-19 cases affecting the medical products companies' legacy business, we are optimistic about IDXX, HSIC, CGC and PODD's results this time around.
- 10/28/2021
|
Earnings Estimates Rising for Abbott (ABT): Will It Gain?
- Abbott (ABT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- 10/27/2021
|
Has Abbott Laboratories (ABT) Outpaced Other Medical Stocks This Year?
- Is (ABT) Outperforming Other Medical Stocks This Year?
- 10/26/2021
|
Abbott's (ABT) Organic Sales Grow Amid Spike in COVID Cases
- Within Nutrition, the robust year-over-year performance of Abbott's (ABT) U.S. pediatric and international adult nutrition arms drives the company in the third quarter.
- 10/25/2021
|
Why Abbott Laboratories Shot Higher Today
- All four of the company's divisions posted strong growth, but one in particular was a standout.
- 10/20/2021
|
Is it too late to buy Abbott shares after raising FY2021 earnings guidance?
- On Wednesday, Abbott Laboratories (NYSE:ABT) shares surged nearly 4% after announcing solid fiscal third-quarter results. The company reported its most recent quarterly revenue and earnings before markets opened, beating the consensus Street expectations.
- 10/20/2021
|
Abbott Laboratories (ABT) CEO Robert Ford on Q3 2021 Results - Earnings Call Transcript
- Abbott Laboratories (ABT) CEO Robert Ford on Q3 2021 Results - Earnings Call Transcript
- 10/20/2021
|
Pre-Markets Opens Flat
- Pre-Markets Opens Flat
- 10/20/2021
|
Abbot Labs and Biogen Outshine Novavax in the Health Care Sector
- Just before Tuesday's close, Netflix (NASDAQ: NFLX) reported better-than-expected earnings by adding 4.4 million subscribers in the third quarter. The company cited a robust slate of content including the hit Korean television show “Squid Game,” which helped bring in new subscribers.
- 10/20/2021
|
ABT Stock: Why The Price Increased Today
- The stock price of Abbott Laboratories (NYSE: ABT) increased by over 4% during intraday trading today. This is why it happened.
- 10/20/2021
|
Abbott's Q3 Profit Jumps 70% On Robust COVID-19 Test Sales
- Abbott Laboratories (NYSE: ABT) reported a 70.5% rise in quarterly profit to $2.1 billion, helped by strength in its medical devices and diagnostics businesses due to a rebound in COVID-19 test sales amid the spread of the Delta variant of the coronavirus. Abbott reported an adjusted EPS of $1.40, beating the consensus estimate of $0.94.
- 10/20/2021
|
Abbott Laboratories stock surges after big profit and sales beats, and upbeat full-year outlook
- Shares of Abbott Laboratories ABT, +2.16% rallied 2.8% in premarket trading Wednesday, after the health care company reported third-quarter profit and sales that rose well above expectations, with the strongest growth seen in its diagnostics business, and provided an upbeat full-year outlook. Net income rose to $2.52 billion, or $1.17 a share, from $1.76 billion, or 69 cents a share, in the year-ago period.
- 10/20/2021
|
Abbott raises annual profit forecast after upbeat quarterly results
- (Reuters) -Abbott Laboratories raised its full-year adjusted earnings forecast after reporting a rise in quarterly profit, driven by strength in its mainstay businesses and a rebound in COVID-19 test sales due to the spread of the Delta variant.
- 10/20/2021
|
5 Must-See Earnings Charts This Week
- What's going on in the economy? These five companies will give us some clues this week.
- 10/19/2021
|
Abbott Laboratories's Earnings Outlook
- Abbott Laboratories(NYSE:ABT) is set to give its latest quarterly earnings report on Wednesday, 2021-10-20. Here's what investors need to know before the announcement.
- 10/19/2021
|
Will Abbott Stock Rise After Its Q3 Results?
- Abbott is scheduled to report its Q3 2021 results on Wednesday, October 20, and we expect it to be slightly above the consensus estimates, driven by a rise in demand for medical devices as well as its established pharmaceuticals business. A rise in Covid-19 cases in Q3 due to the spread of the.
- 10/19/2021
|
Consider Abbott Laboratories Now While It's Dipping
- Abbott Labs has dipped from its recent highs near $130 and presents a buying opportunity under $120.
- 10/18/2021
|
3 Solid Growth Stocks Perfect for Retirees
- In order to combat the effects of inflation, all retirees need some exposure to growth in their portfolios.
- 10/17/2021
|
This 1 Medical Stock Could Beat Earnings: Why It Should Be on Your Radar
- Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
- 10/15/2021
|
Make Money In Your Sleep: 3 Big Dividends To Buy Today
- For high yield hunters, market corrections are an opportunity to enhance their income stream.
- 10/15/2021
|
Abbott (ABT) Gains But Lags Market: What You Should Know
- In the latest trading session, Abbott (ABT) closed at $117.57, marking a +0.49% move from the previous day.
- 10/14/2021
|
Analysts Estimate Abbott (ABT) to Report a Decline in Earnings: What to Look Out for
- Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 10/13/2021
|
Growing COVID-19 Testing Demand to Boost Abbott's (ABT) Q3 Earnings
- Through July to September, Abbott's (ABT) Diagnostic business is likely to have benefited from the significant surge in the new COVID-19 case counts.
- 10/13/2021
|
White House pushes back on Abbott's executive order
- CNBC's Seema Mody reports on the Biden administration's response to Texas Gov. Abbott's ban of vaccine mandates among employers in the state.
- 10/12/2021
|
Upcoming Ex-Dividend Dates: October 12-25, 2021
- We provide a summary of upcoming ex-dividend dates in a quick reference table. The table includes relevant data and key statistics as well as the next payout and pay date.
- 10/10/2021
|
Abbott President & CEO Robert Ford on revolutionizing COVID-19 at-home testing technology
- On this episode of Yahoo Finance Presents, Abbott President & CEO Robert Ford, sat down with Yahoo Finance's Anjalee Khemlani to discuss Abbott's upcoming keynote address at CES 2022 and COVID-19 test pricing and supply chain challenges. Don't Miss: Valley of Hype: The Culture That Built Elizabeth Holmes WATCH HERE: https://youtu.be/Sb179GLPNYE Watch the 2021 Berkshire Hathaway Annual Shareholders Meeting on YouTube: https://youtu.be/gx-OzwHpM9k
- 10/08/2021
|
Abbott Labs CEO on demand for Covid-19 tests amid delta variant
- Abbott Laboratories CEO Robert Ford joins 'TechCheck' to explain why he's confident the company can supply Covid-19 testing to meet demand and whether Abbott is considering investing in AI software.
- 10/07/2021
|
Abbott CEO on health care technology, taking over the company, and at-home COVID-19 testing success
- Anjalee Khemlani spoke with Abbott CEO Robert Ford about the company's historic keynote address at CES, Robert Ford's adjustment to taking the reins of Abbott, at-home testing, and the importance of healthcare technology. Don't Miss: Valley of Hype: The Culture That Built Elizabeth Holmes WATCH HERE: https://youtu.be/Sb179GLPNYE Watch the 2021 Berkshire Hathaway Annual Shareholders Meeting on YouTube: https://youtu.be/gx-OzwHpM9k
- 10/05/2021
|
Upcoming Ex-Dividend Dates: October 5-18, 2021
- We provide a summary of upcoming ex-dividend dates in a quick reference table. The table includes relevant data and key statistics as well as the next payout and pay date.
- 10/02/2021
|
Abbott Commits to Reducing Malnutrition Globally with Launch of Abbott Center for Malnutrition Solutions
- ABBOTT PARK, Ill., Sept. 30, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) announced today the creation of the Abbott Center for Malnutrition Solutions, an innovation hub focused on reducing malnutrition around the world.
- 09/30/2021
|
With Covid-19 Cases Falling Again Will Abbott Stock See Higher Levels?
- The stock price of Abbott has seen a drop of 5% over the last one month (twenty-one trading days). It reached its 52-week high level of around $130 on September 13, before a slight decline to levels of $119 currently.
- 09/30/2021
|
This Stock Is Likely To Outperform Abbott Laboratories
- We think that Dexcom stock currently is a better pick compared to Abbott stock, despite Dexcom being more expensive of the two. Dexcom trades at about 25x trailing revenues, compared to just 5x for Abbott.
- 09/29/2021
|
Abbott (ABT) Stock Moves -1.53%: What You Should Know
- Abbott (ABT) closed the most recent trading day at $118.74, moving -1.53% from the previous trading session.
- 09/28/2021
|
Abbot Laboratories Stock Could Soon Stage a Comeback
- Abbott Laboratories (NYSE:ABT) stock has been falling from its recent September 13 record high of $129.69.
- 09/28/2021
|
Going One Better Than The Dividend Aristocrats
- The Dividend Aristocrats have historically beat the market with less volatility. Can you improve your odds by paying attention to certain metrics such as quality or safety?
- 09/27/2021
|
3 Winning Stocks to Buy No Matter What the Market Is Doing
- These companies are set to increase revenue -- whether the economy is booming or not.
- 09/26/2021
|
BME: Defensive Healthcare Exposure With A Distribution Yield Of ~5%
- BME: Defensive Healthcare Exposure With A Distribution Yield Of ~5%
- 09/24/2021
|
3 Promising MedTech Stocks to Snap Up in Second-Half 2021
- Backed by robust long-term prospects, investors can add three lucrative MedTech stocks, MMSI, ITGR and OFIX, to their watchlist.
- 09/23/2021
|
Else Nutrition hires former Abbott Laboratories executives as it continues its expansion
- Else Nutrition Holdings Inc, a plant-based baby, toddler and children's nutrition company, has announced two strategic additions to its executive team as it moves into its next phase of growth. It also updated investors on its upcoming product launches.
- 09/23/2021
|
Abbott (ABT) Stock Sinks As Market Gains: What You Should Know
- Abbott (ABT) closed at $124.65 in the latest trading session, marking a -0.38% move from the prior day.
- 09/22/2021
|
7 Healthcare Stocks to Buy Now as the Pandemic Forces a Rethink
- Thanks to the coronavirus pandemic, many people are rethinking the medical sector, boding well for healthcare stocks. The post 7 Healthcare Stocks to Buy Now as the Pandemic Forces a Rethink appeared first on InvestorPlace.
- 09/22/2021
|
Abbott's (ABT) Portico With FlexNav System Gets FDA Approval
- Abbott's (ABT) Portico with FlexNav TAVR system is intended to treat people with symptomatic severe aortic stenosis who are at high or extreme risk for open-heart surgery.
- 09/21/2021
|
Abbott Receives FDA Approval for Minimally Invasive Portico™ with FlexNav™ TAVR System to Treat Patients with Aortic Valve Disease
- ABBOTT PARK, Ill., Sept. 20, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's Portico™ with FlexNav™ transcatheter aortic valve replacement (TAVR) system to treat people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery.
- 09/20/2021
|
FDA Warns On Potential False Positive Results With Abbott's COVID-19 Tests
- The FDA has issued a letter to healthcare professionals alerting them to the potential for false-positive results with Abbott Laboratories (NYSE: ABT) two COVID-19 diagnostic tests. Related Link: Abbott Destroyed Several COVID Test Cards, Now Faces Diminished Capacity: NYT.
- 09/17/2021
|
Abbott (ABT) Stock Moves -0.04%: What You Should Know
- Abbott (ABT) closed at $127.44 in the latest trading session, marking a -0.04% move from the prior day.
- 09/16/2021
|
Abbott Declares 391st Consecutive Quarterly Dividend
- ABBOTT PARK, Ill., Sept. 15, 2021 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 45 cents per share.
- 09/15/2021
|
3 Diagnostics Stocks in Focus on Biden's Delta Variant Mandate
- Stocks like Quest Diagnostics (DGX), Quidel Corporation (QDEL) and LabCorp (LH) are the right picks now, thanks to rising COVID-19 testing demand.
- 09/14/2021
|
Abbott (ABT) Nutrition Sales Grow Despite Pandemic Woes
- Abbott's (ABT) Sales of Pedialyte, the global rehydration brand, strongly grows driven by the recently launched products and increased investments in direct consumer promotion.
- 09/13/2021
|
Got $3,000? Keep It Safe With These 3 Healthcare Stocks
- They offer products that their customers absolutely can't do without, and they also pay dividends.
- 09/13/2021
|
3 Dividend Stocks to Buy and Hold Forever
- They all have solid dividends plus attractive growth prospects.
- 09/12/2021
|
Why Biden's Action Plan Is Bullish For COVID-19 Testing Stocks
- On Thursday, President Joe Biden revealed his new COVID-19 action plan, which includes $2 billion in government spending on 280 million rapid point of care and at-home COVID-19 tests. On Friday, Bank of America analyst Bob Hopkins said Biden's new plan is good news for test manufacturers, including Becton Dickinson and Co (NYSE:BDX) and Abbott Laboratories (NYSE:ABT).
- 09/10/2021
|
Shares Of Abbott Laboratories (ABT) Rise Above Previous 52-Week High
- Abbott Laboratories (NYSE: ABT) traded today at a new 52-week high of $129.40. Approximately 642,000 shares have changed hands today, as compared to an average 30-day volume of 4.1 million shares.
- 09/07/2021
|
What's Happening With Abbott Stock?
- The stock price of Abbott has seen a rise of around 20% since early June this year. The company's Q2 results were comfortably above our as well as the consensus estimates driven by continued demand for Covid-19 testing.
- 09/07/2021
|
Shares Of Abbott Laboratories (ABT) Rise Above Previous 52-Week High
- Abbott Laboratories (NYSE: ABT) traded today at a new 52-week high of $129.40. Approximately 642,000 shares have changed hands today, as compared to an average 30-day volume of 4.1 million shares.
- 09/03/2021
|
Abbott (ABT) Expands Vascular Portfolio With New Acquisition
- Abbott's (ABT) acquisition of Walk Vascular's Peripheral Thrombectomy Systems will be included into the former's existing endovascular product portfolio.
- 09/03/2021
|
Abbott Expands Peripheral Vascular Offerings with Acquisition of Walk Vascular, LLC
- ABBOTT PARK, Ill., Sept. 2, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it has acquired Walk Vascular, LLC, a commercial-stage medical device company with a minimally invasive mechanical aspiration thrombectomy system designed to remove peripheral blood clots.
- 09/02/2021
|
This May Be Abbott's Billion-Dollar Opportunity
- Abbott delivered bad news back in June. But the tide has turned.
- 09/02/2021
|
Abbott's (ABT) Heart Failure Device Study Outcome Favorable (Revised)
- Based on the favorable outcome, Abbott (ABT) files a Premarket Approval (PMA) supplement with the FDA for consideration of an expanded indication for the CardioMEMS device.
- 09/02/2021
|
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
- Abbott (ABT) closed at $127.40 in the latest trading session, marking a +0.82% move from the prior day.
- 09/01/2021
|
Abbott's (ABT) Amplatzer Amulet Occluder Trial Data Favorable
- Abbott's (ABT) Amulet IDE trial findings supported the recent FDA approval of Abbott's Amplatzer Amulet LAA Occluder to reduce the risk of stroke in patients with atrial fibrillation.
- 08/31/2021
|
Abbott Says Amulet Superior To Boston Scientific's Watchman In Stroke Study
- Abbott Laboratories (NYSE: ABT) has announced late-breaking data from the Amulet LAA Occluder IDE trial. The head-to-head study compared Abbott's Amplatzer Amulet Left Atrial Appendage (LAA) Occluder with Boston Scientific Corporation's (NYSE: BSX) Watchman device for atrial fibrillation at an increased risk of stroke.
- 08/30/2021
|
Abbott's (ABT) Heart Failure Device Study Outcome Favorable
- Based on the favorable outcome, Abbott (ABT) files a Premarket Approval (PMA) supplement with the FDA for consideration of an expanded indication for the CardioMEMS device.
- 08/30/2021
|
Late-Breaking Data Shows Abbott's Amplatzer™ Amulet™ Occluder Offers Superior Left Atrial Appendage Closure Compared to Watchman‡ Device for People With Atrial Fibrillation at Risk of Stroke
- ABBOTT PARK, Ill., Aug. 30, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking data from the Amulet™ LAA Occluder IDE trial, a multi-center, head-to-head study comparing the company's Amplatzer™ Amulet Left Atrial Appendage (LAA) Occluder with the Watchman‡ device (Boston Scientific) to treat patients with atrial fibrillation (AFib) at an increased risk of stroke.
- 08/30/2021
|
GUIDE-HF Study Data Show Abbott's CardioMEMS™ Device Can Improve Care for More Patients with Heart Failure
- ABBOTT PARK, Ill., Aug. 27, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced results of the landmark GUIDE-HF clinical trial, a 1,000 patient randomized study designed to assess the benefits of the CardioMEMS™ HF System in people living with NYHA Class II, III and IV heart failure.
- 08/27/2021
|
Abbott (ABT) Gains As Market Dips: What You Should Know
- In the latest trading session, Abbott (ABT) closed at $125.47, marking a +0.59% move from the previous day.
- 08/26/2021
|
Abbott Destroyed Several COVID Test Cards, Now Faces Diminished Capacity: NYT
- When demand for rapid COVID-19 screening dropped earlier this year, Abbott Laboratories (NYSE: ABT) lowered its financial outlook for full-year 2021 and announced 400 layoffs. According to The New York Times investigation, Abbott told factory workers to shred millions of paper testing cards that it thought would never sell.
- 08/23/2021
|
Abbott (ABT) Receives FDA Nod for Amplatzer Amulet Device
- The FDA's go-ahead for Abbott's (ABT) Amulet will offer a unique treatment option in the United States that seals off the left atrial appendage entirely without any blood-thinning drugs.
- 08/18/2021
|
FDA Approves Abbott's Atrial Fibrillation Device For LAA Occlusion
- The FDA has approved Abbott Laboratories' (NYSE:ABT) Amplatzer Amulet Left Atrial Appendage Occluder to treat people with atrial fibrillation (AFib) who are at risk of ischemic stroke. The device offers immediate closure of the left atrial appendage (LAA), where blood clots can form in people suffering from AFib, reducing their risk of stroke and immediately eliminating the need for blood-thinning medication.
- 08/16/2021
|
Abbott's Amplatzer™ Amulet™ Device Approved by FDA to Treat People With Atrial Fibrillation at Risk of Stroke
- ABBOTT PARK, Ill., Aug. 16, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) approved the company's Amplatzer™ Amulet™ Left Atrial Appendage Occluder to treat people with atrial fibrillation (AFib) who are at risk of ischemic stroke.
- 08/16/2021
|
3 Big Dividends, Paying Monthly, For Your Retirement Basea
- A monthly income stream provides a lot of flexibility for the income investor. Monthly dividends makes DCA work even better.
- 08/08/2021
|
1 Healthcare Dividend Giant to Bank On Right Now
- The pipeline and consistent dividend history of this Dividend Aristocrat mean its payout is likely to remain strong.
- 08/06/2021
|
Abbott (ABT) Receives FDA Approval for OCT Imaging Platform
- The FDA authorization for Abbott's (ABT) OCT imaging platform powered by the Ultreon Software is expected to broaden its accessibility to physicians.
- 08/04/2021
|
Abbott Receives FDA Clearance for its Imaging Technology Using Artificial Intelligence for Vessels in the Heart
- ABBOTT PARK, Ill., Aug. 3, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug Administration (FDA) clearance for its latest optical coherence tomography (OCT) imaging platform powered by the company's new Ultreon Software.
- 08/03/2021
|
3 Dividend Stocks Safe Enough to Bet the Farm On
- You shouldn't invest your life savings into any one stock, but these three have some serious potential.
- 07/29/2021
|
Anxious About a Market Crash? Start Doing These 3 Things Right Now
- You have the power to turn a negative event into something positive.
- 07/28/2021
|
Medical Device Stocks' Earnings on Jul 28: TMO, ALGN & More
- The sector's Q2 results are likely to reflect solid earnings and revenue growth on strong base business recovery.
- 07/27/2021
|
Worries About the Delta Variant Could Be Overdone Based on Clues From These Healthcare Giants
- What healthcare executives are saying so far about the impact of the coronavirus variant on their businesses is reassuring.
- 07/27/2021
|
Top 5 Trades of the Eaton Vance Worldwide Health Sciences Fund
- The Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) disclosed its portfolio for the second quarter of the year this week.
- 07/26/2021
|
ABT Stock $128 Target From Raymond James
- The shares of Abbott Laboratories (NYSE: ABT) have received a price target increase from $116 to $128 by Raymond James. These are the details.
- 07/25/2021
|
Abbott Laboratories Is Likely To Melt Up Into 2022
- Abbott Laboratories' stock was in a short-term downtrend, but continuing accumulation appears likely in the second half of 2021. Abbott recently reported earnings, which were decent, but shares sold off anyway. They quickly reversed to close the week at prices last seen in April.
- 07/25/2021
|
Abbott Labs stock price forecast for Q3 after Q2 results
- The US medical devices company Abbott Laboratories (NYSE:ABT) announced its fiscal Q2 results on Thursday before markets opened. The company posted higher than expected revenue of $10.22 billion, beating the consensus Street estimate by $550 million.
- 07/22/2021
|
Abbott Laboratories (ABT) CEO, Robert Ford on Q2 2021 Results - Earnings Call Transcript
- Abbott Laboratories (ABT) CEO, Robert Ford on Q2 2021 Results - Earnings Call Transcript
- 07/22/2021
|
Abbott Q2 Profit More Than Doubles As Medical Device Sales Rebound
- Abbott Laboratories (NYSE: ABT) Q2 profit more than doubled to $2.1 billion due to strength in its diagnostics business and a rebound in medical device sales. As curbs lift and vaccinations gather, demand for medical devices is returning as more people opt for non-urgent procedures.
- 07/22/2021
|
Abbott Labs stock gains after profit more than doubles, sales rise above expectations
- Shares of Abbott Laboratories edged up 0.2% in premarket trading Thursday, after the medical devices, diagnostics and nutrition company reported second-quarter profit and sales that rose above expectations, with beats in all of its major business segments. Net income more than doubled, to $1.19 billion, or $1.17 a share, from $537 million, or 57 cents a share, in the year-ago period.
- 07/22/2021
|
Abbott Laboratories: Q2 Earnings Insights
- Shares of Abbott Laboratories (NYSE:ABT) decreased 0.2% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 105.26% over the past year to $1.17, which beat the estimate of $1.02.
- 07/22/2021
|
Abbott Reports Second-Quarter 2021 Results
- ABBOTT PARK, Ill., July 22, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2021.
- 07/22/2021
|
Earnings Preview: Abbott Laboratories
- Abbott Laboratories (NYSE:ABT) announces its next round of earnings this Thursday, July 22. Here is Benzinga's everything-that-matters guide for this Thursday's Q2 earnings announcement.
- 07/21/2021
|
Will Abbott Stock Rise Post Q2?
- Abbott is scheduled to report its Q2 2021 results on Thursday, July 22. We expect Abbott to report revenues and earnings above the consensus estimates, driven by continued growth in diagnostics business, along with a rebound in demand for medical devices.
- 07/21/2021
|
Else Nutrition announces strategic additions to its team, with the appointment of two former Abbott Laboratories executives
- Else Nutrition Holdings Inc. (CVE:BABY) (OTCMKTS:BABYF) (FRA:0YL.F) has announced two strategic additions to the company's executive team, with the appointment of Simeon Saunders as VP Global Medical Marketing and Scientific Affairs and Mike Glick as GM and VP Else North America, both of whom are former executives with Abbott Laboratories. “We are extremely delighted by the addition of Mike and Simeon to the Company.
- 07/21/2021
|
Else Nutrition announces two strategic additions to its team, with the appointment of two former Abbott Laboratories executives
- Else Nutrition Holdings Inc. (CVE:BABY) (OTCMKTS:BABYF) (FRA:0YL.F) has announced two strategic additions to the company's executive team, with the appointment of Simeon Saunders as VP Global Medical Marketing and Scientific Affairs and Mike Glick as GM and VP Else North America, both of whom are former executives with Abbott Laboratories. “We are extremely delighted by the addition of Mike and Simeon to the Company.
- 07/21/2021
|
5 Hottest Earnings Charts This Week
- These companies have earnings surprise track records and charts to envy.
- 07/20/2021
|
How Important Is Re-Investing Dividends? A Five-Year Analysis For Abbott Laboratories
- In a world obsessed with price movements of stocks, it's easy to lose sight of what those prices represent -- the value of holding a company's future profit potential. One of the key ways that profit potential turns into profit actualization in an investor's pocket is the dividend -- cash (usually) payments made to stockholders representing a portion of a company's retained earnings.
- 07/20/2021
|
Lower COVID-19 Testing Demand to Drag Abbott (ABT) Q2 Earnings
- Apart from COVIG-19 test related hiccups, Abbott (ABT) is likely to have suffered from significant sales decline within its pediatric nutrition business in Q2.
- 07/16/2021
|
Abbott (ABT) Earnings Expected to Grow: Should You Buy?
- Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/15/2021
|
Abbott (ABT) Stock Sinks As Market Gains: What You Should Know
- Abbott (ABT) closed the most recent trading day at $117.17, moving -1.25% from the previous trading session.
- 07/14/2021
|
Our U.S. Stock Portfolio, First Half Of 2021 Review
- U.S. stocks moved to new all-time highs in the first half of 2021 as we eye the other side of the pandemic.
- 07/14/2021
|
PAHC vs. ABT: Which Stock Should Value Investors Buy Now?
- PAHC vs. ABT: Which Stock Is the Better Value Option?
- 07/12/2021
|
Will Abbott Stock Continue Its Rally After An 11% Rise In A Month?
- The stock price of Abbott Laboratories has seen an 11% rise over the last twenty-one trading days, while it is up 27% over the last year. Abbott has benefited from a strong demand for Covid-19 testing, which aided its diagnostics business and earnings growth over the recent quarters.
- 07/12/2021
|
Upcoming Ex-Dividend Dates: July 13-26, 2021
- This article series presents upcoming ex-dividend dates. We provide a summary table with relevant data and key statistics, including the next payout and pay date.
- 07/11/2021
|
Grab these 3 MedTech Stocks That Outperformed S&P 500 YTD
- Snap up these three top stocks, WST, PAHC and RMD, which continue to show promise amid the pandemic and can turn out to be prudent investment choices.
- 07/11/2021
|
7 Super-Safe Dividend Stock Performers to Buy
- While growth names still dominate the mainstream narrative, it's wise to consider some exposure to safety in dividend stocks. The post 7 Super-Safe Dividend Stock Performers to Buy appeared first on InvestorPlace.
- 07/09/2021
|
Abbott Lays Off Around 400 Employees As COVID-19 Test Demand Evaporates
- Abbott Laboratories (NYSE: ABT) has begun laying off hundreds of workers at its diagnostic plants a month after it slashed its earnings forecasts for the remainder of 2021 amid diminishing demand for COVID tests as vaccination picks up. According to a report from the ABC television station WMTW in Portland, Abbott is letting go 400 full-time employees at its locations in Westbrook and Scarborough, focused on the production of rapid antigen tests.
- 07/09/2021
|
Grab these 3 MedTech Stocks That Outperformed S&P 500 YTD
- Snap up these three top stocks, WST, PAHC and RMD, which continue to show promise amid the pandemic and can turn out to be prudent investment choices.
- 07/09/2021
|
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
- Abbott (ABT) closed at $119.87 in the latest trading session, marking a +0.88% move from the prior day.
- 07/07/2021
|
This Pharma Stock Is a Surefire Bet for July
- With Independence Day now behind us and the second half of the year officially underway, investors are setting out their investment strategies for the back nine of 2021.
- 07/06/2021
|
Abbott's (ABT) DAPT for High Bleeding Risk Gets FDA Approval
- Abbott's (ABT) DAPT can be discontinued safely early as short as 28 days with no higher risk in patient adverse events.
- 07/06/2021
|
Upcoming Ex-Dividend Dates: July 6-July 19, 2021
- We provide a summary of upcoming ex-dividend dates in a quick reference table. The table includes relevant data and key statistics.
- 07/05/2021
|
The 7 Best Dividend Stocks to Buy for Income Investors In July 2021
- Markets have become choppy due to inflation and uncertainty. These dividend stocks could provide a safe haven in volatile times for the rest of the year.
- 07/02/2021
|
